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Abstract 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, characterised 
by dysfunction and degeneration of motor neurons innervating skeletal muscle. ALS 
patients experience progressive muscle weakness and atrophy, leading to paralysis and 
death within 3-5 years of diagnosis. The mechanisms underlying neurodegeneration in 
ALS are unknown; studies of patient tissue and of transgenic mouse models of ALS 
have implicated oxidative stress, neuroinflammation, aberrant RNA metabolism, 
excitotoxicity, protein misfolding, autophagy and proteasome dysfunction, and 
intracellular transport deficits in disease processes.  
Current ALS therapeutics can only extend lifespan by a matter of months, so it is vital 
that novel therapeutic targets and therapeutic molecules are identified.  The many 
putative “triggers” of ALS are predicted to converge upon common mechanisms of 
degeneration, with oxidative stress being identified as one of the major pathological 
hallmarks of ALS. Therapeutics capable of modulating oxidative stress and preventing 
neuronal death may be of value in treating human ALS.  
In this thesis, the temporal correlations between microglial activation, development of 
pathological alterations in the spinal cord, and functional decline, were explored in the 
transgenic SOD1 mouse model of ALS (carrying the ALS-linked mutant human Cu,Zn-
superoxide dismutase gene SOD1
G93A
), with non-transgenic (WT) mice used as 
controls. The ability of three putative therapeutic compounds for ALS – Gemals, 
metallothionein-2 protein, and Emtin peptides – to increase survival time in SOD1 mice 
was also examined. 
Pathological alterations in motor neurons preceded an increase in microglial numbers, 
suggesting microglial activation occurs as a reactive response to neuronal degeneration 
or dysfunction. Microglial activation occurred concurrently with disease onset at 14 
weeks of age, but preceded the development of overt functional deficits around 18 
weeks of age. Interestingly, microglial activation was associated with an increase in the 
number of microglia expressing the M2-like, putative neuroprotective, marker arginase1 
(Arg1), and to a lesser extent with an increase in the number of microglia expressing the 
M1-like, putative neurotoxic, marker inducible nitric oxide synthase (iNOS). These data 
suggest the concurrent presence of ongoing neuroprotective and neuroinflammatory 
processes in the spinal cord of SOD1 mice; microglial activation may not be a primary 
________________________________________________________________Abstract
______________________________________________________________________ 
______________________________________________________________________ 
 
iv 
 
cause of neurodegeneration, but may drive disease progression after onset. Additionally, 
the expression of the antioxidant protein metallothionein-1/2 (MT-1/2) increased from 
18 weeks of age, possibly in response to oxidative stress or neuronal degeneration.  
Gemals, an antioxidant and anti-inflammatory combination therapy, has been previously 
shown to extend the lifespan of an ALS rat model, but has not been tested in ALS mice. 
Here, Gemals was administered subcutaneously to SOD1 mice from the age of 
symptom onset through to disease endpoint. No significant changes in survival time 
were identified in Gemals-treated SOD1 mice compared to controls, indicating that 
Gemals treatment may be less effective when administered after symptom onset.  
MT-1/2 protein has previously shown both antioxidant and neuroprotective properties, 
and its ablation in SOD1 mice has been shown to accelerate disease progression. In this 
study, SOD1 mice were treated with MT2 injections, and/or with treadmill running 
exercise to upregulate endogenous MT-1/2. MT2 treatment slightly but significantly 
delayed disease onset, and tended to increase survival time, in SOD1 mice, whereas 
treadmill running exercise had little effect. However, the mechanism of action for MT2 
is as yet unknown – preliminary data suggest that MT2 treatment did not substantially 
prevent spinal cord motor neuron degeneration or muscle endplate denervation.    
Peptide derivatives of MT-1/2, termed Emtins, have previously displayed similar 
neuroprotective properties to their parent MT-1/2 protein in vitro and in vivo, and 
additionally can readily cross the blood-brain barrier. Emtins were administered 
subcutaneously to SOD1 mice from the onset of disease symptoms, resulting in 
increased survival time compared to control mice, although this result was not 
significant due to a smaller number of animals used during this trial. These data indicate 
that both MT2 and Emtins have pro-survival effects in the SOD1 mice. Emtin peptides 
are thought to have limited metal-binding and antioxidant properties; however, both 
MT-1/2 and Emtins are known to interact with low-density lipoprotein receptor-related 
proteins (LRPs) and activate the Akt pathway, leading to increased cellular survival. It 
is possible that the pro-survival effects of MT2 and Emtins seen in these studies were 
mediated through LRP binding and activation of downstream pathways. MT2 and 
Emtins show potential as therapeutic molecules for ALS, but more work is required to 
elucidate the mechanism of action.     
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1.1 Motor neuron disease 
1.1.1 An overview of the motor system 
Motor neurons are the nerve cells that transmit electrical impulses from motor control 
areas of the brain to skeletal muscles in order to effect voluntary movement. An upper 
motor neuron has its cell body located within Layer V of the primary motor cortex and 
extends its axon to the brainstem via the corticobulbar tract, or to the spinal cord via the 
corticospinal tract, where a glutaminergic synapse is made with a lower motor neuron 
cell body (Figure 1.1). Lower motor neurons, located within either the brainstem motor 
nuclei or Rexed lamina IX of the spinal cord ventral horn, project their axon out of the 
central nervous system and effect target skeletal muscle contraction via the release of 
acetylcholine at the neuromuscular junction (Ravits et al. 2013) (Figure 1.1). 
For voluntary movement of skeletal muscles, the entire pathway from motor cortex to 
muscle must be intact. Motor neuron disease is characterised by the progressive 
dysfunction and death of upper or lower motor neurons, and the resulting progressive 
loss of voluntary movement of skeletal muscles (Ravits et al. 2013).   
1.1.2 Types of motor neuron disease 
Motor neuron diseases comprise a variety of syndromes and diseases caused by 
degeneration in either the upper or lower, or both upper and lower, motor neurons. The 
most common form of adult-onset motor neuron disease is amyotrophic lateral sclerosis 
(ALS) which involves degeneration of both upper and lower motor neurons, and was 
first described by the French neurologist Charcot in the 19
th
 century (Siddique & 
Ajroud-Driss 2011). Other motor neuron diseases may involve only the upper or lower 
motor neurons, such as primary lateral sclerosis (PLS) and progressive muscular 
atrophy (PMA) respectively. Although PLS and PMA are associated with slower 
progression rates and longer survival times than ALS, (Visser et al. 2007; Talman et al. 
2009; Wijesekera et al. 2009), many patients initially diagnosed with a pure upper or 
lower motor neuron disease go on to develop signs of involvement of both motor 
neuron populations (Visser et al. 2007; Kim et al. 2009), suggesting ALS lies at the 
centre of a spectrum of motor neuron diseases. As ALS is both the most common form 
of adult-onset motor neuron disease, and is thought to be at the centre of a continuum of 
upper and lower motor neuron disorders, this thesis will focus primarily on ALS.   
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Figure 1.1 Overview of the motor system 
Upper motor neurons have a cell body located in the primary motor cortex grey matter, 
with their axons extending to either the brainstem or the spinal cord via the 
corticobulbar or corticospinal tracts, respectively. Lower motoe neurons innervating the 
head and neck have their cell bodies located in brainstem motor nuclei, and their axons 
travel via the cranial nerves to the bulbar skeletal musculature. Lower motor neurons 
innervating the trunk and limbs have their cell bodies located in the spinal cord ventral 
horn, and their axons travel to the axial and limb skeletal musculature via peripheral 
nerves. Upper motor neurons release glutamate onto lower motor neurons at the 
synapse, while lower motor neurons release acetylcholine onto nicotinic receptors at the 
neuromuscular junction. 
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1.2 Amyotrophic lateral sclerosis 
1.2.1 Clinical features and disease course 
ALS typically presents as a focal muscle weakness, seen in the limbs in two thirds of 
patients and in the bulbar region in one third of patients, which worsens with time 
(Logroscino et al. 2010; Kiernan et al. 2011; Al-Chalabi et al. 2012). Regardless of the 
site of presentation, the symptoms of motor neuron (MN) degeneration – spasticity, 
clonic reflexes, and psuedobulbar affect from upper MN loss, and muscle weakness, 
atrophy, and fasciculations from lower MN loss – spread progressively through the 
body (Walker 1990; Brooks 1994).  
As MNs degenerate, ALS patients lose control over voluntary skeletal muscle 
movement, resulting in progressive inability to generate limb movement, and also 
causing difficulties in swallowing, speech, and breathing. In addition to motor 
impairment, ALS patients may show impaired executive or cognitive function, or 
behavioural changes; some ALS patients meet the clinical criteria for frontotemporal 
dementia (Lomen-Hoerth et al. 2003; Witgert et al. 2010). Sensory neurons are affected 
to a much lesser extent than motor neurons (Kawamura et al. 1981; Gregory et al. 
1993). ALS ultimately leads to death from failure of the respiratory muscles, with most 
patients only surviving 3-5 years from diagnosis (Al-Chalabi et al. 2012).  
1.2.2 Diagnosis 
A diagnosis of ALS is made according to the modified El Escorial criteria, and requires 
signs of both upper and lower motor neuron degeneration upon clinical, 
electophysiological or neuropathologic examination, with evidence of symptom 
progression over time (Brooks 1994; Brooks et al. 2000; de Carvalho et al. 2008). 
Extensive clinical, neuroimaging and laboratory investigations are required to rule out 
disorders mimicking ALS, which can include polyneuropathies, endocrine 
abnormalities, physical injury to the nervous system, malignancies, exposure to 
exogenous toxins, vasculitis and myelopathies (Kiernan et al. 2011). A recent study 
indicated that average time from symptom onset to diagnosis was over 12 months 
(Logroscino et al. 2010). While less than 10% of patients with diagnoses of ALS are re-
diagnosed with an ALS mimic syndrome, some of these mimic syndromes can be 
effectively treated – making a correct diagnosis extremely important (Ross et al. 1998; 
Traynor et al. 2000).  
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1.2.3 Prevalence and risk factors 
ALS affects 2-3 people per 100,000 each year, with a prevalence of 4-8 people per 
100,000. Onset is most common between 50-65 years of age, and ALS is slightly more 
common in males than females (Logroscino et al. 2010; Kiernan et al. 2011). 
Environmental and lifestyle risk factors such as pesticide, cyanobacteria, or heavy metal 
exposure, electric shock, smoking, and high levels of leisure-time physical activity, are 
associated with increased ALS risk (Das et al. 2012; Huisman et al. 2013; Trojsi et al. 
2013). Approximately 5-10% of all ALS cases have a family history (familial ALS, 
FALS), as opposed to no family history of ALS (sporadic ALS, SALS). Mutations in a 
number of genes are known to cause familial ALS or inherited ALS-like disorders, and 
polymorphisms in a number of genes have been shown in genome-wide association 
studies to increase the risk of developing SALS (Table 1.1); their possible roles in ALS 
aetiology are discussed in section 1.3. Geographical foci such as Guam and the Japanese 
Kii peninsula have historically shown high incidence rates of the 
ALS/parkinsonism/dementia complex (McGeer & Steele 2011; Kaji et al. 2012), 
suggesting that ALS could be caused by a common genetic or environmental factor. 
1.2.4 Prognosis and treatment strategies 
ALS is currently incurable, and invariably fatal, with the average lifespan only 3-5 years 
from symptom onset. The only drug currently available for treatment of ALS is the 
glutamate blocker, Riluzole (Bensimon et al. 1994; Georgoulopoulou et al. 2013). 
However, the average patient can expect a survival increase of only 3-6 months from 
using Riluzole, and the survival-promoting effects of Riluzole are greater for patients 
with bulbar-onset ALS, and less for those with limb-onset ALS (Bensimon et al. 1994). 
Given that Riluzole does not provide a cure for ALS, treatments are based around the 
amelioration of symptoms in order to maintain quality of life for the patient, often in the 
context of a multidisciplinary clinic (Simmons 2005; Mayadev et al. 2008). 
Interventions such as artificial ventilation can increase survival time (Miller et al. 2009; 
Spataro et al. 2012), while percutaneous endoscopic gastrostomy can maintain nutrition 
despite bulbar difficulties (Spataro et al. 2011).  However, it is clear that novel 
treatments for ALS are required to halt the disease processes and improve outcomes for 
patients. However, as the underlying aetiology of ALS is not yet known, more research 
into the mechanisms of motor neuron degeneration is required. The known pathological 
features of ALS, and a mouse model mimicking human ALS, are discussed overleaf.  
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1.2.5 Pathological features of ALS 
End-stage CNS pathology in ALS patients reveals four pathological hallmarks of ALS. 
First, the extensive loss of motor neuron cell bodies in layer V of the motor cortex, in 
the brainstem motor nuclei, and in the spinal cord anterior horns; motor neuron 
degeneration is thought to resemble programmed cell death rather than necrosis (Martin 
2010). Second, axonal degeneration in CNS white matter tracts such as the corpus 
callosum, medullary pyramids, and corticospinal tract; and also in ventral roots and 
peripheral nerves. Third, the presence of ubiquitinated protein aggregates in 
degenerating motor neurons (Lowe et al. 1989) in four neuropathological patterns: (1) 
SALS and most non-SOD1-linked FALS cases show aggregates containing ubiquitin 
and TDP43; (2) SOD1-linked FALS aggregates contain SOD1 but not TDP43; (3) FUS-
linked ALS aggregates can be basophilic inclusions, or contain FUS but not TDP43; (4) 
C9orf72-linked ALS aggregates contain ubiquitin and TDP43, and may also contain 
p62 and ubiquilin2 (Ravits et al. 2013). Fourth, widespread activation of glial cells can 
be seen in the spinal cord and motor cortex (Kamo et al. 1987; Schiffer et al. 1996). A 
mouse model of ALS, discussed below, is commonly used to examine mechanisms of 
motor neuron degeneration.    
1.2.6 Mouse models of ALS 
1.2.6.1 The SOD1 mouse model of ALS 
Sequence alterations in Cu,Zn-superoxide dismutase (SOD1) were the first mutations to 
be linked with familial ALS (Rosen et al. 1993). Transgenic mice, expressing high 
levels of the mutant human SOD1 protein with a glycine to alanine amino acid 
substitution at position 93 (SOD1
G93A
 mice; hereafter, the term ‘SOD1 mice’ refers to 
this mutation unless otherwise specified), mimic the pathological and clinical hallmarks 
of human ALS (Gurney et al. 1994). Clinically, SOD1 mice develop progressive motor 
deficits characterised by hindlimb weakness, muscle atrophy, and gradual paralysis 
(Gurney et al. 1994). Pathologically, SOD1 mice show extensive degeneration of spinal 
cord motor neuron cell bodies, axonal degeneration in the lateral motor columns, ventral 
roots, and peripheral nerves, and denervation at the neuromuscular junction (Gurney et 
al. 1994). Given the similarities of the SOD1 mouse to both familial and sporadic ALS 
patients, SOD1 mice have been widely used to examine the molecular pathology of 
motor neuron degeneration, and to perform pre-clinical testing of potential therapeutic 
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compounds for human ALS. However, it must be noted that no compounds which gave 
positive effects in the SOD1 mouse model have gone on to perform equally well in 
clinical trials (Benatar 2007). Putative mechanisms of SOD1-mediated ALS will be 
discussed in the aetiology section (Chapter 1.3).   
1.2.6.2 The TDP43 mouse model of ALS 
TDP43 was identified as a major component of ubiquitinated protein aggregates in the 
central nervous system of sporadic ALS patients, non-SOD1-linked familial ALS 
patients, and frontotemporal dementia patients (Neumann et al. 2006; Sreedharan et al. 
2008; Ravits et al. 2013). As TDP43 may represent a common pathway between the 
familial and sporadic forms of ALS, the development of a mouse model of TDP43-
based pathology may be a big step forward for ALS research. However, development of 
an ALS mouse model based on TDP43 has encountered some complications. Mouse 
models expressing prion promoter-driven high levels of human TDP43 with the A315T 
mutation (Prp-hTDP43-A315T) show a loss of motor function and premature death 
(Wegorzewska et al. 2009). However, the full motor phenotype of the Prp-hTPD43-
A315T mouse was thought to be masked by the early development of gastrointestinal 
problems (Esmaeili et al. 2013). A recent study showed intestinal motility problems in 
Prp-hTDP43-A315T mice leading to premature death, and showed that when these 
deficits were alleviated by allowing mice to eat a nutrient gel diet, rather than standard 
laboratory chow, these mice survived for longer and developed pronounced 
neurodegeneration (Herdewyn et al. 2014). The mechanisms by which the 
overexpressed Prp-hTDP43-A315T exerts its toxic actions are not yet known; the 
overexpression of TDP43 appears to lead to aberrant mRNA splicing, potentially 
affecting thousands of downstream gene products, including many genes required for 
synaptic function (Lagier-Tourenne et al. 2012; Xu et al. 2013). Interestingly, the 
TDP43-based ALS mouse model appears to show upper motor neuron pathology more 
readily than lower motor neuron pathology (Igaz et al. 2011; Herdewyn et al. 2014). 
The TDP43 mouse model will provide a complementary model for the current SOD1 
mouse model, and the use of both models side by side will help to determine the 
mechanisms underlying upper and lower motor neuron degeneration. 
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1.3 Etiology of ALS 
The exact causative mechanisms underlying motor neuron degeneration in ALS are not 
currently known. Combined evidence from ALS patients, SOD1 ALS mouse models, 
and cell culture models have implicated a wide range of cellular processes in ALS 
pathology. In this section, the possible contributions of these pathways to the molecular 
pathogenesis of ALS will be discussed. These cellular events include oxidative stress, 
glial activation and neuroinflammation, mitochondrial dysfunction, RNA processing, 
excitotoxicity, protein aggregation and protein degradation dysfunction, and 
intracellular transport deficits. Possible convergence points between different 
pathological mechanisms will also be discussed. 
 
1.3.1 Genetic evidence for molecular pathologies in ALS 
Although only 10% of ALS cases show a heritable component, both sporadic and 
familial ALS share similar clinical and pathological characteristics. The identification of 
mutations causative for familial ALS also contributes to the understanding of pathways 
potentially involved in sporadic disease (Al-Chalabi et al. 2012). Mutations linked to 
various juvenile-onset or adult-onset familial ALS are present in a range of genes; a list 
of genes with contributions to various forms of FALS has been compiled in Table 1.1. 
A full list of genes involved in ALS, as well as ALS-associated risk factors from 
genome-wide association studies, can be found at www.alsod.iop.kcl.ac.uk.  
The genes listed in Table 1.1 have been loosely grouped according to their most well-
understood functions. The genes associated with familial ALS, which in some cases 
have also been associated with sporadic ALS, represent pathways with functions in 
antioxidant response, intracellular transport (encompassing axonal transport and vesicle 
trafficking), protein degradation by the proteasome and by autophagy, RNA processing 
and metabolism, and maintenance of the cytoskeletal protein network (Al-Chalabi et al. 
2012). The involvement of these genes in familial ALS gives clues to the 
pathophysiology of ALS. The current hypotheses on ALS aetiology, encompassing the 
pathways represented by the genetic risk factors listed in Table 1.1, will be discussed in 
more detail in subsequent sections on disease aetiology. 
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Table 1.1 Genes associated with familial amyotrophic lateral sclerosis 
Gene Gene product (abbreviation) Normal function Mutations are known to cause:  %patients with mutations* 
FALS SALS 
SOD1 Cu,Zn-superoxide dismutase (SOD1) Antioxidant FALS 12% 2-7% 
DCTN1 Dynactin-1 (DCTN1) Axonal transport Familial PMA   
ALS2 Alsin Vesicle trafficking Familial juvenile-onset PLS   
OPTN Optineurin (OPTN) Vesicle trafficking Familial juvenile-onset ALS <1% <1% 
VAPB Vesicle-associated membrane protein 
(synaptobrevin)-associated protein B (VAPB) 
Vesicle trafficking 
ER stress 
FALS   
FIG4 Fig4 homologue, SAC1 lipid phosphatase domain 
containing (S. cerevisiae) (FIG4) 
Vesicle trafficking 
 
FALS; CMT   
VCP Valosin-containing protein (VCP) Protein degradation FALS; IBMPFD 1% 1% 
UBQLN2 Ubiquilin 2 (UBQLN2) Protein degradation FALS <1% <1% 
SQSTM1 Sequestosome 1 (p62) Protein degradation FALS 1% <1% 
SIGMAR1 Sigma non-opioid intracellular receptor 1 
(SIGMAR1) 
ER stress Familial juvenile-onset ALS   
TARDBP TAR-DNA binding protein 43 (TDP43) RNA processing FALS; FTD 4% 1% 
FUS Fused in sarcoma (FUS) RNA processing 
DNA damage response 
FALS 4% 1% 
TAF15 TAF15 RNA polymerase II, TATA box binding 
protein-associated factor, 68kDa (TAF15) 
RNA processing FALS   
ELP3 Elongation protein 3 (ELP3) RNA processing Increased risk of sporadic ALS   
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Table 1.1 (continued) 
Gene Gene product (abbreviation) Normal function Mutations are known to cause:  %patients with mutations* 
FALS SALS 
SETX Senataxin (SETX) RNA processing 
DNA damage response 
Familial juvenile-onset ALS; 
hereditary ataxia 
  
ANG Angiogenin (ANG) Blood vessel formation 
Neuronal protection 
RNAse function 
FALS; increased risk of SALS   
PFN1 Profilin 1 (PFN1) Cytoskeletal network FALS <1% <1% 
PON Paraoxonase (PON) Detoxification of toxins Increased risk of SALS   
NEFH Neurofilament heavy chain (NEFH) Cytoskeletal network FALS; increased risk of SALS   
DAO D-amino-acid oxidase (DAO) Serine metabolism FALS; increased risk of SALS   
SPG11 Spastic paraplegia 11, spatacsin Axonal development 
DNA damage repair 
Familial juvenile-onset ALS   
C9orf72 Chromosome 9 open reading frame 72 (C9orf72) Unknown FALS; FTD 40% 7% 
ALS, amyotrophic lateral sclerosis; CMT, Charcot-Marie-Tooth disease; FALS, familial ALS; FTD, frontotemporal dementia; IBMPFD, inclusion body myopathy and 
Paget’s disease of bone with frontotemporal dementia; PLS, primary lateral sclerosis; PMA, progressive muscular atrophy; SALS, sporadic ALS. *Percentage of ALS cases 
explained by mutations in the given gene (please note: many genes have been associated with ALS, but these gene alterations occur in few patients, and therefore the 
occurrence of these genes in sporadic and familial ALS is likely to be infrequent (<1%); the known percentages for well-investigated genes are presented here). Source: Table 
adapted from information found in the ALSoD database (www.alsod.iop.kcl.ac.uk) and published papers (Schymick et al. 2007; Lill et al. 2011; Al-Chalabi et al. 2012; 
Renton et al. 2014). 
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1.3.2 Oxidative stress 
1.3.2.1 Reactive oxygen species and oxidative damage 
The mediators of oxidative damage to macromolecules are reactive oxygen species 
(ROS) such as hydroxyl and superoxide radicals. Endogenous ROS are formed during 
normal cellular metabolism; a major source of endogenous superoxide radicals is 
electron leakage from the mitochondrial respiratory chain during oxidative 
phosphorylation (Mates et al. 1999). Superoxide can react with nitric oxide (NO) to 
form peroxynitrite (ONOO-), another highly-reactive species. ROS can cause oxidative 
damage to a variety of cellular macromolecules. Oxidative damage to DNA, left 
unrepaired, can give rise to mutations in the DNA sequence or block transcription from 
the affected gene (Cooke et al. 2003). Oxidative damage to mRNA leads to reduced 
protein expression from the affected sequence (Chang et al. 2008). Protein oxidation 
and nitration, through the reaction of peroxynitrite with tyrosine amino acid residues to 
form nitrotyrosine, can alter protein structure and function (Radi 2013).  
Mammalian cells have a complex array of endogenous antioxidants and antioxidant 
enzymes, to prevent macromolecules from oxidative damage (Mates et al. 1999). 
Antioxidant enzymes include cytosolic Cu,Zn-superoxide dismutase (SOD1) and 
mitochondrial-localised Mn-superoxide dismutase (SOD2), which catalyse the 
conversion of superoxide to hydrogen peroxide; cytosolic catalase, glutathione 
peroxidase, and peroxiredoxin enzymes can then degrade hydrogen peroxide to water 
and molecular oxygen (Mates et al. 1999). A number of endogenous antioxidant 
compounds, such as vitamins A, C, and E, β-carotene, glutathione, and the 
metallothionein (MT) protein family, are potent intracellular scavengers of ROS (Mates 
et al. 1999). Oxidative stress occurs when the endogenous protection mechanisms are 
overwhelmed, resulting in oxidative damage to lipids, nucleic acids and proteins.  
1.3.2.2 Oxidative stress in ALS 
Increased markers of oxidative damage to macromolecules are present in both ALS 
patients and ALS rodent models. ALS patient CNS tissue shows marked evidence of 
carbonyl and nitrotyrosine protein modifications (Bowling et al. 1993; Shaw et al. 
1995; Beal et al. 1997; Ferrante et al. 1997; Sasaki et al. 2000), lipid peroxidation 
(Ferrante et al. 1997; Shibata et al. 2001), DNA damage (Ferrante et al. 1997) and 
mRNA damage (Chang et al. 2008). Markers of oxidative damage can also be found in 
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the cerebrospinal fluid (CSF), plasma and urine of ALS patients (Oteiza et al. 1997; 
Smith et al. 1998; Bogdanov et al. 2000). Markers of oxidative damage are similarly 
elevated in the central nervous system of SOD1 mice (Andrus et al. 1998; Chang et al. 
2008). In particular, lipid peroxidation occurs very early in disease progression in SOD1 
mice (Hall et al. 1998a). The occurrence of oxidative stress is a common factor between 
patients with familial and sporadic ALS, and also in ALS model mice, suggesting an 
important role of oxidative stress in the pathophysiology of ALS.  
1.3.2.3 Oxidative stress mediated by mutant SOD1 protein 
The identification of SOD1 as the first ALS-associated protein was a major driver for 
investigating the role of oxidative stress in ALS (Rosen et al. 1993). Over 170 ALS-
associated mutations have been identified to date in SOD1, accounting for 
approximately 20% of familial ALS cases. The normal function of SOD1 is to catalyse 
the dismutation of superoxide radicals into hydrogen peroxide, and it was initially 
thought that oxidative stress might result from a loss of SOD1 function upon mutation 
(Rosen et al. 1993). The loss of dismutase function may contribute to oxidative stress in 
patients with SOD1-linked FALS (Bowling et al. 1993; Browne et al. 1998). However, 
many ALS-associated mutant SOD1 proteins show minimal changes in dismutase 
activity, suggesting that an aberrant gain of function rather than a loss of function may 
be responsible for SOD1-mediated toxicity (Borchelt et al. 1994; Borchelt et al. 1995; 
Bowling et al. 1995; Rabizadeh et al. 1995). This view is strengthened by the fact that 
SOD1-deficient mice do not develop the same symptoms of motor neuron disease as 
transgenic mice expressing mutant SOD1 protein (Reaume et al. 1996). Given that 
oxidative stress is commonly observed both in ALS patients and in mice expressing 
high levels of mutant SOD1, the question arose as to whether the mutant SOD1 protein 
itself could catalyse the formation of ROS.  
There is some evidence to suggest that the mutant SOD1 protein participates in 
oxidative damage. Many ALS-associated SOD1 mutations result in structural changes 
to the protein (Deng et al. 1993; Wang et al. 2002), with mutant SOD1 showing 
reduced metal-binding ability compared to wild-type SOD1 (Lyons et al. 1996; 
Hayward et al. 2002; Das & Plotkin 2013). Structural changes to the SOD1 protein may 
expose the bound metal ions to novel substrates, resulting in metal-catalysed formation 
of reactive oxygen species (Beckman et al. 1993; Kitamura et al. 2011). Alternatively, it 
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has been demonstrated that metal-deficient mutant SOD1 species have an increased 
capacity for nitration of tyrosine residues with peroxynitrite (Ischiropoulos et al. 1992; 
Crow et al. 1997). Interestingly, oxidised wild type SOD1 protein also shows increased 
peroxidase-mediated nitration of tyrosine residues (Crow et al. 1997). In SOD1 mice, 
SOD1 proteins themselves are highly susceptible to oxidation (Andrus et al. 1998), 
indicating that under conditions of oxidative stress, oxidation of mutant or wild type 
SOD1 may change its function from a ROS scavenger to a mediator of oxidative 
damage, exacerbating disease processes. The metal status of SOD1 also appears 
important, with both zinc-deficient mutant SOD1 and zinc-deficient wild type SOD1 
protein inducing apoptosis in cultured motor neurons (Estevez et al. 1999).  
1.3.2.4 Nitric oxide synthesis in ALS 
Nitric oxide plays an important role in regulating blood flow and synaptic plasticitiy in 
the central nervous system (Iadecola et al. 1994; Holscher 1997). However, nitric oxide 
is also involved in oxidative damage through protein tyrosine nitration by peroxynitrite 
(Drechsel et al. 2012); formation of nitrotyrosine can alter protein enzymatic activity 
and increase the propensity of a protein to aggregate (Reynolds et al. 2007).  
Nitric oxide is synthesised from L-arginine by one of three nitric oxide synthase (NOS) 
enzymes: endothelial NOS (eNOS), neuron-specific NOS (nNOS), or inducible NOS 
(iNOS). eNOS and nNOS are constituitively expressed in endothelial cells and neurons, 
respectively, whereas iNOS expression is induced in glial cells in response to 
inflammatory cytokines or tissue damage (Murphy 2000). Upregulation of nNOS and 
iNOS in neurons and glial cells, respectively, has been observed in the spinal cord of 
ALS patients (Phul et al. 2000; Sasaki et al. 2000). iNOS was also observed in 
degenerating motor neurons, while nNOS expression has been observed in glial cells 
(Sasaki et al. 2000; Anneser et al. 2001). The induction of iNOS and nNOS in both 
neurons and glia indicates scope for increased nitric oxide production in both neuronal 
and glial cells, potentially increasing peroxynitrite formation and protein nitration.  
SOD1 mice show a depletion of nNOS-positive motor neurons (Lee et al. 2009). The 
loss of nNOS-positive motor neurons suggests that lower nNOS expression may confer 
a survival advantage when mutant SOD1 is expressed, possibly due to a lower rate of 
peroxynitrite formation and less oxidative damage to proteins in nNOS-negative motor 
neurons. Additionally, the increased expression of iNOS in glial cells of SOD1 mice 
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(Almer et al. 1999; Lee et al. 2009) may lead to increased NO synthesis in the ALS 
spinal cord. Microglial activation, and the increased production of NO due to alterations 
in the expression of the L-arginine-metabolising enzymes, iNOS and arginase 1 (Arg1), 
will be discussed in more detail in section 1.3.3.2.    
Thus, in both ALS patients and SOD1 mice, the increased production of nitric oxide 
may mediate increased oxidative damage to motor neurons. However, the cytotoxicity 
generated by mutant SOD1 in primary motor neuron cultures and in NSC34 motor 
neuron-like cells cannot be abrogated by inhibition of nitric oxide synthase, indicating 
that SOD1-mediated toxicity is not entirely explained by the formation of peroxynitrite 
species (Doroudchi et al. 2001; Cookson et al. 2002). 
1.3.2.5 The role of mitochondrial dysfunction in oxidative stress 
Mitochondria may play multiple roles in the pathogenesis of ALS, via oxidative stress, 
energy production, apoptosis, and interactions with misfolded SOD1 proteins. In 
relation to oxidative stress, mitochondria are a major source of cellular superoxide; 
superoxide is produced by the reaction of oxygen molecules with electrons which have 
escaped the respiratory electron transport chain (ETC) during oxidative phosphorylation 
(Mates et al. 1999). Inhibition of ETC components can increase the production of 
superoxide radicals, by causing upstream electron carriers to become fully reduced and 
unable to accept electrons from subsequent substrates, increasing electron leakage 
(Pelicano et al. 2003; Turrens 2003). Oxidative damage to ETC proteins can inhibit 
respiration, increasing the amount of superoxide produced and further damaging the 
respiratory chain proteins in a detrimental feedback cycle (Palacios-Callender et al. 
2004). Altered function of the mitochondria and of respiratory enzyme complexes has 
been reported in ALS patients and SOD1 mouse models – the possible role of 
mitochondria in ALS pathogenesis will be explored further in section 1.3.4.  
1.3.2.6 Oxidative stress and exposure to environmental toxins 
Exposures to pesticides and heavy metals are thought to be risk factors for developing 
ALS (Das et al. 2012; Trojsi et al. 2013). The toxicity of various pesticides has been 
linked to cholinesterase inhibition, but is increasingly also linked to oxidative stress 
(Banerjee et al. 2001; Turrens 2003). Similarly, the toxicity of heavy metal exposure is 
partly linked to redox-active and antioxidant-depleting properties of the metal in excess 
(Ercal et al. 2001). Genetic variants in PON genes, encoding paraoxonase enzymes 
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involved in the detoxification of organophosphate pesticides and the prevention of lipid 
oxidation (Shih et al. 1998), are associated with the development of sporadic ALS 
(Saeed et al. 2006; Slowik et al. 2006). Polymorphisms in glutathione synthetase, an 
enzyme which modulates production of the antioxidant glutathione, increased the risk of 
ALS under conditions of exposure to metals or solvents (Morahan et al. 2007). Thus, 
excessive exposure to environmental toxins, or the failure to appropriately detoxify 
toxic compounds, could be linked with the development of ALS due to oxidative stress.  
1.3.2.7 The Nrf2-ARE antioxidant response pathway in ALS 
A key cellular response to oxidative stress is mediated via the translocation of the 
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) to the nucleus, 
where Nrf2 binds to antioxidant-responsive elements (AREs) in the promoter region of 
antioxidant genes and promotes their transcription (Joshi & Johnson 2012). Genes under 
Nrf2-ARE control include enzymes involved in redox regulation such as superoxide 
dismutase, catalase, peroxiredoxin, thioredoxin, sulfiredoxin, and enzymes for 
glutathione synthesis (Joshi & Johnson 2012). The antioxidant protein metallothionein 
(MT), while containing an ARE sequence in its promoter region, is activated more 
strongly by the related Nrf1 transcription factor than by Nrf2 (Ohtsuji et al. 2008).  
In ALS patient spinal cord motor neurons, Nrf2 mRNA and protein levels were reduced 
compared with those of controls (Sarlette et al. 2008). Expression of mutant SOD1 in 
embryonic neurons depleted Nrf2-controlled glutathione synthesis enzymes and 
increased susceptibility to apoptosis induced by nerve growth factor/p75 signalling 
(Pehar et al. 2007). Interestingly, expression of mutant TDP43 in NSC34 cells 
prevented Nrf2-ARE-mediated induction of antioxidant genes (Duan et al. 2010), 
indicating that reduced oxidative stress responses may contribute to cell death in ALS.  
It is worth noting that the Nrf2-ARE pathways are activated more strongly in astrocytes 
than in neurons, but induction of Nrf2-ARE-mediated genes in astrocytes confers 
protection to neurons (Johnson et al. 2008). The role of astrocytes in ALS will be 
discussed further in section 1.3.3 on glia and neuroinflammation.     
From the evidence presented above, it appears that oxidative stress is involved in 
multiple aspects of ALS pathology. The convergence between oxidative stress and other 
potential pathogenic mechanisms in ALS will be discussed further in section 1.3.9.  
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1.3.3 Glial activation and neuroinflammation 
The mechanisms of neurodegeneration in ALS were originally thought to be cell-
autonomous; that is, intrinsic to the motor neurons themselves. However, there is 
increasing evidence to support the non-cell-autonomous hypothesis, that the 
involvement of non-neuronal cells is a central driver in disease pathology in ALS. 
Neuroinflammation, involving activation of both astrocytes and microglia, controls the 
production of neuroprotective or pro-inflammatory components and may modulate 
motor neuron degeneration in ALS. ALS patients show indications of 
neuroinflammation such as increased cytokine levels in the CSF (Sekizawa et al. 1998; 
Ilzecka et al. 2002), activation of astrocytes and microglia (Evans et al. 2013), and 
infiltration of immune cells from the systemic circulation (Kawamata et al. 1992).  
1.3.3.1 Astrocytes 
Astrocytes are glial cells which normally provide trophic support and maintain optimum 
conditions in the CNS for neuronal growth and survival (Vargas & Johnson 2010). 
Extensive astrogliosis is found in the brain and spinal cord of ALS patients (Kushner et 
al. 1991; Schiffer et al. 1996) and SOD1 mouse models of ALS (Wong et al. 1995; 
Bruijn et al. 1997b; Hall et al. 1998b). Astrogliosis is the abnormal proliferation of 
astrocytes, usually induced by neuronal damage; these proliferating astrocytes form a 
glial scar and produce growth-inhibitory extracellular matrix molecules (Fitch & Silver 
2008). While astrogliosis in ALS was initially thought to be a reactive response 
triggered by the presence of degenerating neurons, some SOD1 animal models of ALS 
have shown astrogliosis preceding motor neuron loss (Wong et al. 1995; Bruijn et al. 
1997b); suggesting that astrocytes may play an active role in neuronal degeneration in 
SOD1-mediated ALS (Vargas & Johnson 2010).  
SOD1-expressing astrocytes can induce motor neuron death in co-cultures (Nagai et al. 
2007) and when transplanted into WT mouse spinal cord in vivo (Papadeas et al. 2011). 
While astrocyte-specific expression of mutant SOD1 protein is not sufficient to induce 
an ALS phenotype (Gong et al. 2000), astrocyte-specific knockdown of mutant SOD1 
expression can delay disease onset in SOD1
G85R
 mice (Wang et al. 2011a) and affect the 
rate of disease progression in SOD1
G37R
 mice (Yamanaka et al. 2008). The difference 
between the two SOD1 mouse models may be due to differences in dismutase activity 
of the SOD1
G86R
 and SOD1
G37R
 mutant proteins (Wang et al. 2011a). Interestingly, 
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cultured astrocytes derived from both sporadic and familial ALS patients can induce 
motor neuron cell death, indicating a common link between SOD1-FALS and sporadic 
ALS (Haidet-Phillips et al. 2011; Meyer et al. 2014). 
SOD1-mediated pathology in SOD1 mice is not limited to motor neurons; SOD1-
positive inclusions can be observed in both motor neurons and astrocytes (Watanabe et 
al. 2001). The same pathological changes caused by mutant SOD1 expression in motor 
neurons, such as oxidative stress, mitochondrial dysfunction, dysregulation of protein 
homeostasis, and inhibition of intracellular transport, could easily be present in SOD1-
expressing astrocytes, and may disrupt normal astrocyte function. Activated astrocytes, 
or astrocytes expressing mutant SOD1 protein, show changes in protein expression 
which may contribute to motor neuron degeneration, as outlined below. 
Astrocytes expressing mutant SOD1 show a decrease in global protein secretion, 
indicating possible impairment of normal trophic support for motor neurons (Benkler et 
al. 2013). However, SOD1 astrocytes secrete increased amounts of mutant SOD1 
protein; this exosome-secreted SOD1 is internalised into motor neurons and causes 
toxicity, although the toxicity of other additional soluble astrocyte-released factors 
cannot be ruled out (Nagai et al. 2007; Basso et al. 2013). Activated astrocytes show 
decreased expression of glutamate reuptake transporters, which may exacerbate 
excitotoxicity in ALS (Bruijn et al. 1997b; Howland et al. 2002). Reactive astrocytes 
show increased production of neuroinflammatory molecules such as iNOS and nitric 
oxide (Cassina et al. 2002; Barbeito et al. 2004), cyclooxygenase and prostaglandins 
(Yiangou et al. 2006), nerve growth factor (Pehar et al. 2004), and pro-inflammatory 
cytokines (Hensley et al. 2006; Lee et al. 2013a), with detrimental effects on the health 
of motor neurons (Cassina et al. 2002; Barbeito et al. 2004; Okuno et al. 2004). 
Reactive astrocytes in ALS also show increased production of Fas ligand and nerve 
growth factor, which may trigger cell death in Fas-expressing or p75 neurotrophin 
receptor-expressing motor neurons (Vargas & Johnson 2010). The neuroinflammatory 
factors produced by astrocytes may play a direct role in motor neuron damage, or may 
cause activation of microglia and exacerbate neuroinflammation (Wang et al. 2011b). 
Thus, there are multiple possible mechanisms by which astrocytes may contribute to 
motor neuron degeneration. 
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1.3.3.2 Microglia 
Microglia are the resident immune cells of the central nervous system. Resting 
microglia constantly sense their environment and are rapidly activated in response to 
cytokines, chemokines, cellular debris, pathogen motifs such as LPS, and factors 
released by degenerating neurons (Dewil et al. 2007; Kraft & Harry 2011). Activated 
microglia can produce variable amounts of growth factors, cytokines, and reactive 
oxygen species, depending on the activating stimulus (Appel et al. 2011).  
Microglial proliferation and activation is widespread in the spinal cord tissue of ALS 
patients (Kawamata et al. 1992; Appel et al. 1993; Henkel et al. 2004), and also in 
SOD1 rat (Graber et al. 2010) and mouse (Hall et al. 1998b; Almer et al. 1999; 
Alexianu et al. 2001) ALS models. Some SOD1 rodent models show microglial 
activation preceding the onset of disease symptoms, implicating a possible causative 
role for neuroinflammation in the development of ALS (Alexianu et al. 2001; Graber et 
al. 2010). Replacement of SOD1
G93A
 microglia with wild type microglia by bone 
marrow transfer, or by microglia-specific knockdown of the mutant SOD1 transgene, 
increases survival time but does not alter disease onset (Boillee et al. 2006; Lee et al. 
2012), indicating that microglial SOD1 expression and microglial activation may 
accelerate the rate of disease progression after onset. However, ablation of proliferating 
microglia from SOD1 mice also caused an exacerbation of disease progression, 
indicating a protective role for microglia in ALS (Audet et al. 2012).  
These seemingly dual neuroprotective and pro-inflammatory roles for microglia may be 
explained by different phenotypes of microglial activation (Appel et al. 2011). As 
occurs with macrophages, microglia can adopt either an M1-like neurotoxic phenotype, 
or an M2-like neuroprotective phenotype, depending on the stimulus inducing 
microglial activation (Evans et al. 2013). The M1 phenotype is characterised by 
increased production of reactive oxygen species such as NO and pro-inflammatory 
cytokines such as TNFα and IL-6, and reduced production of growth factors and anti-
inflammatory cytokines; conversely, the M2 phenotype is characterised by increased 
production of BDNF and anti-inflammatory cytokines such as TGFβ and IL-10, and 
decreased production of pro-inflammatory cytokines (Appel et al. 2011). However, 
these M1 and M2 phenotypes likely exist on a spectrum of possible phenotypes rather 
than as a ‘pure M1’ or ‘pure M2’ phenotype, with the ultimate pro- or anti-
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inflammatory output of individual microglia based on their relative expression of 
protein markers and cytokines, and their reactive oxygen species production.  
In SOD1 mice, recent reports suggest that the M2 microglial phenotype appears to 
prevail until disease onset, and the M1 microglial phenotype appears predominant 
throughout the rapidly-progressing phase of disease (Beers et al. 2011b; Liao et al. 
2012). Cultured microglia expressing SOD1 show increased production of superoxide 
(Ferraiuolo et al. 2011) and decreased neuroprotective abilities (Sargsyan et al. 2011), 
indicating that expression of mutant SOD1 may push microglia towards an M1 
neurotoxic phenotype. In addition, activation of cultured microglia by extracellular or 
motor neuron-secreted mutant SOD1 increases microglial TNFα and ROS production; 
in turn, the factors produced by these SOD1-activated microglia are cytotoxic to motor 
neurons (Urushitani et al. 2006; Roberts et al. 2013).  
The toxicity of activated microglia to motor neurons may involve the production of NO 
(Thonhoff et al. 2012). Two enzymes involved in the metabolism of L-arginine, 
Arginase1 (Arg1) and iNOS, control NO production from microglia; increasing 
expression of Arg1 reduces NO production, while increasing expression of iNOS 
increases NO production (Andrew & Mayer 1999; Gobert et al. 2000; Ash 2004). M1-
activated microglia produce more NO than M2-activated microglia (Lewis et al. 2012a); 
the M2 phenotype displays higher levels of Arg1 and lower levels of iNOS, while the 
M1 phenotype displays lower levels of Arg1 and higher levels of iNOS (Colton 2009). 
Therefore, Arg1 and iNOS are putative markers of the microglial activation phenotype.   
The M1/M2 activation status of spinal cord microglia in SOD1 mice is also influenced 
by infiltrating T-cells (Beers et al. 2008), with T-regulatory cells promoting the 
neuroprotective M2 microglial phenotype (Beers et al. 2011a). The modulation of CNS 
microglial phenotype by T cells from the systemic circulation indicates that the 
peripheral immune system may play a role in determining microglial activation in ALS 
mice. Interestingly, ALS patients show alterations in circulating immune components 
such as plasma cytokine levels (Houi et al. 2002; Cereda et al. 2008) and T lymphocyte 
levels (Banerjee et al. 2008), which would suggest alterations of the adaptive immune 
system in ALS. 
Together these data suggest that neuroinflammation, mediated by astrocytes, microglia, 
and infiltrating immune cells, may prove detrimental to motor neurons in ALS.   
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1.3.4 Mitochondrial dysfunction  
Mitochondria are responsible for oxidative phosphorylation, intracellular calcium 
buffering, lipid metabolism, and regulation of apoptosis (Karbowski & Neutzner 2012). 
Damage to the mitochondria or the electron transport chain (ETC) results in a loss of 
ATP production (Berg et al. 2002), increased ROS production (Turrens 2003), loss of 
intracellular calcium buffering (Ferraiuolo et al. 2011), collapse of mitochondrial 
membrane potential, and ultimately cell death via apoptosis (Beltran et al. 2002). In 
ALS, mitochondrial alterations may be present in both motor neurons and muscle fibres.  
1.3.4.1 Mitochondrial alterations in ALS motor neurons 
ALS patients show reduced mitochondrial numbers in spinal cord motor neurons, and 
exhibit axonal clustering of mitochondria compared with controls (Sasaki & Iwata 
1996; Wiedemann et al. 2002). Spinal cord mitochondria from ALS patients are 
reported to have reduced levels and activity of electron transport chain protein 
complexes (Borthwick et al. 1999; Wiedemann et al. 2002; Ilieva et al. 2007); in some 
ALS patients, this may be explained by alterations in the mitochondrial DNA encoding 
ETC subunit proteins (Dhaliwal & Grewal 2000; Wiedemann et al. 2002).  
SOD1 mouse models of ALS show mitochondrial vacuolation and degeneration in 
spinal cord motor neurons (Wong et al. 1995; Kong & Xu 1998), with activation of the 
mitochondrial permeability transition pore thought to play a role in mitochondrial 
damage (Martin 2010). Spinal cord mitochondria from SOD1 rodents also show 
decreased ETC activity and increased ROS production, even preceding disease onset 
(Browne et al. 1998; Jung et al. 2002; Panov et al. 2011). Decreased ETC activity in 
symptomatic SOD1 mice is thought to result from decreased respiratory capacity, rather 
than uncoupling of the ETC from ATP synthesis (De Vos et al. 2012). Interestingly, 
there are reports of increased respiratory activity in the frontal and motor cortices of 
patients with SOD1-linked familial ALS (Bowling et al. 1993; Browne et al. 1998), 
which may indicate that disease processes differ between human and rodent SOD1-
linked ALS.  
1.3.4.2 Mitochondrial alterations in ALS muscle 
Mitochondria from the muscle tissue of ALS patients show impaired respiratory 
function, with reduced activity of ETC enzymes (Wiedemann et al. 1998; Krasnianski 
et al. 2005; Crugnola et al. 2010). Deficits in muscle mitochondrial function may be 
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minor at early stages of disease, but increase as the disease progresses (Echaniz-Laguna 
et al. 2002; Echaniz-Laguna et al. 2006). An energy deficit in skeletal muscle may 
induce denervation of neuromuscular junctions (Dupuis et al. 2004; Dupuis et al. 2009).  
Mitochondrial dysfunction and disorganisation has also been reported in the muscle of 
several animal model systems expressing ALS-related proteins. ATP production was 
decreased in isolated muscles from SOD1 mice (Leclerc et al. 2001; Derave et al. 
2003), with a pre-symptomatic upregulation of mRNA for alternative ATP-generating 
pathways in SOD1
G86R
 mice indicating a possible compensatory response to 
mitochondrial dysfunction (Gonzalez de Aguilar et al. 2008). Additionally, ALS-
associated mutations in vesicle-associated membrane protein (synaptobrevin)-associated 
protein B (VAPB) prevent the secretion of its major sperm protein domain from 
Drosophila melanogaster neurons (Tsuda et al. 2008); the loss of this secreted ligand 
leads to motor impairment in Caenorhabditis elegans due to altered mitochondrial 
positioning and function in the muscle (Han et al. 2013); thus, alterations in muscle 
mitochondrial function may predispose to ALS.  
1.3.4.3 Interaction between mutant SOD1 and mitochondria 
Two SOD isoforms are normally present in the mitochondria to detoxify superoxide 
radicals produced by the ETC: SOD1 in the intermembrane space, and SOD2 (Mn-
SOD) in the mitochondrial matrix (Turrens 2003). However, ALS-linked mutant SOD1 
shows abnormal binding to the cytosolic face of the outer mitochondrial membrane 
(MM) (Mattiazzi et al. 2002; Liu et al. 2004; Ferri et al. 2006; Vande Velde et al. 
2008), and to the inner MM in the intermembrane space (Mattiazzi et al. 2002; 
Ahtoniemi et al. 2008), with detrimental effects on mitochondrial function. Mutant 
SOD1 bound to the inner MM may produce ROS which damage ETC components 
(Ahtoniemi et al. 2008), potentially inhibiting respiration. Oligomeric forms of mutant 
SOD1 are associated with induction of apoptosis when bound to the outer MM are 
(Rabizadeh et al. 1995). Mutant TDP43 also causes mitochondrial injury in NSC34 
cells (Duan et al. 2010), indicating a possible shared mechanism between SOD1- and 
TDP43-mediated ALS. 
Thus, evidence from both ALS patients and ALS mouse models indicates that 
pathogenesis of ALS may be due to disruption of mitochondrial function in either motor 
neurons or skeletal muscle.   
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1.3.5 RNA processing dysfunction 
Sporadic ALS patients show widespread changes in motor neuron gene expression and 
mRNA splicing (Rabin et al. 2010). A number of RNA-processing proteins are 
associated with ALS and other motor neuron diseases, as discussed below.   
1.3.5.1 TDP43 and FUS 
TAR-DNA binding protein 43 (TDP43) and fused in sarcoma (FUS) are both 
DNA/RNA binding proteins which are major components of ubiquitinated protein 
inclusions in ALS and in frontotemporal dementia (FTD) (Neumann et al. 2006; 
Kwiatkowski et al. 2009; Vance et al. 2009). Mutations in TDP43 and FUS are 
associated with both familial and sporadic forms of ALS (Sreedharan et al. 2008; 
Kwiatkowski et al. 2009; Vance et al. 2009). TDP43 and FUS are usually localised to 
the nucleus, and have roles in multiple aspects of RNA processing such as transcription, 
exon splicing, microRNA biogenesis, and mRNA transport and stabilisation (Strong et 
al. 2007; Lagier-Tourenne & Cleveland 2009; Buratti et al. 2010). ALS-associated 
mutations cause mislocalisation of TDP43 and FUS to the cytoplasm, with their 
subsequent aggregation (Kabashi et al. 2008; Winton et al. 2008; Igaz et al. 2009; 
Kwiatkowski et al. 2009; Vance et al. 2009). Cytoplasmic aggregation of ALS-linked 
mutant TDP43 or FUS implies the development of pathology in ALS by either 
impairment of normal RNA processing, or sequestration of RNA and RNA-binding 
components in the cytoplasm (Siddique & Ajroud-Driss 2011; Lagier-Tourenne et al. 
2012). 
TDP43 and FUS are involved in the processing of thousands of pre-mRNA transcripts 
(Polymenidou et al. 2011), and regulate splicing of several genes involved in neuronal 
differentiation, survival, and synaptic function (Polymenidou et al. 2011; Tollervey et 
al. 2011; Lagier-Tourenne et al. 2012). TDP43 and FUS also show roles in stabilisation 
of mRNA for transport down the axon for localised protein translation (Kanai et al. 
2004; Wang et al. 2008; Fallini et al. 2012). Additionally, FUS plays a role in DNA 
damage repair (DDR) by recruiting DDR proteins to the sites of double-stranded breaks 
(Rulten et al. 2013; Wang et al. 2013). Aggregated pathological TDP43 proteins, and C-
terminal TDP43 fragments, appear hyperphosporylated and insoluble (Neumann et al. 
2006; Kabashi et al. 2008; Winton et al. 2008; Igaz et al. 2009), supporting the idea that 
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the loss normal TDP43 RNA-processing function may lead to the development of ALS 
(Polymenidou et al. 2011), 
However, aggregated cytoplasmic TDP43 displays aberrant interactions with other 
cytoplasmic components (Ravits et al. 2013), and may sequester essential RNA-
processing components such as heterogeneous nuclear ribonuclear proteins, with which 
TDP43 would normally associate in a spliceosome complex (Buratti et al. 2005). 
TDP43 aggregation may indirectly affect RNA processing by sequestration of other 
RNA-processing proteins. Thus, the loss of RNA-binding function by TDP43 and FUS, 
or their sequestration of other RNA-binding components in the cytoplasm, may play a 
role in ALS pathogenesis.  
1.3.5.2 Other RNA-binding proteins associated with motor neuron diseases  
Several proteins with various functions in RNA metabolism are associated with the 
development of motor neuron diseases other than ALS.  
Mutations in senataxin (SETX), a DNA/RNA helicase with roles in the initiation and 
termination of mRNA transcription, the resolution of DNA /RNA hybrids, and mRNA 
splicing (Suraweera et al. 2009; Skourti-Stathaki et al. 2011; Bennett et al. 2013; Yuce 
& West 2013), are associated with childhood- and juvenile-onset forms of ALS and 
hereditary ataxia (Chen et al. 2004; Moreira et al. 2004). Varying lengths of poly-
glutamine repeat expansions in the RNA-binding protein, Ataxin2, lead to 
spinocerebellar ataxia type 2 and increased risk for sporadic ALS (Imbert et al. 1996; 
Pulst et al. 1996; Sanpei et al. 1996; Elden et al. 2010). Angiogenin, mutations in which 
are associated with ALS (Greenway et al. 2004), requires its RNAse activity to provide 
neuroprotection in response to stress (Aparicio-Erriu & Prehn 2012). Reduced 
expression of survival of motor neuron (SMN) protein, required for the formation of 
small nuclear ribonucleoproteins in the spliceosome complex, causes spinal muscular 
atrophy (Lefebvre et al. 1995; Fischer et al. 2011). Variations in the FUS-related RNA-
processing protein, TAF15, are linked with ALS risk (Ticozzi et al. 2011).  
Finally, the ALS/FTD-associated hexanucleotide repeat expansion in C9orf72 produces 
repeat-containing RNA, which forms nuclear RNA foci (DeJesus-Hernandez et al. 
2011). These foci sequester RNA-binding proteins and prevent normal RNA processing, 
causing cellular toxicity (Lee et al. 2013b).  
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Together, these data suggest a role for impaired RNA processing in ALS aetiology.  
1.3.6 Excitotoxicity 
In the motor system, signals are transmitted from upper to lower motor neurons through 
the release of the neurotransmitter glutamate from the pre-synaptic membrane. 
Glutamate activates glutamate receptors on the lower motor neuron, allowing influx of 
calcium into the cell. Calcium activates many intracellular pathways, so intracellular 
calcium levels are tightly controlled. Excitotoxicity is the excessive stimulation of 
ionotropic glutamate receptors, overloading intraneuronal calcium-buffering capacity 
and leading to cell death through calcium-dependent pathways (Ferraiuolo et al. 2011; 
Bae et al. 2013). Excitotoxicity is implicated in ALS pathogenesis, with increased levels 
of neuronal calcium reported in ALS patients (Siklos et al. 1996).  
Furthermore, the only effective drug which can mildly slow disease progression in ALS 
patients is Riluzole (Bensimon et al. 1994), a drug which is thought to act by altering 
multiple aspects of glutamate dynamics around the synapse (Martin et al. 1993; 
Lamanauskas & Nistri 2008; Cheah et al. 2010). Together, these data suggest that 
excitotoxicity plays an aetiological role in ALS. Glutamate excitotoxicity in ALS could 
be mediated by deficits in glutamate-reuptake proteins, by excessive glutamate release 
from upper motor neurons, or by intrinsic factors specific to motor neurons. 
1.3.6.1 Deficits in glutamate handling 
In line with deficits in glutamate handling, the distribution of glutamate appears to be 
altered in ALS. ALS patients show elevated levels of glutamate in both CSF (Rothstein 
et al. 1990) and plasma (Plaitakis et al. 1988), but show decreased glutamate levels 
within the spinal cord tissue, implicating redistribution of glutamate from the 
intracellular to the extracellular compartment (Plaitakis et al. 1988).  
Glutamate is normally cleared from the synaptic cleft by astrocytes expressing the 
glutamate transporter, excitatory amino acid transporter 2 (EAAT2). The glial 
expression of EAAT2 was reduced in the spinal cord of ALS patients (Rothstein et al. 
1995), and the expression level of the mouse EAAT2 homologue was reduced in the 
SOD1 mouse spinal cord (Bendotti et al. 2001). These data indicate that faulty 
glutamate reuptake from the synaptic cleft in ALS may be responsible for the increased 
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levels of glutamate in ALS CSF, potentially leading to excitotoxicity in ALS via 
excessive activation of glutamate receptors on the post-synaptic membrane.  
1.3.6.2 Excessive glutamate release and glutamate receptor stimulation 
In line with excessive glutamate release from upper motor neurons, cortical motor 
neurons exhibit hyperexcitability (Bae et al. 2013). Excessive firing of upper motor 
neurons would lead to increased glutamate levels in the synaptic cleft, chronically 
stimulating glutamate receptors on lower motor neurons and potentially leading to 
excitotoxicity. The hyperexcitability of motor neurons could be due to loss of inhibitory 
synaptic inputs from cortical or spinal interneurons (Sunico et al. 2011; Turner & 
Kiernan 2012; Bae et al. 2013).  
Excitotoxicity may be exacerbated in ALS by elevated levels of the NMDA receptor co-
agonist, D-serine, which have been reported in both SOD1 mouse and ALS patient 
spinal cord (Sasabe et al. 2007). Familial ALS in some patients is associated with 
mutations in D-amino oxidase, which normally degrades D-serine (Mitchell et al. 
2010), strengthening an association between excitotoxicity and ALS. 
Additionally, the diet of the Chamorro people of the Mariana Islands can be high in 
cyanobacteria-derived glutamate receptor agonist and excitotoxin, β-methylamino-L-
alanine, implicating the dietary ingestion of an environmental excitotoxin  in the 
historical high prevalence of ALS in Guam (Papapetropoulos 2007; Chiu et al. 2011).  
1.3.6.3 Motor neuron-specific vulnerability to excitotoxicity 
Motor neurons may be specifically vulnerable to glutamate-mediated excitotoxicity. 
This may be partly due to low expression of calcium-binding proteins, which might 
limit ability of motor neurons to handle a large calcium influx (Appel et al. 2001). 
Motor neurons express low levels of the calcium-impermeable GluR2 AMPA receptor 
subunit (Kawahara et al. 2003). Additionally, motor neurons in ALS show deficient 
editing of the GluR2 AMPA receptor subunit mRNA at the Q/R site, resulting in ALS-
affected motor neurons expressing calcium-permeable AMPA receptors (Kawahara et 
al. 2004; Kwak & Kawahara 2005). These motor neuron-specific factors may 
predispose motor neurons to excitotoxic cell death, and underlie the selective 
degeneration of motor neurons and the relative sparing of sensory neurons in ALS (Van 
Den Bosch et al. 2000).  
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Therefore, multiple lines of evidence suggest excitotoxicity as a possible mechanism for 
motor neuron degeneration in ALS.  
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1.3.7 Protein misfolding and protein degradation pathways 
1.3.7.1 Misfolded proteins in ALS 
Ubiquitinated protein aggregates are a pathological hallmark of both sporadic and 
familial ALS. Polyubiquitin chains target misfolded proteins for degradation through 
the proteasome or via autophagy. The protein products of many ALS-related genes are 
found within ubiquitinated aggregates in the cytoplasm of motor neurons in ALS, 
notably SOD1, TDP43, FUS, p62, OPTN, UBQLN2 and neurofilaments (Ravits et al. 
2013). ALS-linked mutations in SOD1 and TDP43 proteins increase their propensity for 
misfolding and aggregation (Bruijn et al. 1998; Johnston et al. 2000; Wang et al. 2002; 
Furukawa & O'Halloran 2005; Johnson et al. 2009). In addition, the ALS-associated 
C9orf72 repeat expansion (DeJesus-Hernandez et al. 2011) produces RNA which 
undergoes repeat-associated non-ATG translation (Zu et al. 2011) to produce dipeptide 
repeat proteins, which form cytoplasmic aggregates (Mori et al. 2013).  
Misfolded and aggregated proteins could perturb normal neuronal metabolism in a 
number of ways. The aggregation of proteins into cytoplasmic inclusions may impair 
the normal function of the aggregated proteins, sequester other protein or mRNA 
species which interact with the aggregated proteins, or overwhelm protein degradation 
mechanisms (Blokhuis et al. 2013). Mammalian cells have several mechanisms for 
dealing with the presence of unfolded proteins. Misfolded proteins in the endoplasmic 
reticulum (ER) trigger ER stress responses, while ubiquitinated proteins in the 
cytoplasm are degraded by the proteasome or through autophagy (Xu et al. 2005). Some 
proteins found in ALS aggregates have normal functions in protein degradation 
pathways, such as p62, OPTN, and UBQLN2 (Fecto & Siddique 2011). The formation 
of aggregates containing ubiquitinated proteins, including those with roles in protein 
degradation pathways, links faults in protein degradation pathways with the 
development of ALS pathology (Fecto & Siddique 2011).  
1.3.7.2 ER stress and the unfolded protein response 
The ER is an important site for the folding of nascent polypeptides (Schroder 2008). 
Accumulation of unfolded proteins within the ER (ER stress) triggers a series of events 
intended to clear the ER of unfolded proteins, the unfolded protein response (UPR) (Xu 
et al. 2005). Initially, the UPR upregulates protein chaperones involved in protein 
folding, and promotes removal of unfolded proteins from the ER for degradation by the 
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proteasome; however, prolonged ER stress triggers pro-apoptotic pathways (Xu et al. 
2005). Induction of the UPR, and of apoptotic mediators, can be observed in the spinal 
cords of sporadic ALS patients and SOD1 rodents (Ilieva et al. 2007; Atkin et al. 2008). 
Mutations in VCP, a protein which mediates removal of misfolded proteins from the ER 
for degradation (Raasi & Wolf 2007; Yang et al. 2013), are associated with familial 
ALS (Johnson et al. 2010). VAPB, whose mutations are also associated with ALS 
(Nishimura et al. 2004), is thought to induce the UPR in response to ER stress 
(Kanekura et al. 2006; Suzuki et al. 2009; Chen et al. 2010). Mutations in SIGMAR1, 
another ER-stress-modulating protein, have been implicated in familial ALS (Al-Saif et 
al. 2011; Ha et al. 2011), although a recent study suggests that SIGMAR1 mutations 
segregate closely with c9orf72 expansions (Belzil et al. 2013). Impairment of UPR 
pathways may exacerbate ER stress and induce cell death in ALS.  
1.3.7.3 The ubiquitin-proteasome system and the autophagy system 
The proteasome complex mediates the unfolding and degradation of polyubiquitinated 
proteins (Jung & Grune 2013), while autophagy engulfs protein aggregates and 
organelles in membrane-bound vesicles for degradation through fusion with lysosomes 
(Chen et al. 2012). Autophagy degrades long-lived proteins, but excessively-induced 
autophagy can lead to autophagic cell death (Nagley et al. 2010; Chen et al. 2012). 
Several proteins whose mutations are associated with ALS are involved in protein 
degradation pathways. VCP is required for the maturation of autophagic vesicles (Ju et 
al. 2009). UBQLN2 binds to polyubiquitin chains and to the proteasome, directing the 
degradation of ubiquitinated proteins (Deng et al. 2011); ubiquilins are also required for 
the formation of autophagic vesicles (N'Diaye et al. 2009). p62 is also involved in the 
transport of ubiquitinated proteins to the proteasome and to autophagic vesicles 
(Seibenhener et al. 2004; Pankiv et al. 2007; Fecto et al. 2011). Charged multivesicular 
body protein 2B (CHMP2B) acts in an endosomal sorting complex in the formation of 
multivesicular bodies in autophagy (Parkinson et al. 2006; Rusten & Simonsen 2008). 
FIG4 may mediate formation and clearance of autophagic vesicles (Chow et al. 2009; 
Ferguson et al. 2009), while OPTN functions as an adaptor molecule facilitating 
autophagosome-lysosome fusion (Maruyama et al. 2010; Tumbarello et al. 2013).  As 
multiple genes involved in ER stress and protein degradation pathways show ALS-
linked mutations, accumulation of misfolded proteins and protein degradation pathway 
dysfunction could play a role in ALS pathogenesis.  
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1.3.8 Intracellular transport deficits  
Intracellular transport to deliver cellular components to their required location is a vital 
function for all living cells; motor neurons, however, have a particularly high demand 
for intracellular transport in order to sustain the distal portions of their long axons 
(Collard et al. 1995). Deficits in axonal transport may result in insufficient distal 
delivery of organelles and proteins required for axonal maintenance and synaptic 
function, insufficient recycling of faulty synaptic components, and blockage of trophic 
factor signalling pathways (Breuer et al. 1987). The delivery of cytoskeletal proteins, 
and their proper assembly at the distal axon, is essential for axonal maintenance in 
motor neurons (Lariviere & Julien 2004). At the cell body, transport deficits may 
interfere with ER-Golgi transport and with autophagy. Trafficking of organelles, 
vesicles, and proteins around the cell body and along axons is mediated by molecular 
motor proteins moving along cytoskeletal protein tracks (Hirokawa 1998). Intracellular 
transport deficits appear to play a role in the pathophysiology of ALS – both 
anterograde and retrograde axonal transport are decreased in ALS patients (Breuer et al. 
1987; Sasaki & Iwata 1996), and SOD1 and TDP43 mouse models of ALS also show 
impairment of axonal transport (Zhang et al. 1997; Murakami et al. 2001; Magrane et 
al. 2013).  
1.3.8.1 Molecular motor proteins in ALS 
Dyneins and kinesins are the motor proteins responsible for retrograde and anterograde 
transport, respectively. The dynein molecular motor is a large complex of proteins 
including dynein subunits and dynactin, which plays a role in facilitating interaction 
between the dynein motor, the cargo and the microtubule track (Waterman-Storer et al. 
1995; Waterman-Storer et al. 1997). Both ALS patients and SOD1 mice show 
decreased levels of dynactin mRNA (Kuzma-Kozakiewicz et al. 2013b), and mutations 
of dynactin subunits cause a slowly-progressive MN disease in humans (Puls et al. 
2003; Munch et al. 2004) and in mice (Hafezparast et al. 2003; Laird et al. 2008). 
Additionally, ALS patients show lower expression of kinesin family proteins than 
controls (Pantelidou et al. 2007; Kuzma-Kozakiewicz et al. 2013a), showing that ALS 
may be associated with the disruption of both retrograde and anterograde transport. The 
mutant SOD1 protein may interact with kinesin-associated proteins or with subunits of 
the dynein/dynactin complex (Ligon et al. 2005; Zhang et al. 2007; Tateno et al. 2009), 
disrupting their normal roles in axonal transport.   
______________________________________________Chapter 1 – Literature Review 
______________________________________________________________________ 
______________________________________________________________________ 
 
30 
 
1.3.8.2 Cytoskeletal protein alterations in ALS 
Cytoskeletal elements in motor neurons comprise microtubules, intermediate filaments, 
and actin microfilaments, and alterations to these proteins are associated with ALS.  
1.3.8.2.1 Microtubule alterations 
Microtubules provide structural support for the neuron and form the network along 
which molecular motor proteins move, but may become destabilised in ALS. 
Microtubule-associated proteins (MAPs), which stabilise microtubules, are 
downregulated or show production of aberrant isoforms in SALS patients (Binet & 
Meininger 1988; Jiang et al. 2005), while aberrant isoform production and increased 
phosphorylation of the MAP tau are observed in SOD1 mouse models (Farah et al. 
2003; Usarek et al. 2006). Disruptions of the microtubule cytoskeleton may play a role 
in ALS, through the loss of cytoskeletal structure or the inhibition of axonal transport.  
1.3.8.2.2 Intermediate filament alterations 
Intermediate filament proteins – neurofilaments, peripherin, and α-internexin – anchor 
organelles, maintain cytoarchitecture, and prevent tension on the axon (Szaro & Strong 
2010). The correct expression level and phosphorylation status of peripherin and of the 
neurofilament triplet protein subunits are important for the normal formation of 
neurofilament networks (Straube-West et al. 1996; Beaulieu et al. 2000; Robertson et 
al. 2001). Intermediate filaments are normally moved down the axon via anterograde 
axonal transport, but are frequently observed in motor neuron cell body inclusions and 
in proximal axonal spheroids in ALS patients (Migheli et al. 1993) and SOD1 mice 
(King et al. 2011), suggesting improper intermediate filament trafficking in ALS.      
Mutations in neurofilament and peripherin genes are associated with a small number of 
sporadic ALS patients; these mutations may promote intermediate filament aggregation 
and impair axonal transport, through aberrant isoform production or through 
hyperphosphorylation (Figlewicz et al. 1994; Al-Chalabi et al. 1999; Gros-Louis et al. 
2004; Leung et al. 2004; Xiao et al. 2008). Expression of aberrant neurofilament 
isoforms in mice leads to neurofilament aggregation and motor neuron degeneration 
(Cote et al. 1993; Lee et al. 1994; Collard et al. 1995). The presence of accumulated 
neurofilaments in the proximal axon may impair the process of axonal transport as a 
whole, by sequestering motor proteins or by physically blocking the axon (Zhang et al. 
1997).  
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1.3.8.3 Vesicle trafficking deficits in ALS 
Several proteins involved in vesicle transport and intracellular protein trafficking are 
associated with ALS (Ferraiuolo et al. 2011; Soo et al. 2011). ALS patient motor 
neurons show fragmentation of the Golgi apparatus, indicating possible disruption of 
the intracellular protein shuttling pathways (Gonatas et al. 1992; Okamoto et al. 2010). 
Many ALS-associated gene mutations are in proteins involved in vesicle trafficking.  
Actin filaments and their associated myosin motor proteins, as well as microtubules and 
their dynein/kinesin motor proteins, facilitate transport of membrane-bound vesicles 
between intracellular compartments (Chevalier-Larsen & Holzbaur 2006; Laird et al. 
2008). Mutations in profilin1, a protein required for actin filament formation, are 
associated with familial ALS (Wu et al. 2012). Mutations in alsin, a protein involved in 
endosomal trafficking and fusion, and actin cytoskeleton rearrangement in growth cones 
(Topp et al. 2004), are linked to juvenile-onset primary lateral sclerosis (Yang et al. 
2001). FIG4, a phosphoinositide phosphatase which mediates the retrograde trafficking 
of endosomal vesicles to the Golgi network, shows mutations in sporadic and familial 
ALS patients (Chow et al. 2009). Mutations in OPTN were identified in familial and 
sporadic ALS patients (Maruyama et al. 2010); OPTN is involved in vesicle and 
lysosome trafficking, and protein secretion from the Golgi apparatus, in conjunction 
with Rab8 and myosin IV proteins (Sahlender et al. 2005). 
VAPB is an integral membrane protein which localises to the ER and to ER-Golgi 
intermediates, and is involved in vesicle transport (Skehel et al. 2000; Tran et al. 2012). 
Mutations in VAPB are associated with ALS, and VAPB expression may be reduced in 
the motor neurons of ALS patients (Nishimura et al. 2004; Teuling et al. 2007). 
Mutations in VAPB may perturb its interaction with microtubules, disorder the ER, 
contribute to the fragmentation of the Golgi apparatus and prevent transport of proteins 
on the ER-Golgi axis (Mitne-Neto et al. 2007; Teuling et al. 2007; Gkogkas et al. 2008; 
Fasana et al. 2010; Papiani et al. 2012). Additionally, expression of mutant SOD1 
inhibits the classical ER-Golgi secretory pathway (Atkin et al. 2013), and the normal 
function of C9orf72 may relate to membrane trafficking (Levine et al. 2013). 
Thus, several proteins involved in ALS have vital functions in both axonal transport and 
intracellular protein and vesicle trafficking, suggesting transport deficits contribute to 
the pathophysiology of ALS.  
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1.3.9 Convergent pathological mechanisms in ALS aetiology 
The major pathophysiologies involved in ALS are oxidative stress, neuroinflammation 
and glial activation, mitochondrial dysfunction, RNA processing, excitotoxicity, protein 
aggregation and dysfunction of protein degradation, and inhibition of intracellular 
transport. The presence of multiple molecular mechanisms causing similar phenotypes 
suggests a downstream convergence of mechanisms (Ravits et al. 2013). While each 
possible cause of ALS has been considered separately in the previous sections, these 
cellular processes are in reality interwoven, with alterations in a given pathway having 
downstream effects on other ALS-related pathways. This section will attempt to outline 
some of the convergence points which may be related to ALS pathophysiology.   
1.3.9.1 Oxidative stress as a convergence point 
Oxidative stress is intricately linked to a number of other pathways affected in ALS, 
occurring either upstream of, or as a consequence of, other ALS-associated pathways. 
First, oxidative stress could contribute to protein aggregation. Protein oxidation and 
nitration can increase the propensity of proteins such as SOD1 to aggregate and can 
induce improper neurofilament assembly and aggregation (Chou et al. 1996; Crow et al. 
1997; Sasaki et al. 2000; McLean & Robertson 2011). An oxidative environment may 
also promote the formation of protein aggregates through inter-molecular disulphide 
bond formation (Banci et al. 2008), with protein aggregation placing pressure on the 
proteasome and autophagy systems. Oxidative stress can cause ER stress (Soo et al. 
2011); interestingly, mutant proteins undergoing several rounds of oxidative folding in 
the ER due to their incorrect folding may increase the production of ROS from the ER 
as well as triggering ER stress (Schroder 2008).  
Second, oxidative stress is both an upstream cause of and a downstream effect of 
mitochondrial dysfunction. Oxidative damage can inhibit the mitochondrial respiratory 
chain enzymes, causing mitochondrial dysfunction (Poderoso et al. 1996; Drechsel et 
al. 2012), and contributing to mitochondrial permeability transition pore opening and 
apoptosis (Chernyak 1997). In turn, respiratory chain inhibition increases the formation 
of reactive oxygen species and further contributes to oxidative stress (Turrens 2003).  
Third, oxidative stress is linked to excitotoxicity. Oxidative damage to the glutamate 
reuptake transporter EAAT2 in astrocytes may inactivate the receptor, prevent 
glutamate clearance from the synaptic cleft, and contribute to excitotoxicity (Trotti et al. 
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1999). Stimulation of NMDA receptors can induce the production of superoxide 
radicals (Lafon-Cazal et al. 1993; Al-Chalabi et al. 1995), and elevated calcium 
concentration can cause isolated mitochondria to produce hydroxyl radicals (Dykens 
1994), providing a link between excitotoxicity and oxidative stress. 
Fourth, oxidative stress may play a role in glial cell activation. Nitric oxide is a key 
effector of astrocyte-mediated toxicity to motor neurons (Ferri et al. 2004; Vargas & 
Johnson 2010), while Fas ligand released from activated astrocytes causes ROS-
mediated damge in motor neurons through respiratory chain inhibition (Beltran et al. 
2002). Oxidative stress also acts as a trigger for neuroinflammation (Mates et al. 1999).  
Fifth, protein and RNA oxidation may contribute to global protein dysregulation and 
dysfunction. Oxidative or nitrative damage to proteins can alter normal protein structure 
and function (Reynolds et al. 2007); oxidative stress could conceivably impact on any 
of the other pathways involved in ALS by oxidative damage to the relevant proteins. As 
mentioned earlier, mRNA oxidation can prevent normal protein expression (Chang et 
al. 2008); uncontrolled oxidative stress therefore has the potential to alter the expression 
levels of proteins involved in multiple cellular pathways.  
Much of the information on ALS-associated pathways comes from research on animal 
models expressing mutant SOD1 protein, so it is reasonable to question their validity 
when applied to non-SOD1 ALS. However, the gain of toxic properties by oxidised 
wild-type SOD1 protein (Deng et al. 2006; Furukawa et al. 2006; Ezzi et al. 2007), and 
production of oxidative stress associated with mutant TDP43 (Duan et al. 2010), 
suggest that motor neurons in both sporadic ALS and SOD1-mediated familial ALS 
may experience common degenerative pathways downstream of mutant or oxidatively-
damaged SOD1 protein, further implicating oxidative stress in the pathogensis of ALS. 
1.3.9.2 Mitochondrial dysfunction as a convergence point 
Mitochondrial dysfunction is closely linked to oxidative stress, as outlined above, but is 
also linked to excitotoxicity and to activation of the autophagy system. Increased 
calcium levels from excitotoxic stimuli contribute to mitochondrial dysfunction, loss of 
the electrochemical gradient across the inner mitochondrial membrane, mitochondrial 
permeability transition pore formation, and apoptosis (Martin 2010). The autophagy 
system functions in mitochondrial quality control, by degrading damaged mitochondria 
______________________________________________Chapter 1 – Literature Review 
______________________________________________________________________ 
______________________________________________________________________ 
 
34 
 
to limit their production of ROS (Dodson et al. 2013). Widespread dysfunction of 
mitochondria may overwhelm the normal capacity of the autophagy system, and impair 
the autophagy-mediated degradation of protein aggregates.  
Mitochondrial dysfunction and the associated loss of ATP production can impair 
energy-dependent cellular processes necessary for normal cellular function; in motor 
neurons, the energy demands are large due to the large cytoplasmic volume and the 
requirement to maintain appropriate axonal transport to and from the neuromuscular 
junction (Ferraiuolo et al. 2011; Ludolph et al. 2012). The energy deficit created by 
dysfunction of mitochondria could potentially impact on any of the ATP-dependent 
cellular processes which are linked with ALS.  
1.3.9.3 Excitotoxicity as a convergence point 
The role of excitotoxicity and elevated calcium levels have been discussed in the 
context of oxidative stress and mitochondrial dysfunction; but intracellular calcium 
levels also modulate other pathways related to ALS. Intracellular calcium levels are a 
regulator of axonal transport, with elevated calcium dissociating molecular motors from 
microtubules (Breuer & Atkinson 1988a, 1988b; Morotz et al. 2012). Neurofilament 
phosphorylation and aggregation can also be mediated by glutamate-stimulated 
activation of calcium-sensitive kinases (Al-Chalabi et al. 1995; Takeuchi et al. 2005), 
implicating excitotoxicity as a potential upstream mechanism of impaired intracellular 
transport. Additionally, excitotoxicity and calcium dysregulation can induce ER stress 
and autophagy (Tarabal et al. 2005; Ilieva et al. 2007; Soo et al. 2011), possibly due to 
dysfunction of calcium-sensitive folding proteins within the ER (Prell et al. 2013).  
1.3.9.4 Glial activation as a convergence point 
Astrocytes are intricately linked with excitotoxicity due to their modulation of the 
expression of glutamate reuptake transporters (Vargas & Johnson 2010). Interactions 
between glial cells and motor axons may underlie the formation of axonal spheroids 
(King et al. 2011) – microglial activation in culture induces both the accumulation of 
neurofilaments and the decrease of axonal transport by molecular motors, through the 
activation of NMDA receptors (Takeuchi et al. 2005). TNFα can also disrupt kinesin 
function, by activation of intracellular kinase pathways (De Vos et al. 2000).  
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1.3.9.5 Intracellular transport as a convergence point 
Intracellular transport impairments in ALS may be linked to functional deficits in the 
axon terminal, excitotoxicity and protein degradation impairment. Impaired intracellular 
transport of mitochondria and other essential synaptic components to the axon terminal 
may result in an energy deficit or impaired function at the neuromuscular junction, 
causing the axon terminal to detach from the muscle in a ‘dying-back’ mechanism 
(Cozzolino & Carri 2012). It is possible that altered intracellular trafficking pathways 
may result in reduced internalisation of glutamate receptors from the post-synaptic 
membrane, contributing to excitotoxicity (Hirling 2009). Motor proteins contribute to 
the trafficking of autophagic vesicles, and thus play a role in autophagic clearance of 
misfolded and aggregated proteins (Soo et al. 2011; Ikenaka et al. 2013).  
1.3.9.6 Protein degradation pathways as convergence points 
The argument for protein aggregation and protein degradation pathways as a common 
downstream pathway is led by the ubiquitous presence of aggregated proteins in ALS, 
and the presence of ALS-associated mutations in a number of genes encoding protein 
degradation pathway proteins (Fecto & Siddique 2011). The accumulation of misfolded 
proteins, and resultant ER stress, could alter ER-mitochondrial calcium dynamics, 
making motor neurons more susceptible to excitotoxic stress (Ferraiuolo et al. 2011).  
1.3.9.7 RNA processing as a convergence point 
Deficits in RNA processing could impact a wide range of ALS-associated pathways. In 
particular, TDP43 and FUS appear to regulate splicing of several genes encoding ALS-
associated, autophagy-related proteins – CHMP2B, FIG4, OPTN, VAPB, and VCP 
(Ling et al. 2013). Aberrant astrocytic RNA processing may additionally impair the 
function of the EAAT2 astrocytic glutamate transporter, contributing to glutamate 
excitotoxicity (Lin et al. 1998). In addition, oxidative stress and ER stress may increase 
the formation of neuronal stress granules, sequestering RNA-binding proteins and their 
associated RNAs into aggregates (Kedersha et al. 1999; Bentmann et al. 2013; Walker 
et al. 2013). Pathological events resulting in irreversible protein aggregation in stress 
granules, or inability to reverse stress granule formation, may result in TDP43- or FUS-
containing aggregates in ALS (Ling et al. 2013). 
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1.3.9.8 Summary of convergence points 
In summary, many pathways appear to be involved in the disease pathogenesis of ALS, 
and there is much cross-talk between the various pathways involved. However, as 
outlined above through the convergence of ALS-linked pathways, oxidative stress does 
appear to stand out as a highly involved pathway. Oxidative stress is a potential cause of 
mitochondrial dysfunction, protein aggregation, ER stress, autophagy and glial 
activation; oxidative stress is also produced downstream of mitochondrial dysfunction, 
glial activation, and ER stress. The oxidative stress seen in mouse models of ALS and in 
ALS patients may be a primary initiator of disease processes or a downstream 
consequence of disease processes. The targeting of oxidative stress may therefore be an 
efficient way to 1) prevent primary oxidative damage to motor neurons and their 
organelles, and 2) prevent the downstream oxidative damage caused by upstream 
aetiological events such as mitochondrial dysfunction. Antioxidant-based therapies may 
be useful in preventing damage to cells and organelles in ALS. 
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1.4 Therapeutic strategies to combat ALS 
As demonstrated by the multitude of convergence points in ALS (section 1.3.9), there 
are many pathways that are thought to be involved in ALS aetiology and many possible 
therapeutic strategies to combat these pathways. Multi-functional therapeutic strategies, 
involving compound mixtures or compounds known to have multiple functions, may be 
the best approach in providing a treatment for ALS. Some potential therapeutic options 
in the treatment of ALS, namely Gemals compound, metallothionein protein, and Emtin 
peptide derivatives of metallothionein, are discussed briefly below.  
1.4.1 Gemals 
Gemals is a cocktail of small molecules – fatty acids, amino acids, vitamins, and 
antioxidants – that has been shown to have beneficial effects on the survival of a SOD1 
rats, but has not yet been tested in SOD1 mice (Nicaise et al. 2008). Gemals is a kind of 
‘Endotherapia’ therapy, intended to have antioxidant, immunomodulatory, and 
neuroprotective activity for the amelioration of complex neurodegenerative disease 
(Geffard et al. 2010). The compounds comprising Gemals are listed in Table 3.1, and 
the chemical composition of the drug mixture is detailed in Table 3.2.  
1.4.2 Metallothionein and Emtins 
Metallothioneins (MTs) are small, metal-binding proteins rich in cysteine residues 
(Aschner 1996). MT proteins act as potent antioxidants (Thornalley & Vasak 1985), and 
the MT-1 and MT-2 isoforms (MT-1/2) are known to have neuroprotective properties:  
MT-1/2 is upregulated by astrocytes and secreted extracellularly in response to neuronal 
damage (Chung et al. 2008a); extracellularly applied MT-1/2 promotes neurite 
outgrowth in vitro (Chung et al. 2003; Kohler et al. 2003) and in vivo after neuronal 
injury (Chung et al. 2003; Fitzgerald et al. 2007). MT-1/2 is known to be protective in 
the context of ALS: genetic alteration of MT-1/2 levels in SOD1 mice show a positive 
correlation between MT-1/2 expression and survival time (Nagano et al. 2001; 
Puttaparthi et al. 2002; Tokuda et al. 2013). Therefore, administration of MT-2 may be 
able to increase survival time in SOD1 mice. Emtins are peptide derivatives of the 
human MT2 protein that show similar neuroprotective properties to the parent MT2 
molecule (Ambjorn et al. 2008; Asmussen et al. 2009a; Sonn et al. 2010). Emtins have 
an additional advantage of readily being able to cross the intact blood-brain barrier 
(Sonn et al. 2010), and may also be appropriate therapeutic molecules for ALS.  
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1.5 Research questions and aims 
Given the many pathways involved in the aetiology of ALS, multi-purpose therapeutics 
which have some component addressing oxidative stress may provide the best defence 
for motor neurons against the development of ALS pathology. In seeking to understand 
which therapeutic targets might be important in ALS, the contribution of microglial 
phenotype to oxidative stress, through the production of nitric oxide, should be further 
investigated. In addition, given that oxidative stress is a common pathology between 
sporadic and familial ALS, multi-functional therapies with some antioxidant properties 
such as Gemals and metallothionein treatment should be trialled in SOD1 mice as 
potential treatments for ALS.   
 
Research Question 1:  
How does the expression of the neuroinflammatory markers, Arg1 and 
iNOS, change over time in SOD1 mice and what does this tell us about 
the role of neuroinflammation and oxidative stress in ALS pathogenesis? 
 
Aim 1: To characterise spinal cord microglia changes in Arg1 and iNOS expression 
over time in SOD1 mice, and to temporally correlate these changes with 
development of pathology in motor neurons, induction of oxidative stress 
responses, and functional decline over time. This aim is addressed in Chapter 2.  
 
Aim 2: To establish baseline measures of functional decline in SOD1 mice over time, to 
determine measures of disease progression for later pre-clinical studies. This 
aim is addressed in Chapter 2. 
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Research Question 2:  
Will treatment with an antioxidant therapy for ALS, Gemals, extend 
survival time and prevent the decline of functional ability in SOD1 mice? 
 
Aim 3: To examine the effects of Gemals treatment on SOD1 mice in a pre-clinical 
study, with treatment starting from the age of disease onset and continuing until 
disease endpoint, with survival and maintenance of functional ability as outcome 
measures. This aim is addressed in Chapter 3.  
 
 
Research Question 3:  
Will treatment with the neuroprotective protein MT2, or its  
peptide derivatives, or increasing spinal cord MT levels through  
treadmill exercise, extend survival time and prevent the  
decline of functional ability in SOD1 mice? 
 
Aim 4: To examine the effects of pre-symptomatic MT2 administration, or treadmill 
exercise, on disease onset and survival time in SOD1 mice. This aim is 
addressed in Chapter 4.  
 
Aim 5: To examine the effects of post-symptom-onset administration of the MT2 
derivatives, Emtin peptides, on survival time in SOD1 mice. This aim is 
addressed in Chapter 5. 
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Chapter 2  
 
Characterisation of neuroinflammatory and 
functional changes over time in SOD1 mice 
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2.1 Background  
2.1.1 Microglial activation status in ALS 
Microglial activation is a major pathology in the spinal cord of ALS patients and SOD1 
mice, as discussed in Chapter 1. Microglial activation is commonly seen in the spinal 
cord of SOD1 animal models at disease onset, and increases with disease progression 
(Hall et al. 1998b; Almer et al. 1999; Chiu et al. 2008; Gowing et al. 2008; Beers et al. 
2011b; Yang et al. 2011), although microglial activation has also been demonstrated to 
precede disease onset in some studies (Alexianu et al. 2001; Graber et al. 2010; Sanagi 
et al. 2010). Microglial activation may play an active role in disease progression, as 
replacing SOD1 microglia with WT microglia in SOD1 mice modulated the rate of 
disease progression (Boillee et al. 2006; Lee et al. 2012). SOD1 mice are thought to 
show a biphasic pattern of disease symptoms, with a brief plateau after onset where 
symptoms progress slowly, followed by a more rapid decline in functional ability (Beers 
et al. 2011a). This switch, from slowly-progressing to rapidly-progressing phases of 
disease, is thought to correspond to a switch between anti-inflammatory and pro-
inflammatory phenotypes of microglial activation (Beers et al. 2011b; Liao et al. 2012).  
Microglia can show two phenotypes of activation, which are best characterised by 
protein expression and cytokine production. The M1-like, neurotoxic, pro-inflammatory 
phenotype of microglial activation is characterised by the elevated expression of pro-
inflammatory cytokines and production of reactive oxygen species and nitric oxide 
(NO); whereas the M2-like, neuroprotective, anti-inflammatory phenotype of microglial 
activation is characterised by increased expression of anti-inflammatory cytokines and 
reduced production of free radicals (Colton 2009; Appel et al. 2011).   
The microglial production of NO is a key factor in the toxicity of activated microglia to 
motor neurons (Zhao et al. 2004; Zhao et al. 2006; Thonhoff et al. 2012). Microglial 
production of NO is controlled by the inducible nitric oxide synthase enzyme (iNOS), 
which converts L-arginine to L-citrulline, producing NO in the process (Andrew & 
Mayer 1999). L-arginine, the iNOS substrate, is also metabolised by another enzyme, 
arginase-1 (Arg1), which converts L-arginine to L-ornithine and urea but does not 
produce NO (Ash 2004). The relative expression of these two L-arginine-metabolising 
enzymes, iNOS and Arg1, determines how much NO will be produced from a given cell 
(Gobert et al. 2000). Accordingly, high levels of Arg1 and low levels of iNOS are 
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associated with the M2-like, neuroprotective microglial phenotype, while high levels of 
iNOS and low levels of Arg1 are associated with the M1-like, neurotoxic microglial 
phenotype (Colton 2009). 
The reported switch between M2-like and M1-like microglial phenotypes in mouse 
models of ALS has mainly been investigated using cytokine mRNA expression levels 
(Beers et al. 2011a). It is therefore of interest to determine whether changes in iNOS 
and Arg1 protein expression also occur over time in the microglia of SOD1 mice, and 
how these changes are temporally related to the development of motor neuron pathology 
and functional deterioration, as any such protein changes may be reflective of a change 
in microglial phenotype. As oxidative damage from microglial-produced NO is thought 
to injure motor neurons, the expression of the antioxidant-response protein, 
metallothionein-1/2 (MT-1/2), should also be examined in the spinal cord of SOD1 
mice to examine the evolution of oxidative stress over the disease course. The timing of 
oxidative stress response induction may relate to the production of NO by microglia, 
which in turn may be increased by any shift from an M2-type (Arg1-expressing) 
microglial phenotype to an M1-type (iNOS-expressing) microglial phenotype.       
 
2.1.2 Measuring disease progression in SOD1 mice 
As the underlying aetiology of ALS is as yet unknown, current therapeutic strategies 
involve addressing the known pathologies which occur in ALS patients and SOD1 
mouse models, such as oxidative stress and neuroinflammation. Addressing these 
pathologies may limit disease processes, and slow disease progression. It is therefore 
necessary to track the functional decline in SOD1 mice over time, in order to evaluate 
any beneficial effects of therapeutic compounds. The age of onset, rate of symptom 
progression, and survival times vary in SOD1 mice according to the level of mutant 
SOD1 protein expression, gender, and genetic background strain (Alexander et al. 2004; 
Heiman-Patterson et al. 2005; Acevedo-Arozena et al. 2011; Bame et al. 2012).  
The SOD1 colony maintained at the University of Tasmania expresses the SOD1 
transgene on a congenic C57BL/6 background. As this colony was to be used for 
evaluation of potential disease therapeutics (see Chapters 3, 4 and 5), it was necessary to 
establish baseline measurements of functional decline over time.  
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2.1.3 Aims and hypothesis 
This study had two aims. First, to characterise the spinal cord microglia changes in 
Arg1 and iNOS expression over time in SOD1 mice, and to examine these changes in 
the temporal context of the appearance of pathological changes in motor neurons, 
induction of oxidative stress responses, and onset of functional deficits in SOD1 mice. 
Second, to establish baseline measures of functional decline in SOD1 mice compared to 
their wild-type littermates which could be used in future studies to monitor disease 
onset and progression.   
Hypothesis: Microglia will shift their expression of L-arginine metabolising 
enzymes with disease onset: prior to disease onset, the expression of Arg1 will be 
prevalent, while the expression of iNOS will be prevalent after disease onset, 
indicating a shift in the spectrum of microglial phenotypes from an M2-
predominant to an M1-predominant phenotype in the lumbar spinal cord of SOD1 
mice.  
Two cohorts of SOD1 mice and their WT littermates were examined in this chapter. 
Spinal cord samples were obtained from the first cohort at various ages between 6 and 
25 weeks of age, and these samples were immunostained for the glial markers Iba1, 
tomato lectin, and GFAP, for the M1/M2 markers Arg1 and iNOS, for the pathological 
markers ubiquitin, neurofilament, and protein from the human SOD1 transgene, and for 
the antioxidant protein MT-1/2. The second cohort of SOD1 and WT mice were 
monitored for body weight, stride pattern, wire hang duration ability, and neurological 
score between 6 and 25 weeks of age, in order to characterise functional aspects of 
disease progression.   
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2.2 Methods 
2.2.1 Animal ethics 
All procedures and protocols involving animals were approved by the University of 
Tasmania’s Animal Ethics Committee (permit numbers A10995 and A11958) and were 
carried out in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes.   
 
2.2.2 Maintenance and genotyping of SOD1 mice 
2.2.2.1 Strain and colony maintenance 
High copy-number founder SOD1 mice, expressing the human SOD1
G93A
 transgene on 
a C57Bl/6J background, were originally obtained from The Jackson Laboratory (B6.Cg-
Tg(SOD1*G93A)1Gur/J, Strain #004435, ME, USA) and a breeding colony of 
heterozygotes was maintained by the University of Tasmania Animal Services. Animals 
were housed in OptiMICE cages (Animal Care Systems, CO, USA) in a controlled 
environment with a 12 hour light/dark cycle and a temperature range of 21-23°C. All 
mice had access to standard laboratory rodent chow and water ad libitum. As SOD1 
mice experienced progressive paresis with disease progression, food pellets were placed 
directly on cage bedding at later stages of disease to ensure continued nutrition.    
2.2.2.2 Genotyping 
Mice carrying the SOD1 transgene, and their non-transgenic wild type (WT) littermates, 
were identified by polymerase chain reaction (PCR) and gel electrophoresis, and copy 
number homogeneity was assessed by quantitative real time PCR (qPCR).  
2.2.2.2.1 DNA extraction 
Tail-tip samples were collected upon weaning by University of Tasmania Animal 
Services staff. Genomic DNA was extracted using the GenElute Mammalian Genomic 
DNA Miniprep Kit (Sigma-Aldrich, NSW, Australia) according to the manufacturer’s 
instructions, with the exception that all centrifugation steps were performed in a 
benchtop microcentrifuge (Heraeus Biofuge Pico) at 10,000g.     
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2.2.2.2.2 PCR and gel electrophoresis for the presence of the SOD1G93A transgene: 
PCR reactions (12.75µL) were prepared containing 1x GoTaq Green Master Mix 
(Promega, WI, USA), 1µL of genomic DNA template, nuclease-free water (Qiagen, 
VIC, Australia), and 0.39µM forward and reverse primers for either the human SOD1 
(hSOD1) or the murine interleukin-2 gene (mIL-2) (GeneWorks, SA, Australia) (Table 
2.1). 
PCR was performed using a Corbett Research thermocycler (Qiagen). Reactions were 
held at 95°C for 3 minutes, then cycled through 95°C for 30 seconds, 60°C for 30 
seconds and 72°C for 30 seconds (35 cycles), then held at 72°C for 5 minutes, 30°C for 
3 minutes and 24°C for 30 seconds. PCR products were transferred to an agarose gel for 
electrophoresis, containing 1% w/v agarose (Bioline, NSW, Australia) and 0.01% v/v 
SYBR-Safe (Life Technologies, CA, USA) in tris-acetate-EDTA (TAE) buffer (40mM 
tris [Sigma-Aldrich], 20mM acetic acid [Merck Millipore, VIC, Australia], 1mM 
ethylenediaminetetraacetic acid [EDTA] disodium salt [Sigma-Aldrich]). The PCR 
products were electrophoresed in TAE buffer for 30 minutes at 100V using a Horizon58 
electrophoresis rig (Biometra, NI, Germany) and PowerPac power source (BioRad, CA, 
USA), and band presence/absence was assessed under UV light in a gel doc imager 
(BioRad). SOD1 mice showed a PCR product from both the mIL-2 and the hSOD1 
reactions, while WT mice showed only a PCR product from the mIL-2 reaction (Table 
2.1). Positive controls (SOD1), negative controls (WT) and no-template controls were 
included in each PCR run. SOD1 mice were then assessed for transgene copy number.  
2.2.2.2.3 qPCR for SOD1G93A transgene copy number 
Homogeneity of transgene copy number in the genomic DNA of SOD1 mice was 
assessed using multiplex quantitative PCR. qPCR reactions (12.5µL) contained 1x 
KAPA ProbeFast Universal Master Mix (KAPA Biosystems, MA, USA), 0.15µM 
forward and reverse primers for human SOD1 (hSOD1), 0.50µM forward and reverse 
primers for murine apolipoprotein-B (mApoB), 0.16µM labelled oligonucleotide probes 
for hSOD1 and mApoB (Table 2.1) (GeneWorks), and nuclease-free water (Qiagen). 
qPCR was performed using a RotorGene Q real-time PCR cycler (Qiagen) – reactions 
were held at 95°C for 5 minutes, and cycled through 95°C for 15 seconds and 60°C for 
15 seconds (45 cycles); a ramped melt curve from 60°C to 99°C was then performed. 
Positive (SOD1), negative (WT) and no-template controls were included with each run. 
All SOD1 samples were run in triplicate.  
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The relative take-off points of the hSOD1 and mApoB fluorescence curves were 
compared using the comparative quantitation tool in the RotorGene Q Series software 
v2.0.2 (Qiagen). The delta-CT (ΔCT) value, representing the difference in the take-off 
points for the hSOD1 and mApoB curves (measured as the number of cycles), was 
compared to that of SOD1 positive control DNA. Average ΔCT values for all mice were 
recorded, for inclusion in statistical analyses of survival if necessary; SOD1 mice 
showing very low ΔCT values were excluded from trials. 
 
Table 2.1 Primers and probes for genotyping and copy number check 
Primers for PCR / gel electrophoresis genotyping 
Gene Primers PCR product 
hSOD1 
F: 5’-caccaagtagacaggctctc-3’ 
R: 5’-cagtaaccttagttccgcag-3’ 
321bp from last intron
1
  
 
mIL-2 
F: 5’-ctaggccacagaattgaaagatct-3’  
R: 5’-gtaggtggaaattctagcatcatcc-3’ 
324bp from exon 3
2
  
 
Reagents for qPCR copy number check 
Gene Primers PCR product 
hSOD1 
F: 5’-gggaagctgttgtcccaag-3’ 
R: 5’-caaggggaggtaaaagagagc-3’ 
88bp from last intron 
mApoB 
F: 5’-cacgtgggctccagcatt-3’ 
R: 5’-tcaccagtcatttctgcctttg-3’ 
74bp from exon 26 
Gene Labelled oligonucleotide probe 
hSOD1 6-FAM-ctgcatctggttcttgcaaaacacca-BHQ-1                    
mApoB HEX-ccaatggtcgggcactgctcaa-BHQ-1 
1
(Rosen et al. 1993); 
2
(Schorle et al. 1991) 
 
2.2.3 Spinal cord changes between SOD1 and WT mice 
Characterisation of spinal cord changes between SOD1 and WT mice was carried out 
under ethics permit A11958. To examine temporal changes in oxidative and microglial 
markers in the spinal cord of SOD1 mice, a tissue library of spinal cord samples from 
SOD1 and WT mice from 6 to 25 weeks of age was created by Dr Bill Bennett.  
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2.2.3.1 Preparation of a time series of spinal cord tissue 
Lumbar spinal cord samples were obtained from SOD1 mice and WT mice at 6, 10, 14, 
18 and 22 weeks of age. Three animals per genotype per time point were used, with the 
exception of 2 WT mice at 6 weeks of age and 4 SOD1 and 4 WT mice at 22 weeks of 
age. A mixture of male and female mice was used. Spinal cords of three SOD1 mice 
were obtained at disease endpoint (a 20% reduction of their pre-disease maximum body 
weight, at 24.8±0.1 weeks of age); three WT mice at 25-26 weeks of age were used as a 
comparison for endpoint SOD1 mice.  
At the appropriate time point, animals were deeply anaesthetised with sodium 
pentobarbitone (60mg/kg, i.p.). When all reflexes were absent, mice were transcardially 
perfused with 10mL of 10mM phosphate-buffered saline (PBS; 2mM sodium phosphate 
monobasic; 8mM sodium phosphate dibasic, 154mM sodium chloride [all Sigma-
Aldrich]; pH 7.4) followed by 20mL of 4% w/v paraformaldehyde (PFA, Sigma-
Aldrich) in PBS. The T12-L1 vertebrae, containing the L2-L5 lumbar spinal cord 
segment, were dissected and post-fixed in 4% w/v PFA overnight at 4°C, then stored in 
PBS with 0.01% w/v sodium azide (Fluka, Sigma-Aldrich). The cervical vertebrae, 
containing the cervical spinal cord, were collected from a subset of mice (2 WT and 2 
SOD1 mice at 10 weeks of age, 3 WT and 2 SOD1 mice at 14 weeks of age, and 3 WT 
and 3 SOD1 mice at 18 and 22 weeks of age).    
The vertebrae surrounding the spinal cord were decalcified by incubation of the sample 
in fast decalcification solution (5% v/v nitric acid [Fluka, Sigma-Aldrich] with 0.05% 
w/v urea [Sigma-Aldrich] in distilled water) for 2 hours at room temperature; 
decalcified samples were washed thoroughly with distilled water, then stored in 50-70% 
ethanol until being dehydrated and embedded in paraffin wax using an automated tissue 
processor (Leica Biosystems ASP200-S, NSW, Australia). Wax sections (5µm) were 
cut on a microtome (Microm HM325, BW, Germany), mounted on Flex slides (Dako, 
CA, USA), dried at 37°C overnight and then stored at room temperature. Prior to 
immunohistochemistry, paraffin-embedded sections were dewaxed in two changes of 
xylene, and rehydrated through a series of graded ethanols to distilled water.     
2.2.3.2 Immunostaining of SOD1 and WT spinal cord tissue 
Normal goat serum (NGS), Mouse on Mouse immunolabelling (MOM) kit, 3,3’-
diaminobenzidine substrate (DAB), biotin/streptaviding blocking kit, and biotinylated 
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Lycopersicon esculentum (tomato) lectin were all obtained from Vector Laboratories 
(CA, USA). Primary antibodies were obtained from various sources (Table 2.2). 
AlexaFluor (AF)-conjugated secondary antibodies, AF-conjugated streptavidins and 
Nuclear Yellow (NY) dye were obtained from Molecular Probes (Life Technologies). 
Unless otherwise specified, all steps were carried out at room temperature in a 
humidified light-safe chamber; buffer solutions for antibodies and washing were either 
PBS or PBS containing 0.05% v/v Tween-20 (Sigma-Aldrich) (PBS-T) unless otherwise 
specified; slides were washed in buffer solution between each immunolabelling step. 
2.2.3.2.1 Microglia and inflammatory markers 
Microglia were labelled with an antibody against ionised calcium binding adaptor 
molecule 1 (Iba1) (Imai et al. 1996), or with tomato lectin (TL) (Herbert et al. 2012) 
(Table 2.2). Tomato lectin binds (N-acetylglucosamine)2-4 residues, and in addition to 
microglia also appeared to label endothelial cells and motor neurons, which could be 
identified as such by their different morphology.  
To detect Iba1, citrate buffer antigen retrieval was employed. Slides were immersed in a 
10mM citrate buffer (2mM citric acid, 8mM sodium citrate [both from Sigma-Aldrich], 
pH 6) and heated in a pressure cooker (Russell Hobbs, VIC, Australia) at 100% power 
for 6 minutes followed by 60% power for 14 minutes, then allowed to cool. Sections 
were then blocked in 10% v/v NGS for 1 hour, incubated with rabbit anti-Iba1 (1:500) 
for 2 hours, biotinylated goat-anti-rabbit (1:500) for 1 hour, and streptavidin-AF488 
(1:500) for 1 hour; nuclei were stained with NY (1:10000) for 15 minutes.  
Tomato lectin labelling was carried out in conjunction with immunolabelling for 
putative markers of microglial status, Arg1 (M2-like microglia) and iNOS (M1-like 
microglia) (Colton 2009). Citrate buffer antigen retrieval, as above, was required for 
Arg1 immunoreactivity but not that of iNOS. The MOM kit was used according to the 
manufacturer’s instructions for Arg1 or iNOS detection. Slides were blocked with 
MOM blocking reagent for 1 hour, then rinsed in PBS and incubated with MOM diluent 
for 5 minutes. The diluent was removed but the section was not washed in buffer; 
primary antibody was applied in fresh MOM diluent and incubated either overnight at 
4°C (Arg1, 1:100) or for 2 hours at room temperature (iNOS, 1:100). Primary antibody 
was detected by incubation with MOM biotinylated anti-mouse secondary antibody 
(1:250) for 20 minutes and streptavidin-AF488 (1:500) for 1 hour. Any free 
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streptavidin-binding sites were then blocked with either the biotin/streptavidin blocking 
kit as per the manufacturer’s recommendations, or with avidin and biotin solutions as 
follows: sections were incubated in diluted, filtered egg white solution (1 egg white in 
80-100mL distilled water) for 20 minutes, washed in water, incubated with 0.001% w/v 
biotin (Sigma-Aldrich) solution for 20 minutes, and washed in water again. Sections 
were then incubated with biotinylated tomato lectin (1:500) for 1 hour and with 
streptavidin-AF594 (1:500) for 2 hours; nuclei were stained with NY (1:10000) for 15 
minutes, and slides were coverslipped with fluorescence mounting medium (Dako).   
2.2.3.2.2 Pathological, astroglial, and oxidative stress markers 
For qualitative analysis, pathological alterations in motor neurons were detected using 
antibodies against ubiquitin (Ubi, 1:1000), dephosphorylated neurofilaments (SMI32, 
1:500), and human SOD1 protein (hSOD1, 1:500); astrocytes were detected using an 
antibody against glial fibrillary acidic protein (GFAP, 1:1000) (Table 2.2). Sections 
were blocked with 5% v/v NGS for 1 hour, incubated with the appropriate primary 
antibody for 1 hour, then with goat anti-mouse-AF or goat anti-rabbit-AF secondary 
antibody (1:500) for 1 hour and with NY (1:10000) for 15 minutes, then coverslipped 
with fluorescence mounting medium (Dako).  
For quantitative analysis, the antioxidant protein MT-1/2 was detected using DAB 
immunohistochemistry. The MT-1 and MT-2 isoforms are structurally and functionally 
similar (West et al. 2008); an antibody recognizing both isoforms (MT-1/2, Table 2.2) 
was used. Endogenous peroxidases were quenched with 3% hydrogen peroxide (Sigma-
Aldrich) in PBS for 20 minutes. Sections were blocked with MOM kit blocking reagent 
for 1 hour, incubated with MOM diluent for 5 minutes followed by mouse anti-MT-1/2 
(MT, 1:300, Table 2.2) in MOM diluent for 1 hour. Primary antibody was detected with 
biotinylated MOM anti-mouse-IgGs (1:250) in MOM diluent for 10 minutes and HRP-
conjugated streptavidin (1:1000) for 1 hour. The sections were exposed to DAB for 1 
minute, then counterstained with nuclear fast red for 3 minutes, dehydrated with graded 
alcohols, cleared in xylene and coverslipped with Pertex mounting medium. 
Double immunolabelling was performed sequentially using the above procedures where 
appropriate; for double immunolabelling of GFAP and MT-1/2, the quenching step was 
omitted from the MT-1/2 procedure, and the biotinylated MOM anti-mouse secondary 
was detected with AF-conjugated streptavidin instead of HRP-conjugated streptavidin.  
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2.2.3.2.3 Image analysis and cell counts 
Fluorescence images were captured on an Olympus BX50 microscope (Olympus, VIC, 
Australia) and CoolSNAP-HQ2 camera (Photometrics, AZ, USA) using NIS-Elements 
software (Nikon Instruments, NY, USA). Bright field images were captured using a 
Leica DM2500 microscope and DFC495 camera (Leica Biosystems, NSW, Australia).  
To quantify the microglial markers Iba1, TL, Arg1 and iNOS, immunostaining was 
performed on 3 sections from each lumbar spinal cord, separated by a minimum 
distance of 45µm. The spinal cord ventral horn (VH) was defined as the region of grey 
matter on the ventral side of a horizontal line crossing through the central canal, 
bounded by a vertical line through the sagittal plane. VH images for cell counts were 
taken at 400x magnification and cells were counted using ImageJ software (National 
Institutes of Health, MD, USA) and Adobe CS6 (Adobe Systems Incorporated, CA, 
USA). Counts from the right and left ventral horns of each section were averaged and 
divided by the area in square millimetres. To avoid pseudoreplication, the average count 
from three sections was used as a single measurement per animal for statistical analysis.  
Semi-quantitative analysis of the expression level of Arg1 and iNOS was performed in a 
subset of SOD1 microglia. For both Arg1 and iNOS, one section was randomly selected 
from each animal at 6 weeks (n=3) and 22 weeks of age (n=4). The cell bodies of eight 
microglia, showing the strongest Arg1 or iNOS staining in these sections, were outlined 
in ImageJ, and the percentage area occupied by positive Arg1 or iNOS labelling was 
calculated. To account for variations in intensity and background between sections, 
positive labelling in 8-bit black and white images was defined as any pixels having a 
grey value greater than 3.5 standard deviations above the mean grey value of the image.  
To quantify the number of MT-1/2 positive cells, immunostaining was performed on 
one section from the lumbar spinal cord of each animal. MT-1/2-positive cell bodies 
were counted in each spinal cord region outlined in the diagram shown in Figure 2.7A. 
 At each time point, SOD1 and WT counts were compared using an independent 
samples t-test. A Welch t-test correction was applied if Levene’s test showed that the 
variance in WT and SOD1 measurements was substantially different. Data are presented 
as mean ± standard error of the mean, and the statistical test used for the comparison is 
indicated (t-test = independent samples t-test for equal variances; Welch t-test = 
independent samples t-test for unequal variances), with p<0.05 considered significant.  
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Table 2.2 Antibodies used for immunostaining of mouse spinal cord 
Antibody target Cell type 
Species and type 
(clone) 
Company 
(catalogue 
number) 
Dephosphorylated 
neurofilaments (SMI32) 
Motor 
neurons 
Mouse monoclonal 
IgG1 (SMI32) 
Covance, NJ, USA 
(SMI-32R) 
    
Ubiquitin (Ubi1) - Rabbit polyclonal 
Dako, CA, USA 
(Z0458) 
    
Human Cu,Zn-superoxide 
dismutase (hSOD1) 
- Rabbit polyclonal 
Abcam, MA, USA 
(ab52590) 
    
Glial fibrillary acid protein  
(GFAP) 
Astrocytes Rabbit polyclonal 
Dako, CA, USA 
(Z0334) 
    
(N-acetylglucosamine)2-4 
residues (TL)  
Microglia; 
endothelium 
Biotinylated lectin 
from Lycopersicum 
esculentum; tomato 
lectin 
Vector 
Laboratories, CA, 
USA (B1175) 
    
Ionised calcium-binding 
adaptor molecule1 (Iba1) 
Microglia Rabbit polyclonal 
Wako, Osaka, 
Japan (019-19741) 
    
Arginase1 (Arg1) - 
Mouse monoclonal 
IgG1 (E-2) 
Santa Cruz 
Biotechnology, 
CA, USA  
(sc-271430) 
    
Inducible nitric oxide 
synthase (iNOS) 
- 
Mouse monoclonal 
IgG1 (C-11) 
Santa Cruz 
Biotechnology, 
CA, USA  
(sc-7271) 
    
Metallothionein-1/2  
(MT-1/2) 
- 
Mouse monoclonal 
IgG1 (E9) 
Dako, CA, USA 
(M0639) 
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2.2.4 Functional characterisation of SOD1 and WT mice 
The functional characterisation of SOD1 and WT mice was carried out under ethics 
permit A10995. A cohort of female SOD1 mice (n=17) and their female WT littermates 
(n=13) was assessed for changes in body weight, stride pattern, wire hang duration and 
neurological score rating over time. Mice in this cohort ranged from 5-13 weeks of age 
when measurements were commenced, and all mice were followed through to disease 
endpoint in SOD1 mice (23-25 weeks of age) and up to 28 weeks of age in WT mice.  
2.2.4.1 Survival time and humane endpoint 
As SOD1 mice are known to display progressive paralysis with disease progression 
(Gurney et al. 1994), a humane endpoint was employed in order to prevent a slow death 
by starvation due to inability to feed. Disease endpoint was considered to have been 
reached when mice displayed the earliest of either 1) a drop in body weight to 80% of 
pre-disease maximum body weight, or 2) inability to right themselves within 30 seconds 
of being placed on their back (Solomon et al. 2011). Having reached disease endpoint, 
mice were euthanised with carbon dioxide (2 litres/minute; 10 minutes).  
2.2.4.2 Body weight measurements 
Body weight, measured in grams, was recorded at least twice each week for each 
mouse, and more frequently in SOD1 mice approaching disease endpoint.  
2.2.4.3 Stride pattern testing 
Stride pattern testing was performed weekly. Nontoxic BodyArt face paint (Global 
Colours, NSW, Australia), diluted to a thin consistency with water, was placed on the 
front (red) and hind (blue) paws of a gently-restrained mouse. The mouse was then 
allowed to walk along a 7cm x 60cm strip of white paper bounded on each side by 
10cm-high plastic barriers, leaving a trail of paw prints from which various measures 
could be recorded.  The mouse’s feet were rinsed in water and dried in a tissue-lined 
cage; the mouse was then returned to its home cage. A detailed diagram of stride pattern 
testing setup is included in the Appendix. If the initial walk did not yield a clear set of 
prints, the procedure was repeated once more, and the most consistent pattern from the 
two attempts was used for measurement. 
Parameters measured from the stride pattern test were stride length (distance between 
consecutive rear paw prints on the same side), hind-base width (distance between right 
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and left hind paws), front-base width (distance between right and left front paws) and 
uniformity measurement (difference in placement of the hind paw compared with that of 
the front paw from the previous step) (Figure 2.11A,B). From each stride pattern test 
strip, stride length and uniformity were measured for 1-3 steps on the right and the left 
sides, and hind-base width and front-base width were measured for 1-3 steps.   
2.2.4.4 Wire hang duration testing  
The wire hang duration test was assessed weekly as an indicator of muscle strength. 
Mice were placed on the wire bars (1mm diameter) of a large transport cage lid, which 
was gently inverted and suspended approximately 20cm over a foam pad (Appendix 1). 
Mice were able to move about freely on the inverted bars in a 250cm
2
 area for the 
duration of the test. The wire hang duration was recorded as the time the mouse could 
remain suspended from the bars while inverted, before releasing the bars and dropping 
onto the foam pad below. The longest wire hang duration of three attempts was 
recorded for analysis, with a maximum possible value of 60 seconds.      
2.2.4.5 Neurological scoring 
Visible signs of neurological deficit in SOD1 mice were assessed at least twice weekly 
according to neurological score criteria (Table 2.3) developed by the ALS Therapy 
Development Institute (ALSTDI, MA, USA) (Scott et al. 2008).  
 
Table 2.3 Neurological score criteria 
Score Score Criteria 
NS=0 Full extension of hind legs away from lateral midline when mouse is 
suspended by its tail, and mouse can hold this for 2 seconds. 
NS=1 Collapse or partial collapse of leg extension towards lateral midline, 
or trembling of hind legs, during tail suspension. 
NS=2 Toes curl under at least twice during walking of 12 inches, or any 
part of foot is dragging along cage bottom/table. 
NS=3 Rigid paralysis or minimal joint movement, foot not being used for 
forward motion. 
NS=4 Mouse cannot right itself within 30 seconds from either side. 
NS, neurological score. 
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2.2.4.6 Statistical methods for analysis of functional data 
All statistical analyses were carried out in either IBM SPSS Statistics, version 20 (IBM 
Corporation, NY, USA) or Stata IC, version 12.1 (StataCorp LP, TX, USA). All data 
are presented as mean ± standard error of the mean unless otherwise specified, with 
p<0.05 considered significant.  
Mean and median survival times were evaluated using Kaplan-Meier survival analysis. 
The influence of transgene copy number (ΔCT value from genotyping) on survival time 
was examined using Cox proportional hazards (CPH) regression, and was reported as 
the hazard ratio for reaching endpoint (HR, equal to e
β
) and 95% confidence interval for 
the hazard ratio (95% CI).      
To avoid pseudoreplication, stride pattern parameters (stride length, uniformity, front-
base width and hind-base width) were averaged to give a single measurement per mouse 
per week for each parameter; values for WT and SOD1 mice were then compared using 
the Mann-Whitney U test (MWU) for non-parametric data. Similarly, average body 
weight and the maximum wire hang duration times for WT and SOD1 mice were 
compared using the MWU. Maximum body weight and the age at which the maximum 
body weight was reached could be calculated.   
Additionally, an exploration of body weight analysis using linear mixed modelling was 
conducted. A linear mixed model contains both ‘fixed’ effects and ‘random’ effects: 
fixed effects alter the value of the mean, whereas random effects alter the amount of 
variation around the mean. Mixed models can be particularly useful in longitudinal 
experiments where repeated measurements are made on the same experimental subjects 
over time. For example, genotype is expected to affect the value of the body weight 
measurement, so genotype would be included as a fixed effect. In contrast, giving 
identifiers to each individual mouse in the dataset, and including these identifiers in 
random effects, allows variation around the overall body weight mean to be partly 
explained due to unique changes over time for individual mice. This allocation of 
variance results in a better model fit to the data, and allows differences between 
genotypes or treatment groups to be identified, despite differences in starting body 
weight and rate of change over time between individual mice in each group.  
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The steps taken for model fitting are included in Supplementary Data 1 and 
Supplementary Data 2, with the final model demonstrated in the results. 
In modelling SOD1 and WT body weight, a random slope and random intercept were 
included, allowing for unique starting body weights and unique rates of weight gain and 
loss over time for individual mice. Age in days was used as a fixed effect, allowing 
inclusion of all daily body weight measurements, rather than using a weekly average for 
each mouse. Age
2
 and Age
3
 fixed effects were sequentially added to the model, to 
examine whether their inclusion resulted in a better model fit to the observed data than a 
linear trajectory alone. Model fit was evaluated by examining log-likelihood (as -2LL, 
in smaller-is-better format) values between models with and without the covariate being 
tested; the covariate was considered to give a significantly better model fit if a 
significant result (p<0.05) was obtained from the right-tailed chi-squared test of the 
difference in log-likelihood between models (i.e., if χ2(LR, df) <0.05, where LR 
(likelihood ratio) = -2LLmodel without covariate - -2LLmodel with covariate; df = dfmodel with covariate – 
dfmodel without covariate). 
To examine at what age the body weight trajectories for SOD1 and WT mice became 
significantly different, the final model was centred at a range of Age values, and the 
intercept parameter p-value was recorded. The intercept parameter p-value gives a direct 
test of whether the two curves differ in body weight value as they cross the intercept 
(where ‘Age’=0); this is normally of no use then looking at body weight because weight 
at birth was outside the range of recorded raw data. However, when the model was 
centred by substituting, for example, Age for (Age-50), the intercept parameter p-value 
gives a direct test of whether the SOD1 and WT body weights are different at 50 days of 
age. By centring at a range of Age values (between 80 and 110 days), the age at which 
SOD1 and WT body weight estimates were significantly different could be obtained.    
The non-linear combination of estimators (nlcom) procedure (Stata IC, StataCorp LP) 
was used to provide point estimates for maximum body weight of SOD1 mice and age 
at which the maximum body weight was reached. The estimates from the linear mixed 
model / non-linear combination of estimators could then be compared with those 
generated from the averaged data alone.  
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2.3 Results 
2.3.1 Cellular changes over time in SOD1 mouse spinal cord 
2.3.1.1 Total microglial numbers 
The microglial markers Iba1 and TL both indicated an increase in the number of 
microglia over time in SOD1 mice, but not in WT mice (Figure 2.1A-E). In the lumbar 
spinal cord VH, SOD1 mice had more Iba1-positive microglia than WT mice from 18 
weeks of age (SOD1 178±7 vs. WT 85±26 microglia/mm
2
, t-test p=0.025) and 
thereafter (Figure 2.1D). TL labelling proved more sensitive, indicating differences 
between the SOD1 and WT VH microglia from 14 weeks of age (SOD1 208±9 vs. WT 
169±8 microglia/mm
2
, t-test p=0.034), although these differences were more substantial 
from 18 weeks of age onwards (Figure 2.1E).    
2.3.1.2 Changes in inflammatory marker expression over time 
The number of TL-positive microglia expressing the M2 marker Arg1 or the M1 marker 
iNOS were counted in the lumbar and cervical spinal cord regions. 
2.3.1.2.1 Expression of Arg1 and iNOS in lumbar ventral horn microglia 
Within the lumbar spinal cord VH, a subset of TL-positive microglial cells expressed 
Arg1 (Figure 2.2). The proportion of Arg1-positive and Arg1-negative microglia stayed 
relatively constant in WT mice over time, with more Arg1-negative than Arg1-positive 
microglia present at all time points (Welch t-test p=0.079 at 6 weeks; t-test p<0.05 at 
10-25 weeks) (Figure 2.2A-C, G). Few Arg1-positive microglia were observed at 6 and 
10 weeks of age in the SOD1 VH; however, the number of Arg1-positive microglia 
(arrows in Figure 2.2B,E,F) increased from 14 weeks of age, while the number of Arg1-
negative microglia did not change substantially with time (Figure 2.2D-F, H). By 22 
and 25 weeks of age, many more Arg1-positive than Arg1-negative microglia were 
present in the SOD1 VH (22 weeks, 286±29 Arg1-positive vs. 157±22 Arg1-negative 
microglia/mm
2
, t-test p=0.006; 25 weeks, 377±24 Arg1-positive vs. 180±27 Arg1-
negative microglia/mm
2
, t-test p=0.005) (Figure 2.2H). These changes represent an 18-
fold increase in Arg1-expressing microglia between 10 weeks of age (21±3 Arg1-
positive microglia/mm
2
) and 25 weeks of age (377±24 Arg1-positive microglia/mm
2
) in 
the lumbar spinal cord VH. Additionally, the percentage of total microglia expressing 
Arg1 increased from 14% at 10 weeks of age to 65% at 22 weeks of age (Figure 2.5F).  
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Figure 2.1 Microglia in the lumbar spinal cord of SOD1 mice over time 
Tomato lectin binds to both endothelial cells (asterisks, A,B) and microglial cells 
(arrowhead, B). The number of microglia increased over time in the lumbar spinal cord 
of SOD1 mice, as measured by both Iba1 immunoreactivity (D) and tomato lectin 
labelling (A-C, E). SOD1 mice showed greater numbers of Iba1-positive microglia than 
WT mice from 18 weeks of age (D), and greater numbers of tomato lectin-positive 
microglia than WT mice from 14 weeks of age (E). Scale bar 20µm. *p<0.05, **p<0.01, 
***p<0.001. Iba1, ionised calcium-binding adaptor molecule 1; TL, tomato lectin; NY, 
Nuclear Yellow. Error bars represent standard error of the mean. 
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Figure 2.2 Arg1-positive microglia in the lumbar spinal cord ventral horn 
Arg1 immunolabelling in tomato lectin-positive microglia is shown in the WT (A-C, G) 
and SOD1 (D-F, H) lumbar spinal cord ventral horn at 6 weeks (A,D), 14 weeks (B,E), 
and 22 weeks (C,F) of age. WT mice show few Arg1-positive microglia (arrows, B,C) 
throughout the time series (G), while SOD1 mice show an increasing number of Arg1-
positive microglia (arrows, E,F; inset in E shows Arg1 labelling) from 14-18 weeks of 
age (H). Scale bar 10µm for A-F, 6.7μm for inset in E. *p<0.05, **p<0.01, ***p<0.001. 
Arg1, arginase1; TL, tomato lectin; NY, Nuclear Yellow. Error bars represent standard 
error of the mean.  
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A subset of microglia within the lumbar ventral horn showed iNOS expression (Figure 
2.3). More iNOS-negative than iNOS-positive microglia were present in the WT lumbar 
VH at all time points (Welch t-test p=0.126 at 6 weeks; t-test p<0.05 at 10-25 weeks) 
(Figure 2.3A-C, G). The number of iNOS-positive microglia increased from 14 weeks 
of age in the SOD1 lumbar VH (Figure 2.3D-F, H; arrow in Figure 2.3F). Additionally 
in SOD1 mice, the number of iNOS-negative microglia increased from 18 weeks of age 
onwards (Figure 2.3H; arrowheads in Figure 2.3E,F). Due to the concomitant increase 
in both iNOS-positive and iNOS-negative microglia, the SOD1 VH contained more 
iNOS-negative than iNOS-positive microglia at all time points (t-test p<0.05 from 6 to 
22 weeks; t-test p=0.069 at 25 weeks) (Figure 2.3H).  
The number of iNOS-positive microglia increased approximately 8-fold between 10 
weeks of age (15±8 iNOS-positive microglia/mm
2
) and 22 weeks of age (116±18 iNOS-
positive microglia/mm
2
) (Figure 2.3H). The percentage of microglia expressing iNOS 
increased from 8% at 10 weeks of age to 33% at 22 weeks of age (Figure 2.5F). 
When the numbers of Arg1-positive microglia (Figure 2.2H) and iNOS-positive 
microglia (Figure 2.3H) in the SOD1 lumbar spinal cord ventral horn are compared, the 
numbers of Arg1-positive microglia were greater than those of iNOS-positive microglia 
as the disease progressed over time. 
2.3.1.2.2 Expression level of Arg1 and iNOS in SOD1 lumbar VH microglia 
Ventral horn microglia from randomly-selected lumbar spinal cord sections (see 
methods) showed an increase in the percentage area occupied by Arg1 or iNOS 
immunoreactivity between 6 weeks and 22 weeks of age (Figure 2.4A-E). Arg1 
immunoreactivity occupied approximately 6% of microglial cell body area at 6 weeks of 
age, which increased five-fold to approximately 30% of the cell body area at 22 weeks 
of age (Figure 2.4A,B,E). iNOS immunoreactivity was present in less than 1% of the 
cell body area at 6 weeks of age, which increased 25-fold to around 5% at 22 weeks of 
age (Figure 2.4C-E). These data indicate that in addition to the increase in the number 
of Arg1-expressing and iNOS-expressing microglial cells (Figure 2.2, Figure 2.3), the 
expression level of Arg1 and iNOS protein also increases over time in SOD1 lumbar 
spinal cord VH microglia. 
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Figure 2.3 iNOS-positive microglia in the lumbar spinal cord ventral horn 
iNOS immunolabelling in tomato lectin-positive microglia is shown in WT (A-C, G) 
and SOD1 (D-F, H) lumbar spinal cord at 6 (A,D), 14 (B,E), and 22 (C,F) weeks of age. 
WT mice show few iNOS-positive microglia at any time point (G), while SOD1 mice 
show an increase in both iNOS-positive (arrow, F; inset in F shows iNOS labelling) and 
iNOS-negative (arrowheads, E,F) microglia over time (H). Scale bar 10µm for A-F, 
6.7μm for inset in F. *p<0.05, **p<0.01, ***p<0.001. iNOS, inducible nitric oxide 
synthase; TL, tomato lectin; NY, Nuclear Yellow. Error bars represent standard error of 
the mean.  
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Figure 2.4 Percentage area occupied by Arg1 or iNOS immunoreactivity in SOD1 
lumbar spinal cord microglia 
The percentage area of the microglial cell body occupied by Arg1 (A,B) or iNOS (C,D) 
immunoreactivity was examined at 6 (A,C) and 22 weeks (B,D) of age in a subset of 
microglia displaying the strongest immunoreactivity. The percentage of cell body area 
occupied by Arg1 was higher at 22 weeks than at 6 weeks; the percentage of cell body 
area occupied by iNOS was also higher at 22 weeks than at 6 weeks (E). Scale bar 
10µm in A-D. *** p<0.001. TL, tomato lectin; Arg1, arginase1; iNOS, inducible nitric 
oxide synthase; NY, Nuclear Yellow. Error bars represent standard error of the mean. 
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2.3.1.2.3 Expression of Arg1 and iNOS in cervical ventral horn microglia 
Motor weakness in the SOD1 mice is first detectable in the hindlimbs, with later 
involvement of the forelimbs (Kuntz et al. 2000); thus, the lumbar spinal cord was the 
primary focus in this study. However, a brief comparison of microglial Arg1 and iNOS 
expression was made in the cervical spinal cord of WT and SOD1 mice from 10 to 22 
weeks of age, to examine any temporal differences in expression of these inflammatory 
markers between the lumbar and cervical spinal cord which may correlate with later 
involvement of the forelimb muscles. 
Similar to the lumbar spinal cord, there were more Arg1-negative microglia than Arg1-
positive microglia at all time points in the WT cervical spinal cord VH (Welch t-test 
p=0.120 at 10 weeks; t-test p<0.05 at 14-22 weeks) (Figure 2.5A). In the SOD1 cervical 
VH, there were equal numbers of Arg1-positive and Arg1-negative microglia from 10-
18 weeks of age (Figure 2.5B). At 22 weeks of age, there were more Arg1-positive than 
Arg1-negative microglia (265±39 Arg1-positive microglia/mm
2
 vs. 71±22 Arg1-
negative microglia/mm
2
, t-test p=0.012). In contrast, the number of Arg1-negative 
microglia remained constant in the SOD1 cervical VH from 10 to 22 weeks of age 
(Figure 2.5B). The SOD1 cervical VH also showed an increase in the percentage of 
microglia expressing Arg1 over time, from 45% at 10 weeks of age to 79% at 22 weeks 
of age (Figure 2.5E).  
Microglial iNOS expression in the cervical spinal cord remained fairly constant over 
time in the WT VH, with more iNOS-negative than iNOS-positive microglia at all time 
points (Welch t-test p<0.05 at 10 weeks; t-test p<0.05 from 14 to 22 weeks), despite a 
slight increase in iNOS-positive microglia over time (Figure 2.5C). In the SOD1 ventral 
horn, both the number of iNOS-positive and iNOS-negative microglia increased over 
time (Figure 2.5D). There were more iNOS-negative than iNOS-positive microglia in 
the SOD1 mice at each time point (Figure 2.5D), however these differences did not 
reach statistical significance (Welch t-test p=0.051-0.076 from 10 to 22 weeks). The 
percentage of SOD1 cervical VH microglia expressing iNOS increased from 11% at 10 
weeks of age to 24% at 18 weeks of age, then slightly decreased to 20% at 22 weeks of 
age (Figure 2.5E). Similar to the lumbar spinal cord, more cervical microglia were 
Arg1-positive than iNOS-positive (Figure 2.5E). 
   
_________________________Chapter 2 – Neuroinflammatory and functional changes 
______________________________________________________________________ 
______________________________________________________________________ 
 
63 
 
 
Figure 2.5 Arg1 and iNOS expression in cervical spinal cord ventral horn 
microglia 
In WT mice the majority of tomato lectin-positive microglia are negative for Arg1 (A) 
and for iNOS (C). In the SOD1 cervical ventral horn, there are equivalent numbers of 
Arg1-positive and Arg1-negative microglia until 22 weeks of age, when Arg1-positive 
microglia are more prevalent (B). In SOD1 mice, the numbers of both iNOS-positive 
and iNOS-negative microglia increase over time (D). A higher percentage of microglia 
in both the cervical (E) and lumbar (F) spinal cord express Arg1 than iNOS at later time 
points. *p<0.05, **p<0.01, ***p<0.001. Error bars represent standard error of the mean. 
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2.3.1.3 Neurofilament, ubiquitin and hSOD1 labelling over time 
To examine timing of degenerative changes in SOD1 motor neurons, immunolabelling 
for dephosphorylated neurofilaments (SMI32), ubiquitinated inclusions (Ubi), and 
protein produced from the human SOD1 transgene (hSOD1) was performed in the 
lumbar spinal cord VH of SOD1 and WT mice. Changes over time in SOD1 spinal cord 
were not present in WT spinal cord, unless otherwise specified below.  
  Diffuse ubiquitin immunolabelling was present in motor neuron nuclei in both 
SOD1 and WT lumbar VH at all time points examined (Figure 2.6A-C, I). The SOD1 
lumbar VH showed ubiquitin-positive inclusions (arrows, Figure 2.6A-C) in the cell 
bodies of SMI32-positive motor neurons as early as 6 weeks of age (Figure 2.6A), and 
in both motor neuron somas and in the neuropil from 10 weeks of age (Figure 2.6B). 
The number of ubiquitinated inclusions in the lumbar spinal cord increased over time; at 
25 weeks of age, the SOD1 VH showed many large ubiquitin-positive inclusions which 
were not located within SMI32-positive cell bodies (arrow, Figure 2.6C). These 
ubiquitinated inclusions may be present within neuritic processes, glial cells, or the 
remnants of degenerating neurons. No inclusions were found in WT VH (Figure 2.6I). 
SMI32 labelled motor neuron somas and processes within the neuropil (Figure 2.6A-F, 
I). SMI32-encircled vacuoles developed in the cytoplasm of SOD1 motor neurons from 
10 weeks of age (asterisks, Figure 2.6B); at 14 weeks of age, some of these cytoplasmic 
vacuoles contained hSOD1 protein (asterisk, Figure 2.6E). SMI32 formed ring-like, 
annular structures in the neuropil from 10 weeks of age (arrowheads, Figure 2.6B,C). 
Interestingly, while some hSOD1 was present in a diffuse cytoplasmic pattern in motor 
neurons at 6 weeks of age (Figure 2.6D), hSOD1 also formed ring-like, annular 
structures in the neuropil from 6 weeks of age onwards (chevrons, Figure 2.6D-F). At 
14 weeks of age, some hSOD1-positive annular structures partially colocalised with 
SMI32-positive annular structures (inset, Figure 2.6E; magnified in Figure 2.6G). The 
size and complexity of both SMI32-positive and hSOD1-positive annular structures 
increased with time; at 22 weeks of age, large, complex annular structures positive for 
SMI32, hSOD1, or both, were present in the SOD1 lumbar spinal cord ventral horn 
(inset, Figure 2.6F; magnified in Figure 2.6H). The presence of annular structures, 
particularly in a grouped arrangement (as seen in Figure 2.6F,H) may indicate internal 
partitioning or vacuolisation of motor neuron axons or somas. No neurofilament 
alterations were present in the motor neurons of the WT lumbar VH (Figure 2.6I).   
_________________________Chapter 2 – Neuroinflammatory and functional changes 
______________________________________________________________________ 
______________________________________________________________________ 
 
65 
 
 
Figure 2.6 Ubiquitin, SMI32, and hSOD1 labelling in the SOD1 lumbar spinal cord 
Motor neurons showed cytoplasmic ubiquitinated inclusions from 6 weeks of age 
(arrow, A), and ubiquitin aggregates in the neuropil from 10 weeks of age (arrows, 
B,C). SMI32-edged vacuoles were present in the cytoplasm from 10 weeks of age 
(asterisks, B), some of which contained hSOD1 protein from 14 weeks of age (asterisk, 
E). SMI32-positive annular structures were also present in the neuropil from 10 weeks 
of age (arrowheads, B). hSOD1 protein formed annular structures in the neuropil from 6 
weeks of age (chevrons, D-F); these were closely associated or colocalised with SMI32-
positive annular structures from 14 weeks of age (arrowhead, G). Annular structures in 
the neuropil, consisting of hSOD1 and/or SMI32, increased in size and complexity with 
disease progression, and at 22 weeks of age some annular structures showed 
colocalisation between SMI32 and hSOD1 (arrowhead, H). Wild type (WT) mice 
showed no ubiquitinated aggregates or neurofilament abnormalities at 25 weeks of age. 
Scale bar 10µm for A-F, I; 5µm for G,H. hSOD1, protein produced from the 
SOD1G93A transgene; NY, Nuclear Yellow; SMI32, dephosphorylated neurofilament 
medium chain; Ubi, ubiquitin.  
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2.3.1.4 Changes in MT-1/2 over time 
2.3.1.4.1 Metallothionein-1/2 immunoreactivity 
Immunostaining for metallothionein-1/2 isoforms (MT-1/2) revealed that expression of 
MT-1/2 was quite varied between individual mice. Despite this variation, WT and 
SOD1 mice showed differences in MT-1/2 expression over time (Figure 2.7A-J).The 
density of MT-1/2-positive cells was evaluated in the ventral horn and dorsal horn grey 
matter, and in the dorsal and the ventral/lateral white matter, as outlined in Figure 2.7A. 
MT-1/2 expression in the ventral horn grey matter of WT mice was generally quite low, 
with the exception of 14 weeks of age when many MT-1/2-positive cells were counted 
in the VH (Figure 2.7B,C,G). In SOD1 mice, few MT-1/2-positive cells were observed 
in the VH at 6, 10, and 14 weeks of age (Figure 2.7D). However, there was a marked 
increase in the density of MT-1/2-positive cells in the VH of SOD1 mice compared to 
WT mice at 18, 22, and 25 weeks of age (18wks, WT 3±2 vs. SOD1 141±35 MT-1/2-
positive cells/mm
2
, Welch T-test p=0.059; 22wks, WT 17±1 vs. SOD1 253±16 MT-1/2-
positive cells/mm
2
, T-test p=0.001; 25wks, WT 22±21 vs. SOD1 156±11 MT-1/2-
positive cells/mm
2
, T-test p=0.005) (Figure 2.7G). In addition to the increase in MT-
1/2-positive cells in the SOD1 VH, some diffuse staining with no apparent cellular 
localisation was also seen in the VH parenchyma; this diffuse immunoreactivity was 
absent in WT mice (Figure 2.7B-F).   
In the dorsal horn of WT mice, MT-1/2-positive cells and diffuse MT-1/2 
immunoreactivity were predominantly present in lamina II-III near the most dorsal 
portion of the dorsal horn, although the intensity of immunolabelling in this region 
varied amongst WT mice (Figure 2.7B,C). In SOD1 mice, MT-1/2 immunoreactivity at 
the top of the dorsal horn appeared either absent or present to a lesser extent than in age-
matched WT mice; however, from approximately 18 weeks of age onwards, the number 
of MT-1/2-positive cells in the lower half of the dorsal horn increased in SOD1 mice 
but not in WT mice (Figure 2.7B-F). Diffuse MT-1/2 immunoreactivity in the lower 
half of the ventral horn was also noted from 18 weeks of age in SOD1 mice but not in 
WT mice. Overall quantitation of MT-1/2-positive cells in the dorsal horn revealed 
more MT-1/2-positive cells in the WT dorsal horn than SOD1 dorsal horn at 6 weeks of 
age (WT 107±18 vs. SOD1 6±4 MT-1/2-positive cells/mm
2
, T-test p=0.006), but no 
significant differences at other time points.  
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MT-1/2 immunoreactivity in the white matter showed no significant differences 
between WT and SOD1 mice at any time point (Figure 2.7B-E, I,J), due to variable 
staining between individual mice. Qualitatively, WT mice showed slightly more MT-
1/2-positive cells in the white matter tracts than SOD1 mice at 6-14 weeks of age 
(Figure 2.7I,J). This was not the case at 18-25 weeks of age, when the numbers of MT-
1/2-positive cells in the white matter tracts appeared either equivalent between WT and 
SOD1 mice, or were higher in SOD1 than WT mice (Figure 2.7I,J). However, the high 
variation in white matter MT-1/2 immunolabelling in both WT and SOD1 mice means 
few conclusions about the dynamics of MT-1/2 change in white matter can be drawn 
from this data, and indicates that the changes observed in grey matter MT-1/2 
expression may be more important than changes in white matter MT-1/2 expression.  
2.3.1.4.2 Astrocytic localisation of MT 
Noting that the number of MT-positive cells increased over time, the localisation of 
MT-1/2 in astrocytes was examined. Qualitative examination of GFAP 
immunolabelling indicated that the number of reactive astrocytes appeared to increase 
with disease progression. At 6 weeks of age, astrocyte cell bodies and some processes 
were noted in the grey matter (Figure 2.8A), while extensive staining of astrocyte 
processes was seen within the white matter. The number of astrocytes in the ventral 
horn grey matter appeared to increase progressively between 6 and 22 weeks of age 
(Figure 2.8A-C). The increase in astrocyte numbers was also accompanied by a slight 
change in morphology, with astrocytes at 22 weeks of age showing slightly larger cell 
bodies and thicker processes than those at earlier time points (Figure 2.8C).  
At 18 weeks of age, when the numbers of MT-1/2-positive cells were increased (Figure 
2.7), MT-1/2 was predominantly expressed in GFAP-positive astrocytes (Figure 2.8D, 
shown here in the lumbar spinal cord white matter). Some MT-1/2 immunoreactivity in 
the ventral horn did not colocalise with GFAP (data not shown), indicating that MT-1/2 
may be expressed in other glial cells such as microglia.  
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Figure 2.7 MT-1/2 immunoreactivity in the SOD1 and WT spinal cord 
Line drawing of spinal cord regions (A; not to scale; dh, dorsal horn; vh, ventral horn; 
dwm, dorsal white matter; vlwm, ventral and lateral white matter). The density of MT-
1/2 -positive (MT-pos) cells did not change substantially in WT mice between 6 (B) and 
22 (C) weeks of age, but increased in SOD1 mice between 6 and 22 weeks of age (D-F). 
MT-1/2 increased in the SOD1 ventral horn from 18 weeks of age (G), and in the dorsal 
horn at 22 weeks of age (H), but did not change substantially in the white matter (I, J). 
Scale bars 100µm for B-F. **p<0.01. Error bars represent standard error of the mean. 
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Figure 2.8 Astrocytic expression of MT-1/2 in the lumbar spinal cord of SOD1 
mice 
The number of astrocytes appeared to increase over time in the lumbar spinal cord 
ventral horn of SOD1 mice (A-C). MT-1/2 expression (D, left panel) was 
predominantly seen in GFAP-positive astrocytes (D, middle panel; merged image 
shown in D, right panel), pictured above at 18 weeks of age in the SOD1 lumbar spinal 
cord white matter. In the ventral horn of 18-week-old SOD1 mouse lumbar spinal cord, 
MT-1/2 expression was seen in GFAP-positive astrocytes (E, arrowhead in left and right 
panels), yet some MT-1/2 expression was observed in cells which did not label with 
GFAP (E, arrows in left and right panels). Scale bar 20µm for A-D, 10µm for E. GFAP, 
glial fibrillary acidic protein; MT, metallothionein-1/2; NY, Nuclear Yellow.  
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2.3.2 Functional changes over time in SOD1 mice 
2.3.2.1 Survival 
In this cohort, the ethics-approved disease endpoint was measured as either the loss of 
20% from maximum body weight, or the inability of the mouse to right itself within 30 
seconds of being placed on its side, whichever occurred earlier. All SOD1 mice in this 
cohort reached the body weight endpoint before a loss of their righting reflex, and 
therefore the body weight endpoint was used for survival analysis. As determined by 
Kaplan-Meier analysis, average survival time for SOD1 mice was 163.8±2.1 days; 
median survival time was 166.0±1.5 days (Figure 2.9). All WT mice remained healthy 
past the endpoint ages of their SOD1 littermates. 
CPH regression was used to assess the effect of SOD1
G93A
 transgene copy number 
(using the ΔCT value) on survival times. Survival time was not significantly associated 
with the ΔCT value (HR 2.452, 95% CI 0.071-84.488, p=0.609); perhaps due to the 
small range of ΔCT values recorded for the functional cohort (range 4.62-5.26), which 
would indicate relatively small variations in transgene copy number within this cohort. 
However, copy number could be included in future survival analyses to minimise the 
effect of any copy number variations.           
 
2.3.2.2 Body weight 
2.3.2.2.1 Body weight averages 
Body weight rose continuously for WT mice throughout the duration of the study 
(Figure 2.10A). In contrast, the SOD1 mice displayed a characteristic curved body 
weight trajectory, achieving average maximal weight (21.0±0.3g) at the average age of 
114.1±3.1 days (approximately 16.3 weeks) (Figure 2.10A). The curved body weight 
trajectory in SOD1 mice likely represents growth during the pre-symptomatic phase of 
disease, with a subsequent reduction in body weight after disease onset due to loss of 
muscle mass as part of the disease processes. The average body weight of SOD1 mice 
was significantly lower than that of WT mice at 14 weeks of age (SOD1 20.0±0.2g vs. 
WT 21.0±0.5g, MWU p=0.035) and remained lower than that of WT mice until disease 
endpoint (Figure 2.10A).  
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Figure 2.9 Kaplan-Meier survival curve for SOD1 and WT mice 
Disease endpoint was measured as a loss of 20% from pre-disease maximum body 
weight. Survival times for SOD1 mice ranged from 144-177 days, while WT mice 
remained healthy throughout the study period.    
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Figure 2.10 Body weights of SOD1 and WT mice over time 
Body weight averages (A) were lower for SOD1 mice than WT mice from 14 weeks of 
age onwards, with SOD1 mice reaching maximum body weight at approximately 16 
weeks of age. Body weight trajectory estimates from linear mixed modelling (B, lines, 
from parameters in Table 2.4) appeared a good fit to the raw data (B, data points). 
*p<0.05, **p<0.01, ***p<0.001. Error bars represent standard error of the mean.   
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2.3.2.2.2 Body weight trajectories with linear mixed modelling 
Linear mixed modelling was explored as a way to model the curved body weight 
trajectory of SOD1 mice. Stepwise addition of fixed effects (Age in days, Age
2
, Age
3
) 
and random effects (intercept and slope, accounting for different starting body weights 
and different rates of change over time for different mice), assessment of model fit at 
each step, and variance-covariance matrix estimates for random effects, are detailed in 
Supplementary Data 2. The body weight trajectory of SOD1 mice fits more closely to a 
cubic curve than a quadratic curve (see Supplementary Data 2). The final linear mixed 
model has fixed effects of the form Body weight = β0 + β1*Age + β2*Age
2
 + β3*Age
3
, 
where each β coefficient has a unique value for WT and SOD1 groups (Table 2.4), 
confirming that body weight trajectory in SOD1 mice is altered from that of WT mice. 
When the body weight estimates calculated using these coefficient values are graphed, 
the model confirms the increase in WT body weight over time, and the curved body 
weight trajectory of SOD1 mice (Table 2.4, Figure 2.10B).  
 
Table 2.4 Parameter estimates from linear mixed model of body weight trajectory 
Fixed effects parameter 
Parameter estimates (β) 
p-value* 
WT SOD1 
Intercept (β0) 14.50 14.69 0.868 
Age (β1) 0.128 0.062 0.012 
Age
2
 (β2) -8.53x10
-4
 2.43x10
-4
 <0.001 
Age
3
 (β3) 2.28x10
-6
 -3.19x10
-6
 <0.001 
*p-value for whether the parameter estimates were significantly different between WT and SOD1 mice. 
Coefficient estimates correspond to the equation Body weight = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 
 
The age at which the two trajectory curves diverged was investigated by centring the 
model at various values of Age; SOD1 body weights became significantly lower than 
WT body weights from 99 days (14 weeks) of age onwards (p=0.045). Using the β 
estimates in the nlcom procedure (Stata IC), the point estimate for maximum body 
weight in SOD1 mice was calculated to be 20.0±1.1g, occurring at 110±2 days of age 
(around 15.7 weeks). These estimates are close to those calculated manually from the 
raw body weight data (21.0±0.3g, at 114±3 days of age, approximately 16.3 weeks).  
_________________________Chapter 2 – Neuroinflammatory and functional changes 
______________________________________________________________________ 
______________________________________________________________________ 
 
74 
 
2.3.2.3 Stride pattern testing 
2.3.2.3.1 Stride Length 
The stride length of WT mice stayed constant over time, with only a small decrease 
around 22-24 weeks of age (Figure 2.11A,B,E). From around 17 weeks of age onwards, 
the stride length of SOD1 mice declined markedly (Figure 2.11C-E). SOD1 stride 
length was significantly lower than WT stride length from 18 weeks of age onwards 
(SOD1 18wk 5.2±1.0cm vs. WT 18wk 5.9±0.8cm, MWU p=0.021) (Figure 2.11E). 
2.3.2.3.2 Uniformity 
The uniformity measurement, indicating any disparity between placement of the hind 
paw compared to where the front paw was placed on the previous step (Figure 2.11A), 
differed between WT and SOD1 mice over time. WT mice maintained a consistent 
uniformity measurement of less than 0.5cm over time; whereas uniformity measurement 
increased in SOD1 mice over time (Figure 2.11A-D, F). SOD1 mice showed a larger 
uniformity measurement than WT mice from 18 weeks of age (SOD1 0.7±0.1cm vs. 
WT 0.3±0.1cm, MWU p=0.002) onwards (Figure 2.11F). These data indicate that when 
walking forwards, WT mice were consistently able to bring the hind paw forwards to 
place it within 0.5cm of where the front paw had been on the previous step; however, 
SOD1 mice were increasingly unable to bring the hind paw forwards. The increasing 
uniformity measurement and decreasing stride length over time in the SOD1 mice likely 
reflect diminishing muscle strength in SOD1 mice as the disease progressed.  
2.3.2.3.3 Front-base width and hind-base width 
Front-base width was significantly greater in WT mice than in SOD1 mice at 17 weeks 
and 24 weeks of age (p=0.037 and p=0.034, respectively), however there was no 
consistent difference between WT and SOD1 mice over time (Figure 2.11B,G).  
Measurements of hind-base width appeared variable, with no consistent pattern of 
change between WT and SOD1 mice over time (Figure 2.11B,H). Hind-base width was 
greater for WT mice than SOD1 mice at 10, 11, 14, and 15 weeks of age (p<0.05), but 
between these time points there was no significant difference between WT and SOD1 
hind-base width (Figure 2.11H). Although measurements of hind-base width in SOD1 
mice remained within the range of measurements obtained at earlier time points, they 
showed a gradual decline from 21-24 weeks of age, such that at these time points the 
hind-base width was greater for WT mice than SOD1 mice (p<0.05) (Figure 2.11H).  
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Figure 2.11 Stride pattern testing in SOD1 and WT mice 
Representative stride patterns from WT mice at 16 (A) and 20 (B) weeks of age, and 
from SOD1 mice at 16 (C) and 19 (D) weeks of age, with hind paws in blue and front 
paws in red. SL, stride length; U, uniformity; FBW, front-base width; HBW, hind-base 
width (A,B). SOD1 mice showed decreasing stride length (E) and increasing uniformity 
measurement (F) with age compared to WT mice; front-base width (G) and hind-base 
width (H) did not differ substantially between WT and SOD1 mice over time. Scale bar 
1cm for A-D. *p<0.05, p<0.01, #p<0.001. Error bars show standard error of the mean. 
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2.3.2.4 Wire hang duration 
Wire hang duration, up to a maximum of 60 seconds, was maintained throughout the 
study in WT mice but declined over time in SOD1 mice (Figure 2.12).  
Out of the 13 WT mice, 4/13 (31%) attained the 60-second maximum on every attempt, 
while 9/13 WT mice (69%) showed durations of less than 60 seconds on at least one 
occasion. These sub-maximal results for WT mice can be attributed to either a training 
effect, where wire hang duration increased up to 60 seconds with experience (see 
Appendix 1); or to single-week lapses in hang duration, where WT mice would attain 
less than 60 seconds in a particular week but would return to consistently attaining 60 
seconds in the following weeks. In contrast to WT mice, only 12/17 SOD1 mice (71%) 
ever attained the maximum wire hang duration of 60 seconds; 5/17 SOD1 mice (29%) 
were unable to maintain hang duration for 60 seconds at any time point measured.  
All SOD1 mice displayed reduced wire hang duration as the disease progressed over 
time (Figure 2.12). In the 12 SOD1 mice attaining 60-second wire hang durations, the 
average age at which they were no longer able to maintain the maximum hang duration 
was 114.5±2.4 days of age (approximately 16 weeks of age). SOD1 mice attained a 
significantly lower average wire hang duration than WT mice at 15 weeks of age (42±5 
seconds vs. 58±2 seconds respectively, MWU p=0.012) and thereafter. The average age 
at which SOD1 mice could only hold on for 30 seconds, half of the maximum time, was 
126.3±2.4 days (approximately 18 weeks of age). By 20 weeks of age, SOD1 mice 
could only hang onto the wire bars for less than 10 seconds, representing a clear 
decrease in muscle strength between 15 and 20 weeks of age (Figure 2.12).  
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Figure 2.12 Wire hang duration in SOD1 and WT mice 
After an initial training period, WT mice were able to maintain the maximum wire hang 
duration of 60 seconds throughout the study; SOD1 mice showed a marked decrease in 
wire hang duration from 15 weeks of age onwards. *p<0.05, ***p<0.001. Error bars 
represent standard error of the mean.  
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2.3.2.5 Neurological scoring 
The neurological scoring system employed for this analysis ranged from a neurological 
score (NS) of NS=0 (no symptoms) through to NS=4 (inability to right within 30 
seconds of being placed on side) (Table 2.3). SOD1 mice showed an increase in 
neurological score rating with time, from NS=0 to NS=3 (Figure 2.13). As previously 
mentioned, all SOD1 mice reached their body weight endpoint before reaching the 
righting endpoint.  Upon reaching the body weight endpoint, 1/17 SOD1 mice (6%) 
were scored as NS=1, 10/17 SOD1 mice (59%) were scored as NS=2, and 4/17 SOD1 
mice (24%) were scored as NS=3; endpoint data on neurological score were not 
recorded for 2/17 SOD1 mice. Thus, no SOD1 mice were ever rated as NS=4.  
WT mice were generally rated as NS=0; however, some WT mice were rated as NS=1 
at some time points (Figure 2.13). This may be attributable to the author’s strict 
interpretation of the neurological scoring criteria at NS=1, where the criteria are 
‘Collapse or partial collapse of leg extension towards lateral midline, or trembling of 
hind legs, during tail suspension’ (Table 2.3). Gradual movement of the hind limbs 
during tail suspension might have been interpreted as partial collapse, perhaps caused 
by muscle relaxation in WT mice rather than lack of muscular strength. To ensure that 
NS=1 was assessed in the SOD1 mice as a true indicator of disease onset, disease onset 
was considered to be the point at which the mouse was consistently rated as NS=1, or 
higher, upon every examination. The average age at which SOD1 mice consistently 
displayed symptoms (NS=1) was 110.5±3.3 days, or approximately 15.8 weeks of age.  
There appeared to be a substantial interval between the ages at which SOD1 mice 
reached NS=1 and NS=2; the average age at which SOD1 mice reached NS=2 was 
160.7±2.6 days, or approximately 22.9 weeks of age. Within this interval, observation 
of the mice identified some features of disease which were not described within the 
neurological system used here. As disease progressed, the SOD1 mice appeared to 
display an altered gait pattern in which the legs tended to splay outwards while walking, 
with the hindquarters being lower than those of WT mice – perhaps due to decreased 
muscle strength in the hind limbs. In the ALSTDI criteria (Table 2.3), altered gait as 
required for NS=2 is quite a severe change, with mice dragging their feet and toes along 
the bench only when within a few weeks of disease endpoint (Figure 2.13).  
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Figure 2.13 Neurological scoring in SOD1 and WT mice 
At each week of age, the percentage of mice rated as a particular neurological score 
(NS=0 through NS=3) is indicated. WT mice were rated as either NS=0 or NS=1 
throughout the study (A), whereas SOD1 mice showed a progression from NS=0 (no 
symptoms) through to NS=3 (hindlimb paralysis), indicating increasing neurological 
motor deficits over time in SOD1 mice.    
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2.4 Discussion 
The findings in this chapter show that the number of Arg1-positive microglia and iNOS-
positive microglia increased in the SOD1 lumbar spinal cord from 14 weeks of age 
(Figure 2.1 to Figure 2.5), while ubiquitinated inclusions were  present in SOD1 motor 
neurons from as early as 6 weeks of age (Figure 2.6). Functional deficits in SOD1 mice 
developed from 14 weeks of age onwards (Figure 2.9 to Figure 2.13). The number of 
MT-1/2-positive cells increased from 18-22 weeks of age (Figure 2.7). Thus, motor 
neuron pathology precedes microglial activation and functional decline, while 
microglial activation becomes apparent around the time of symptom onset.  
2.4.1 The relationship between microglial activation and disease progression 
The results of the present study demonstrated a substantial increase in the number of 
microglia in the lumbar spinal cord of SOD1 mice, starting from 14 weeks of age and 
continuing to increase with time (Figure 2.1) The increase in microglial numbers starts 
from 14 weeks of age, concurrent with the onset of disease symptoms, as measured by 
decreased body weight in SOD1 mice compared to their WT littermates. This study 
confirms previous observations that activated microglia are increased in the SOD1 
spinal cord at disease onset, and increase in number throughout disease progression 
(Almer et al. 1999; Chiu et al. 2008; Gowing et al. 2008; Beers et al. 2011b; Yang et al. 
2011). However, a few previous studies have identified a pre-symptomatic increase in 
microglial number in SOD1 mice (Alexianu et al. 2001), SOD1
G93A
 rats (Graber et al. 
2010), and SOD1
H46R
 rats (Sanagi et al. 2010). Earlier apparent activation of microglia 
in these three studies may be due to the use of a different, perhaps more sensitive, 
microglial marker CD11b (Alexianu et al. 2001); or alternatively the disease course in 
SOD1 rodent models may show subtle differences depending on species, transgene 
copy number, or activity level of the mutant SOD1 protein (Pan et al. 2012).  
Pathological changes in motor neurons, including the presence of ubiquitinated 
aggregates and the formation of SOD1-positive annular structures, were observed from 
6 weeks of age onwards, well before the increase in microglia was first detected at 14 
weeks of age (Figure 2.6). The timing of these changes suggests that the increase in 
spinal cord microglia is a reactive response to neuronal dysfunction or degeneration, 
rather than a primary initiator of neuronal damage. However, microglial activation may 
play a key role in modulating disease progression after disease onset (Boillee et al. 
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2006; Beers et al. 2011a; Beers et al. 2011b; Audet et al. 2012). Indeed, we observed 
that SOD1 mice developed overt functional changes in stride pattern from 18 weeks of 
age, four weeks after the initial increase in lumbar spinal cord microglia (Figure 2.1, 
Figure 2.11). Thus, the increase in microglial number preceded the transition into a 
rapidly-progressing phase of disease, where functional ability rapidly declined.  
 
2.4.2 Microglial phenotype in SOD1 mice 
In spinal cord tissue from ALS patients and SOD1 rodents, activated microglia can form 
aggregates in close proximity to motor neurons (Alexianu et al. 2001; Henkel et al. 
2004; Sanagi et al. 2010), suggesting that any microglial activation will directly affect 
motor neurons. As M1-like and M2-like microglial phenotypes appear to be an 
important determinant of disease progression in SOD1 mice (Beers et al. 2011b), SOD1 
lumbar spinal cord ventral horn microglia were characterised through their expression 
of putative M1/M2 markers iNOS and Arg1, respectively (Colton 2009).  
2.4.2.1 Lumbar spinal cord Arg1 and iNOS expression 
In this study it was expected that the lumbar spinal cord microglia in SOD1 mice would 
show a shift in the spectrum of their activation phenotype, from Arg1-predominant to 
iNOS-predominant, in line with other studies which have suggested an M2-to-M1 shift 
over time (Beers et al. 2011a; Beers et al. 2011b; Liao et al. 2012). However, the 
current study found that both Arg1-positive and iNOS-positive microglia increased in 
number with disease progression (Figure 2.2, Figure 2.3). The number of Arg1-positive 
lumbar spinal cord microglia increased at disease onset, and continued to increase with 
disease progression, such that the number of Arg1-expressing microglia increased 18-
fold between the pre-symptomatic stage and disease endpoint (Figure 2.2). Less than 
20% of microglia expressed Arg1 at the pre-symptomatic stage, but this figure rose to 
over 60% at disease endpoint (Figure 2.5F). The increase in Arg1-expressing microglia 
may suggest an increase in the number of microglia displaying an M2-like 
neuroprotective phenotype.  
However, the number of iNOS-positive lumbar spinal cord microglia also increased 
from disease onset, with a 7-fold increase in microglia expressing iNOS between the 
pre-symptomatic stage and disease endpoint (Figure 2.3). Less than 10% of microglia 
_________________________Chapter 2 – Neuroinflammatory and functional changes 
______________________________________________________________________ 
______________________________________________________________________ 
 
82 
 
expressed iNOS at pre-symptomatic stages, with this figure rising to over 30% at 22 
weeks of age (Figure 2.5F). It was noted that the increase in iNOS-positive microglia 
was also accompanied by an increase in the number of iNOS-negative microglia (Figure 
2.3); in the absence of double-immunostaining for Arg1 and iNOS together, one may 
speculate that these iNOS-negative microglia showed an M2-like, possibly Arg1-
positive, phenotype. Despite the reported M2-to-M1 shift in microglial phenotype in 
SOD1 spinal cord (Liao et al. 2012), two studies have shown the maintenance of M2 
markers and M2-like characteristics in SOD1 microglia at disease endpoint (Chiu et al. 
2008; Tada et al. 2011); consequently, the concept of microglia retaining some of their 
neuroprotective function throughout disease progression is not unprecedented. 
A semi-quantitative analysis of Arg1 and iNOS immunoreactivity in individual 
microglia indicated that both Arg1 and iNOS expression levels were increased during 
disease progression (Figure 2.4). The percentage area occupied by Arg1 
immunoreactivity increased approximately 5-fold between 6 and 22 weeks of age, yet 
the percentage area occupied by iNOS immunoreactivity increased approximately 25-
fold between 6 and 22 weeks of age due to the small amount expressed at 6 weeks of 
age (Figure 2.4). Although these data would hint that the percentage area occupied by 
Arg1 appears greater than that occupied by iNOS (Figure 2.4), the absolute levels of 
Arg1 and iNOS protein cannot be reliably compared by immunohistochemistry intensity 
due to different antibody-antigen binding strengths. These data do suggest that iNOS 
shows a greater fold increase than Arg1 between 6 and 22 weeks of age.  
The increasing number of iNOS-positive microglia seen in the present study, along with 
the large fold increase in iNOS immunoreactivity, may represent an increase in M1 
neurotoxic microglia, which could increase the production of toxic factors such as nitric 
oxide within the spinal cord (Appel et al. 2011). In contrast, the continuing increase in 
Arg1-positive microglia may represent an ongoing attempt by M2 neuroprotective 
microglia to limit tissue damage and neuronal degeneration (Colton 2009; Henkel et al. 
2009). The increase in iNOS-positive microglia, while lesser in magnitude than the 
increase in Arg1-positive microglia, may result in a higher net production of nitric oxide 
in the lumbar spinal cord ventral horn, with deleterious effects on the surrounding motor 
neurons. Thus, the results of this study show evidence of concomitant neurotoxic and 
neuroprotective processes in SOD1 spinal cord microglia.  
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2.4.2.2 Cervical spinal cord Arg1 and iNOS expression 
The expression of Arg1 and iNOS was examined in the cervical spinal cord of SOD1 
mice aged 10 to 22 weeks, to determine whether differences in microglial phenotype 
between the lumbar and cervical regions may explain the later involvement of the 
forelimbs in SOD1 mice (Kuntz et al. 2000).  
In the cervical spinal cord ventral horn of SOD1 mice, the number of Arg1-positive 
microglia was increased at 22 weeks of age, while the number of microglia expressing 
iNOS also increased slightly over time (Figure 2.5). Although these trends were similar 
to those seen in the lumbar spinal cord, three pieces of data indicate that the cervical 
spinal cord may present a slightly M2-skewed microglial environment compared with 
the lumbar spinal cord. First, at 10 weeks of age, there were equivalent numbers of 
Arg1-positive and Arg1-negative microglia in the cervical spinal cord, whereas in the 
lumbar spinal cord the majority of microglia did not express Arg1. Second, at 22 weeks 
of age, the cervical spinal cord shows a higher percentage of microglia expressing Arg1 
(79%) than the lumbar spinal cord (64%). Third, at 22 weeks of age, the cervical spinal 
cord shows a lower percentage of microglia expressing iNOS (24%) than the lumbar 
spinal cord (32%). These slight differences indicate that neuroprotective M2-phenotype 
microglia may be more prevalent in the cervical spinal cord than the lumbar spinal cord 
at pre-symptomatic stages of disease, and that the activation state of cervical microglia 
at 22 weeks of age involves greater numbers of microglia expressing of the M2 marker 
Arg1, and lower numbers of microglia expressing the M1 marker iNOS.  
These results are in line with a previous study showing early upregulation of M2 
markers in the cervical spinal cord of SOD1 mice (Beers et al. 2011b). From the current 
study, it is difficult to elucidate whether the apparently less-inflammatory microglial 
environment in the spinal cord is due to a reduced reactive response from decreased or 
delayed neuronal degeneration, or whether the relative prevalence of M2-phenotype 
microglia directly provides a protective environment, delaying neuronal dysfunction 
and degeneration. However, comparing ubiquitin pathology at 10 weeks of age in the 
lumbar spinal cord (aggregates in the motor neuron somas and in the neuropil; Figure 
2.6) and the cervical spinal cord (aggregates in the motor neuron somas, and mostly 
absent from the neuropil) (Lewis et al. 2014) indicates that the microglial expression of 
inflammatory markers may be influenced by the prevalence of ubiquitinated aggregates.     
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2.4.2.3 Technical limitations to discussion of microglial phenotype 
The results from the present study do not show a shift from Arg1-predominant, M2-like 
phenotype to an iNOS-predominant, M1-like phenotype over time, and as such differ 
slightly from previously reported studies. M2 markers such as Ym1 and MCP-1 have 
previously been reported as upregulated in the SOD1 spinal cord during the early, slow-
progressing phase of disease (Beers et al. 2011a; Beers et al. 2011b), with a subsequent 
downregulation of M2 markers, and upregulation of M1 markers such as TNFα, IL-6 
and NOX2 during the rapidly-progressive disease phase (Almer et al. 1999; Yoshihara 
et al. 2002; Gowing et al. 2009; Beers et al. 2011a; Beers et al. 2011b; Liao et al. 
2012). The differences between the current study and these previous studies may be due 
to the use of protein markers rather than mRNA markers of M1/M2 microglial 
phenotype.  
There are both positive and negative aspects to the use of protein markers rather than 
mRNA analysis. While analysis of spinal cord mRNA can provide an excellent 
overview of the proteins cells are capable of producing, not all mRNAs may be 
effectively translated into protein. Furthermore, analysis of mRNA from homogenised 
spinal cord cannot determine the subcellular localisation of specific mRNAs. While 
microglia are likely to be the primary cell type for cytokine production within the spinal 
cord, other cell types including astrocytes, infiltrating immune cells, and even motor 
neurons may also produce cytokines and inflammatory markers; the use of mRNA from 
homogenised spinal cord alone may limit interpretation of protein expression in 
microglia. Indeed, Arg1 expression in motor neurons was observed in the current study 
(data not shown). Immunolabelling allows cell-specific localisation of inflammatory 
markers, ensuring that the results are specific to microglia.  
Conversely, while the use of immunostaining allows identification of cell-specific 
protein expression, persistent antibody cross-reactivity when attempting double-
labelling for Arg1 and iNOS (both mouse monoclonals) meant that the relative 
expression of Arg1 and iNOS within specific cells could not be compared. As Arg1 and 
iNOS are inversely regulated in CNS glia (Bonaparte et al. 2006), it could be assumed 
that cells expressing Arg1 expressed low levels of iNOS, and vice versa – however, it is 
likely that some, but not all, Arg1-positive microglia also express iNOS. Thus, not all 
Arg1-positive microglia may show a neuroprotective phenotype. While the presence of 
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a higher percentage of microglia expressing Arg1 than iNOS does suggest an M2-
predominant, anti-inflammatory environment in the SOD1 spinal cord, this 
interpretation is over-simplistic without the consideration of additional M1 and M2 
markers. It is also possible that the expression of Arg1 and iNOS may not correlate 
directly with M2 and M1 phenotypes. The ideal analysis of microglial phenotypes 
would combine mRNA data, protein immunohistochemistry, and cytokine profiles of 
the SOD1 spinal cord.  
 
2.4.3 Pathological changes in SOD1 motor neurons 
The timing of motor neuron pathology in the SOD1 lumbar spinal cord was examined 
with immunostaining for neurofilaments, ubiquitin and hSOD1. Pathological alterations 
in lumbar motor neurons were seen from as early as 6 weeks of age (Figure 2.6), well 
before the development of microgliosis in the lumbar spinal cord (Figure 2.1). The 
current study confirms previous results showing pre-symptomatic presence of 
ubiquitianted aggregates and vacuolar neurofilament pathology in the SOD1 spinal cord 
(Bruijn et al. 1997a; Vinsant et al. 2013), indicating that the initial increase in microglia 
is likely a neuroprotective response to neuronal degeneration.    
From 6 weeks of age onwards, vacuolar pathology involving both hSOD1 and 
neurofilaments develops in spinal cord motor neurons (Figure 2.6). The source of these 
‘empty’ vacuoles may be due to the breakdown of the Golgi apparatus or the swelling of 
mitochondria (Vinsant et al. 2013), or due to direct effects of mutant SOD1 on 
neurofilament proteins. The formation of ring-like structures in the neuropil, which are 
positive for either hSOD1 or dephosphorylated neurofilament medium chain (SMI32), 
and sometimes both, suggests a direct role for the mutant SOD1 in vacuole formation by 
neurofilament modification. SOD1-mediated protein nitration by nitric oxide may be 
one such detrimental way for SOD1 to disrupt neurofilament formation (Bruijn et al. 
1997a). As neurofilament content normally regulates axonal calibre (Hoffman et al. 
1984; Perrot et al. 2007), it is possible that aberrant accumulations of neurofilament 
protein are misinterpreted as a local stimulus for expansion of axon, creating a vacuole.  
Additionally, the appearance of neuronal pathology precedes the onset of functional 
deficits by several weeks in this study. This is consistent with previous studies showing 
pre-symptomatic degenerative changes at the neuronal cell body well before loss of 
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function, due to compensatory re-innervation of muscle fibres by surviving motor 
neurons (Frey et al. 2000; Nandedkar et al. 2010; Vinsant et al. 2013).  
 
2.4.4 Increasing expression of the antioxidant response protein, MT-1/2 
Increasing iNOS expression in microglia may contribute to the production of nitric 
oxide, and in turn the production of peroxynitrite, in the spinal cord of SOD1 mice. The 
expression of the protein metallothionein-1/2 was examined as a measure of the 
antioxidant response taking place in spinal cord glia. In the lumbar spinal cord, an 
increase in MT-1/2-expressing glial cells was seen in the ventral horn from 18 weeks of 
age (Figure 2.7). The amount of diffuse MT-1/2 immunostaining also qualitatively 
increased from 18 weeks of age in SOD1 mice (Figure 2.7), indicating a possible 
increase in both MT-1/2 expression and MT-1/2 secretion into the extracellular space.  
The increase in MT-1/2 expression with disease progression confirms previous studies 
showing increased MT-1/2 production in the SOD1 spinal cord over time (Gong & 
Elliott 2000; Nagano et al. 2001; Tokuda et al. 2007; Tokuda et al. 2013). However, the 
current study was only able to detect increased MT-1/2 in the ventral horn from 18 
weeks of age onwards, while previous studies have all demonstrated pre-symptomatic 
MT-1/2 increases (Gong & Elliott 2000; Nagano et al. 2001; Tokuda et al. 2007; 
Tokuda et al. 2013). The earlier increase in MT-1/2 seen in previous studies may be due 
to differences in genetic background strain of SOD1 mice – a congenic B6 background 
was used in the current study, compared to a hybrid B6SJL background used in previous 
studies (Gong & Elliott 2000; Nagano et al. 2001; Tokuda et al. 2007; Tokuda et al. 
2013). Alternatively, the earlier detection of MT-1/2 in previous studies may be due to 
the use of more sensitive detection techniques such as radioimmunoassay (Nagano et al. 
2001). The increased production of MT-1/2 during only the symptomatic stage of 
disease in the current study (Figure 2.7) does not negate the presence of oxidative stress 
in pre-symptomatic SOD1 mice, as MT-1/2 is only one of many antioxidant response 
proteins (Mates et al. 1999; Ahsan et al. 2009). The post-symptomatic increase in MT-
1/2 may indicate the presence of detrimental oxidative stresses at later phases of disease.  
The upregulation of MT-1/2 from 18 weeks of age (Figure 2.7) does correlate with the 
increase in microglial activation in the lumbar spinal cord, and occurs around the time 
that overt functional deficits in SOD1 stride pattern were detected (Figure 2.11). 
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Together, these data suggest that the increasing number of iNOS-expressing ventral 
horn microglia increases total NO synthesis; the increased NO- or peroxynitrite-
mediated oxidative stress may damage motor neurons, causing overt functional deficits, 
and inducing expression of MT-1/2 in astrocytes.  
Alternatively, the role of MT-1/2 in SOD1 mice may be more complex than purely 
providing an antioxidant response. MT-1/2 show neuroprotective properties, which will 
be further discussed in Chapter 4, as well as antioxidant properties. Astrocytes increase 
MT-1/2 production upon cortical neuronal injury, and MT-1/2 is secreted from 
astrocytes onto surrounding neurons to elicit pro-survival and pro-outgrowth effects 
(Chung et al. 2008b). In SOD1 mice, the increase in MT-1/2 expression could be in 
response to widespread neuronal degeneration in the later stages of disease from 18 to 
25 weeks of age, as a possible attempt to protect motor neurons from degeneration.    
While MT-1/2 immunoreactivity was mainly colocalised with the astrocyte marker 
GFAP (Figure 2.8), some glial MT-1/2 labelling was not colocalised with GFAP (data 
not shown). In the SOD1 spinal cord, MT-1/2 was originally thought to be expressed 
only in astrocytes (Gong & Elliott 2000); however, a recent publication demonstrated 
MT-1/2 in SOD1 microglia as well as astrocytes (Tokuda et al. 2013). The small 
amount of non-GFAP-associated MT-1/2 immunostaining in the present study (data not 
shown) could be present in microglia. Future studies could examine whether microglial 
MT-1/2 expression may attenuate microglial ROS production, and consequently 
correlate with neuroprotective rather than neurotoxic microglial phenotypes.      
There are some limitations to the interpretation of MT-1/2 induction as an antioxidant or 
neuroprotective response. As mentioned above, MT-1/2 is induced in response to 
neuronal injury; MT-1/2 induction is additionally controlled by the presence of metal 
ions, cytokines, and corticosteroids (Richards et al. 1984; Cousins & Leinart 1988). The 
increased astrocytic MT-1/2 in the SOD1 spinal cord could reflect metal 
dyshomeostasis, which has been proposed as a possible mechanism of ALS (Roos et al. 
2006), or the presence of inflammatory cytokines due to increasing microglial activation 
and T-cell infiltration (Beers et al. 2011a). Alternatively, as the number of astrocytes 
appeared to increase over time in the SOD1 lumbar spinal cord in the present study 
(Figure 2.8), and as astrogliosis has been reported previously in SOD1 mice (Vargas & 
Johnson 2010), the increased amount of MT-1/2 in the spinal cord may purely reflect 
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the increasing number of astrocytes. Regardless of the multiple possible mediators of 
MT-1/2 upregulation, the presence of diffuse MT-1/2 immunoreactivity indicates that 
MT-1/2 is released into the extracellular space of the SOD1 lumbar spinal cord and may 
comprise an attempt at astrocyte-mediated neuroprotection. The protective effects of 
MT-1/2 in SOD1 mice will be further explored in Chapter 4.  
 
2.4.5 Functional decline  
As expected, the present study confirmed the decline in functional ability over time in 
SOD1 mice (Gurney et al. 1994). SOD1 mice showed lower body weights than wild-
type mice from 14 weeks of age (Figure 2.10), deficits in wire hang duration from 15 
weeks of age (Figure 2.12), observable neurological deficits from 16 weeks of age 
(Figure 2.13), and altered stride pattern from 18 weeks of age (Figure 2.11). Thus, 
disease onset was detected around 14 to 15 weeks of age in this study. The timing of 
disease onset is considered a conservative estimate compared to other studies using the 
SOD1 mouse on a congenic B6 background, which found the earliest appearance of 
disease symptoms at around 11 weeks of age (Beers et al. 2011a; Beers et al. 2011b).   
2.4.5.1 The use of mixed modelling to assess body weight peak 
In this study a slightly novel approach to measuring disease onset was used – mixed 
modelling was used to generate a curve to model the body weight trajectory of SOD1 
mice, and the age at which maximum body weight was reached was estimated using 
calculus. This method was compared with the calculation of weekly averages. Both the 
average body weight, and the trajectory estimated with mixed modelling, showed 
differences between SOD1 and WT mice from 14 weeks of age (Figure 2.10). The 
model-derived estimated maximum body weight, and the model-derived age at which 
the maximum body weight occurs, were similar to those calculated from the raw data.  
The mixed model has both advantages and disadvantages over weekly body weight 
averages. The advantages are that: the mixed model allows all recorded body weight 
measurements, even taken on a daily basis, to be used instead of creating a weekly 
average for each mouse; and that the mixed model is able to assign some of the variance 
in the data to variations over time for individual mice, reducing the residual variance 
and increasing statistical power to detect differences between treatment or genotype 
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groups (Murnane & Willett 2011). The disadvantage of a mixed model is that if the 
model is not fitted correctly, the estimates generated by the model will not be an 
accurate reflection of the true data. However, the body weight trajectories of SOD1 
mice appear to be well modelled by a cubic function (Figure 2.10), with a cubic 
function showing superior model fit over a quadratic function (Supplementary Data 1). 
Thus, mixed modelling may be a novel method of increasing statistical power in studies 
which examine body weight measurements in the same mice over time.       
2.4.5.2 Comparison of tests for functional deficits 
Functional decline in SOD1 mice was evident in wire hang duration times prior to 
becoming evident in stride pattern (Figure 2.11, Figure 2.12). This earlier detection 
using the wire hang test may be due to the nature of each task – maintaining grip on 
suspended wire bars requires constant muscle activation, whereas walking along a strip 
of paper likely requires less muscle strength, and has the advantage that each limb gets a 
transient rest period while it is in the stationary phase of walking.  
The wire hang duration, or paw grip endurance, test has been used previously to assess 
functional ability and muscle strength in SOD1 mice, with deficits in wire hang duration 
ability found as early as 12 weeks of age (Weydt et al. 2003). In the present study, wire 
hang duration was tested to a maximum of 60 seconds, compared with a maximum of 
90 seconds in previous studies (Weydt et al. 2003). The use of a longer test time may 
pick up earlier changes in muscle strength, as increasing the hang time requires an 
increased amount of strength and endurance.  
Computerised treadmill analysis of SOD1 gait pattern indicates that changes between 
SOD1 and WT mice occur as early as 8 weeks of age (Wooley et al. 2005); however, in 
the current study differences between SOD1 and WT mice only became apparent from 
18 weeks of age onwards (Figure 2.11). The late change in stride lengths observed here 
are consistent with those observed in other studies using non-treadmill-based footprint 
analysis (Gurney et al. 1994; Knippenberg et al. 2010). These data indicate that 
measurements of stance and stride times during treadmill running (Wooley et al. 2005) 
provide a much more sensitive measure of dysfunction than measurement of stride 
length on paper. However, the late decline in stride length may correspond to the 
rapidly-progressing phase of disease, where motor units are lost without compensatory 
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re-innervation in the muscle; stride length may be useful in monitoring disease 
progression during this phase.  
In this study we report increasing uniformity measure in SOD1 mice; that is, reduced 
ability of hindlimb musculature to move the leg in a forward motion during stepping, 
such that the hindlimb placement falls short of front limb placement on the previous 
step (Figure 2.11). To our knowledge, this measure has not been previously reported in 
SOD1 mice and, like the late change in stride length, may be an appropriate measure of 
measuring the effect of therapeutic interventions on the late phase of disease. 
2.4.5.3 Neurological scoring system  
The neurological scoring system employed in this study, designed by the ALSTDI, was 
used to assess neurological deficits present in SOD1 mice through observation. The 
ALSTDI scoring system allows only five possible neurological scores: no symptoms 
(NS=0), mild symptoms at disease onset (NS=1), dragging of feet due to loss of muscle 
strength (NS=2), rigid paralysis or minimal movement (NS=3), and inability to right 
(NS=4) (Scott et al. 2008). SOD1 mice showed a progressive increase in the 
neurological score rating throughout disease progression (Figure 2.13); however, of the 
four neurological scores observed in this study (NS=0-3), there was a substantial time 
gap between a rating of NS=1 and a rating of NS=2 (see text, Chapter 2.3.2.5). During 
the period when a given mouse was rated NS=1, alterations in gait could be observed 
which did not meet the criteria for a rating of NS=2. Additionally, some WT mice were 
also rated as NS=1 – possibly due to mis-interpretation of the neurological score criteria 
to include any inwards collapse of the legs upon tail suspension, as sometimes occurred 
in WT mice – but no WT mice showed gait abnormalities as seen in SOD1 mice. A 
neurological scoring system with more specific detail around gait abnormalities, such as 
the Beers/Appel/Simpson/Henkel (BASH) scoring system (Beers et al. 2011b), may be 
more appropriate for detailed comparison of neurological symptoms present after 
disease onset in SOD1 mice.  
Although the NS=2 rating was reached rather late in disease progression, a rating of 
NS=2 with dragging feet, or toes curling under while walking, was easily identified and 
may be a useful tool for measuring the age at which mice develop overt difficulties 
maintaining normal hindlimb function.        
_________________________Chapter 2 – Neuroinflammatory and functional changes 
______________________________________________________________________ 
______________________________________________________________________ 
 
91 
 
2.4.5.4 Functional measures of disease progression for evaluating therapeutics 
Peak body weight, and the inability to maintain wire hang duration for 60 seconds, may 
be used to evaluate disease onset in future cohorts of SOD1 mice. Changes in stride 
length, uniformity measure, wire hang duration, body weight, and neurological score 
rating (foot dragging), may be useful for monitoring disease progression over time in 
SOD1 mice.  
 
2.4.6 Summary and conclusions  
There are four main findings of this study:  
First, the increase in microglial numbers does not precede onset of disease symptoms 
but does precede the development of overt functional deficits;  
Second, the number of Arg1-positive microglia and the number of iNOS-positive 
microglia both increase in the SOD1 lumbar spinal cord over time, suggesting ongoing 
conflicting actions of neuroprotective and neurotoxic microglia; 
Third, cervical spinal cord microglia show more common expression of Arg1 and less 
common expression of iNOS than the lumbar spinal cord, indicating that a more M2-
like inflammatory environment may be responsible for the later involvement of the 
forelimbs; 
Fourth, the antioxidant protein MT-1/2 is increased after disease onset, possibly induced 
by neuronal damage, or by the release of free radical species or inflammatory cytokines 
from activated microglia.   
These findings implicate microglial activation and microglial phenotype as contributors 
to the degeneration of motor neurons after disease onset. It is likely that microglial 
activation occurs as a result of early changes in dysfunctional or degenerating motor 
neurons, with microglial activation then affecting disease progression (Beers et al. 
2006; Liao et al. 2012). Microglial activation in the spinal cord involved increased 
numbers of cells expressing the M2 marker Arg1, and increased numbers of cells 
expressing the M1 marker iNOS, showing that both neurotoxic and neuroprotective 
processes are ongoing within the spinal cord of SOD1 mice.  
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The results presented here highlight the need to use a panel of inflammatory markers to 
determine microglial phenotype. Although this study showed a predominance of Arg1-
expressing microglia, the phenotype of each individual cell will depend on the balance 
of Arg1/iNOS expression and on cytokine expression. The ideal study of microglial 
phenotype would combine mRNA, protein, and cytokine expression profiles.  
The modulation of microglial activation remains a key target for ameliorating disease in 
ALS patients (Beers et al. 2008; Chiu et al. 2008; Pollari et al. 2011; Lee et al. 2012). 
Pro-inflammatory microglial activation, as seen by the increasing number of iNOS-
positive microglia, likely causes neuronal damage regardless of an increase in anti-
inflammatory microglial activation as seen by Arg1 expression in this study. It is likely 
that the detrimental effects of an M2-to-M1 microglial phenotype switch come 
primarily from the gain of toxic properties in M1 microglia, but may also involve the 
loss of protective properties in M2 microglia. As such, potential ALS therapies designed 
to modulate microglial activation should concentrate on the reduction of the pro-
inflammatory phenotype and the promotion of the anti-inflammatory phenotype. 
Modulation of microglial immune responses remains an important target for 
ameliorating disease symptoms and slowing the rate of disease progression in ALS.   
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3.1 Background 
3.1.1 The need for multi-action therapies in ALS 
Clinical trials of single-drug interventions in ALS patients have shown little efficacy 
(Gordon & Meininger 2011). In addition, single-drug studies which were successful in 
SOD1 mice have not translated into successful clinical trials in ALS patients (Benatar 
2007). As mentioned in Chapter 1, the etiology of ALS is thought to be highly complex, 
with evidence of multiple pathological changes present. These changes include 
oxidative stress and marked activation of glial cells, in both ALS patients and SOD1 
mice. The multifactorial aetiology of ALS indicates that a single therapeutic compound 
may not be sufficient to successfully address the multiple aspects of ALS pathology. 
Therefore, multifactorial or multi-action therapies may have more success as effective 
therapeutics for preventing neuronal death in ALS.  
 
3.1.2 Endotherapia – a drug cocktail of small molecules 
One such drug cocktail under consideration for an ALS treatment is known as 
Endotherapia, a mixture of small molecules each conjugated to poly-L-lysine (PLL) 
(Geffard et al. 2010). The mixture of small molecules consists of fatty acids, amino 
acids, antioxidant compounds, and vitamins, thought to have neuroprotective, 
antioxidant, and immunomodulatory activity (Geffard et al. 2010). Additionally, while 
the role of chronic infection in neurodegeneration is controversial (Nicolson 2008), the 
fatty acids in Endotherapia may prevent bacterial adhesion to reduce chronic infections 
(Geffard et al. 2010). The multiple potential actions of Endotherapia could affect 
several pathways at once, and thus would have more chance of ameliorating complex 
neurodegenerative diseases. Endotherapia complexes have been tested in the 
neurodegenerative diseases multiple sclerosis (MS) and ALS, using an MS-tailored 
Endotherapia mixture of 19 compounds, named ‘GEMSP’ (Mangas et al. 2006), and an 
ALS-tailored Endotherapia mixture containing 25 compounds, named ‘Gemals’ 
(Nicaise et al. 2008); 12 compounds are common to both GEMSP and Gemals. The 
base components of Gemals, along with information on their functions, are listed in 
Table 3.1. The composition of formulated Gemals, where the components are linked to 
PLL in various combinations, is listed in Table 3.2. 
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Table 3.1 Functional categories of Gemals components 
Constituent Molecule type; function 
Oleic acid Unsaturated fatty acid; antioxidant, anti-inflammatory 
Thioctic acid Dithiol; antioxidant 
Myristic acid Saturated fatty acid  
Palmitic acid Saturated fatty acid  
Lauric acid Saturated fatty acid; anti-inflammatory 
Linoleic acid Unsaturated fatty acid; antioxidant, anti-inflammatory 
Palmitoleic acid Unsaturated fatty acid; anti-inflammatory 
Caprylic acid Saturated fatty acid  
T-T-Farnesyl-L.Cysteine Amino acid derivative;  
Cholesterol Sterol; anti-inflammatory 
L. Cysteine Amino acid; antioxidant 
Taurine  Amino acid derivative; antioxidant, neuroprotective 
L. Methionine Amino acid; antioxidant, anti-inflammatory 
L. Glutathione Tripeptide; antioxidant 
Alpha-tocopherol-succinate Vitamin E; antioxidant 
Ascorbic acid Vitamin C; antioxidant 
Coenzyme Q10 Respiratory chain component; antioxidant, anti-
inflammatory, neuroprotective 
Retinoic acid Vitamin A derivative; antioxidant, anti-inflammatory, 
neuroprotection 
Pantothenic acid Vitamin B5; antioxidant, anti-inflammatory, 
neuroprotection 
Biotin Vitamin B7; essential coenzyme for carboxylases 
Uric acid Organic acid; antioxidant 
Agmatine Amino acid derivative; antioxidant, anti-inflammatory, 
neuroprotective 
Glucosamine Monosaccharide; antioxidant, anti-inflammatory, 
neuroprotective 
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Table 3.2 Gemals components and their concentration in the current study 
Constituent Concentration 
Oleic acid – PLL – Thioctic acid 66µM 
Oleic acid – PLL – Myristic acid 66µM 
Oleic acid – PLL – Palmitic acid 66µM 
Oleic acid – PLL – Lauric acid 66µM 
Oleic acid – PLL – Linoleic acid 66µM 
Oleic acid – PLL – Palmitoleic acid 66µM 
Lauric acid – PLL – Caprylic acid 66µM 
T-T-Farnesyl-L.Cysteine – PLL – Palmitic acid 66µM 
Cholesterol – PLL – Oleic acid 66µM 
L. Cysteine – RG – PLL  66µM 
L. Cysteine – GA – PLL  66µM 
Taurine – RG – PLL  66µM 
Taurine – GA – PLL  66µM 
L. Methionine – RG – PLL  66µM 
L. Methionine – GA – PLL  66µM 
L. Glutathione – RG – PLL  66µM 
Alpha-tocopherol-succinate – PLL 20µM 
Ascorbic acid – PLL  20µM 
Oleic acid – PLL – Coenzyme Q10 20µM 
Oleic acid – PLL – Retinoic acid 20µM 
Pantothenic acid – PLL  20µM 
Biotin – PLL  20µM 
Uric acid – F – PLL 66µM 
Agmatine – RG – PLL  66µM 
Glucosamine – GA – PLL  66µM 
PLL, conjugated to poly-L-lysine; RG, reduced glutaraldehyde linkage; GA, glutaric anhydride linkage; 
F, formaldehyde linkage.  
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3.1.2.1 Endotherapia as a treatment for multiple sclerosis 
The therapeutic effects of Endotherapia have been examined in a rat model of MS and 
in MS patients. The Endotherapia mixture, GEMSP, was able to reduce brain leukocyte 
infiltration across the blood-brain barrier (BBB) after induction of acute experimental 
autoimmune encephalomyelitis (EAE) in rats, but did not diminish the short-term 
neurological symptoms of acute EAE (Mangas et al. 2006). However, in a chronic EAE 
rat model, GEMSP treatment abolished clinical symptoms of nerve damage (Mangas et 
al. 2008), indicating that GEMSP is capable of modulating clinical outcomes in rats in a 
chronic EAE model of multiple sclerosis.  
The use of GEMSP has also been extended beyond rat models of MS, with two open 
clinical trials conducted using Endotherapia compounds. In the first, small, open clinical 
trial, most MS patients treated with GEMSP for 6 months experienced a stabilisation 
(55% of patients) or an amelioration (18% of patients) of disease symptoms (Geffard et 
al. 2010). In the second, larger, open clinical trial, over two thirds of MS patients 
receiving an Endotherapia mixture of PLL-conjugated compounds (exact composition 
unknown, patent pending as of Geffard et al. 2010) showed positive outcomes, with 
35% showing ameliorated disability scores, 17% showing stabilisation of disease, and 
20% showing a lower rate of disease progression than the expanded disability status 
score (EDSS) worldwide reference rate (Geffard et al. 2010). Thus, Endotherapia 
compounds appear to show beneficial effects in slowing disease progression in MS 
patients, with the caveat that these studies did not use an untreated control group. As 
GEMSP and Endotherapia contain multiple compounds, it is unclear whether 
Endotherapia acts through immunomodulatory or direct neuroprotective mechanisms.  
3.1.2.2 Endotherapia as a treatment for ALS 
Endotherapia compounds have also been tested in a rat model of ALS and in ALS 
patients. An Endotherapia mixture of PLL-conjugated compounds known as Gemals 
(Table 3.2) delayed disease onset, delayed body weight decline, delayed the onset of 
limb paralysis and increased survival time when administered pre-symptomatically in a 
SOD1 rat model of ALS (Nicaise et al. 2008). Gemals-treated SOD1 rats also tended to 
maintain motor performance, maintain compound muscle action potentials, and showed 
lower spontaneous muscle activity than vehicle-treated SOD1 rats (Nicaise et al. 2008). 
However, the effect of Gemals when administration was started from the onset of 
disease symptoms has not been investigated.  
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In addition, a Gemals-like Endotherapia compound (exact composition unknown, patent 
pending as of Geffard et al. 2010) was tested in a small, open clinical trial of 12 ALS 
patients (Geffard et al. 2010). Endotherapia-treated ALS patients showed a decreased 
loss of functional capacity on the ALS assessment questionnaire (ALSAQ-40) 
compared with the worldwide ALSAQ-40 reference score (Geffard et al. 2010). Thus, 
preliminary studies of Endotherapia suggest that the drug mixture is not detrimental in 
ALS patients and may even have beneficial effects – however, the absence of a control 
group from the study relies on the assumption that the worldwide ALSAQ-40 reference 
score has not changed over time. Given that these preliminary studies hint that 
Endotherapia may have some positive effects, a randomised, controlled trial would 
provide stronger evidence for a protective effect in ALS patients. Despite its evaluation 
in SOD1 rat models and in ALS patients, the Endotherpia mixture ‘Gemals’ is yet to be 
tested in the commonly-used SOD1 mouse model of ALS.  
 
3.1.3 Aims and hypothesis 
The aim of this chapter was to examine the ability of Gemals compound (Nicaise et al. 
2008) to extend the survival of SOD1 mice when administered after symptom onset, 
compared against untreated control mice.  
Hypothesis: Administration of Gemals to SOD1 mice after disease onset would 
slow disease progression and increase survival time.   
A cohort of SOD1 mice were treated from 100 days of age with Gemals or a vehicle 
control, and were compared in terms of survival, body weight, rotarod performance and 
grip strength over time.  
 
 
 
__________________________________Chapter 3 – Gemals treatment in SOD1 mice 
______________________________________________________________________ 
______________________________________________________________________ 
 
99 
 
3.2 Methods 
3.2.1 Animals 
All procedures and protocols involving animals were approved by the University of 
Tasmania’s Animal Ethics Committee (permit number A12234). Transgenic SOD1 
mice were genotyped and copy number was determined by qPCR at weaning, according 
to the procedure in Chapter 2. Upon genotyping at weaning, gender-paired SOD1 
littermates were identified, with a total of 14 female pairs and 16 male pairs (a total of 
60 mice, born over a 51-day period) used in the current study. All mice were housed in 
standard housing conditions as described in Chapter 2; mice were co-housed with their 
paired littermate, with the only exception when male mice fought with each other and 
were subsequently singly housed. As each littermate pair sequentially reached 95-100 
days of age, each mouse was weighed, and allocated to receive either Gemals or 
vehicle; allocation of littermate pairs between treatment groups was performed on the 
basis of keeping the average body weight each treatment group as close as possible 
(Scott et al. 2008). Copy number, body weight at start of treatment, and age at start of 
treatment were not different in Gemals and vehicle treatment groups, although starting 
body weight was higher in male mice than female mice (Table 3.3). From 20 weeks of 
age onwards, mice were given bacon-flavoured NutraGel cubes in their home cages to 
ensure adequate nutrition and hydration as mice continued through disease progression.  
 
Table 3.3 Cohort demographics at start of treatment 
 Female SOD1 mice Male SOD1 mice 
Factor Gemals Vehicle Gemals Vehicle 
Number (n) 14 14 15* 16 
Copy number (ΔCT) 5.41 ± 0.09 5.53 ± 0.04 5.35 ± 0.05 5.44 ± 0.07 
Body weight 19.6 ± 0.1 19.6 ± 0.1 26.3 ± 0.1 26.3 ± 0.1 
Age (days) 101.1 ± 0.4 101.1 ± 0.4 100.9 ± 0.3 100.9 ± 0.3 
No significant difference in cohort parameters at the start of treatment (copy number, body weight at start 
of treatment). *One of pair was WT; hence 16 male pairs started but the data from the WT was discarded. 
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3.2.2 Drug and dosage schedule 
Lyophilised Gemals was obtained from Gemacbio S.A. (Cenon, France) and was 
resuspended in filter-sterilised PBS at 2.5mg/mL. Gemals-treated mice were injected 
subcutaneously with 100µL resuspended Gemals per mouse (250µg/mouse, equivalent 
to between 10mg/kg and 12.5mg/kg for a 20-25g mouse), 5 days per week, from 
approximately 100 days of age through to disease endpoint. Vehicle control mice 
received an equivalent volume of filter-sterilised PBS. The final concentrations of 
individual components within the 2.5mg/mL Gemals suspension are listed in Table 3.2. 
Injections were carried out under light isoflurane (Attane, Bayer AG, NRW, Germany) 
anaesthesia (The Stinger Anaesthesia Machine, Advanced Anaesthesia Specialists, 
NSW, Australia; 3.5% isoflurane in 2L/min oxygen). The injection site was varied over 
the dorsal back surface and flanks, to minimise any irritation due to repeated injections. 
 
3.2.3 Outcome measures 
3.2.3.1 Survival time 
Survival time was initially measured as the age at which mice had lost 20% of their 
peak body weight. However, in line with the growing preference in the ALS field for 
the use of a function endpoint rather than a body weight endpoint, ethics approval was 
sought and obtained to use loss of the righting reflex (the animal’s normal ability to 
right itself within 30 seconds of being placed on its back) as the disease endpoint. Thus, 
part way through the trial the endpoint measure was changed. A breakdown of the 
survival outcomes for the 60 mice in this trial is given in Table 3.4. For the first 10 mice 
to reach endpoint in the study, only weights endpoint data was collected.  
In order to use all available data, separate survival analyses were carried out using the 
age at the loss of the righting reflex, and the age at loss of 20% from peak body weight. 
For animals with only one endpoint measure recorded (e.g. weight loss endpoint), the 
data was censored at the time of this endpoint for the purposes of analysis of the 
alternative endpoint measure (e.g. righting reflex endpoint analysis).  
Survival curves and average survival time (mean ± standard error of the mean) were 
compared using Kaplan-Meier analysis with the Log Rank test. Factors (categorical 
independent variables) and covariates (continuous independent variables) influencing 
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survival time were examined using Cox proportional hazards regression, and were 
reported as hazard ratios (HR) with 95% confidence interval (CI). 
 
Table 3.4 Numbers of SOD1 mice through trial 
  Female mice Male mice 
Number of mice (n) Gemals Vehicle Gemals Vehicle 
Allocated to trial 14 14 16 16 
Removed from trial     
             Incorrect genotype 0 0 1 0 
Survival data censored     
             Died under anaesthesia 0 0 0 2 
             Culled due to lesion 1 1* 1 1* 
             Found dead in cage   2 1* 
Endpoint conditions     
             Earliest of righting or weights 2 1 3 4 
             Righting only 11 12 9 7 
*culled due to littermate partner affected 
 
3.2.3.2 Body weight 
Body weight was recorded at least twice weekly; after the age of 18 weeks, body weight 
was recorded daily. Body weights were analysed separately for each gender, with 
Gemals-treated and saline-treated mice compared using T-tests at each week of age, 
with a Welch T-test correction applied if Levene’s test showed that variances were 
substantially different between groups.     
3.2.3.3 Rotarod performance 
Motor performance was assessed weekly from 100 days of age, using a 5-lane mouse 
rotarod (Rotarod Advanced for 5 mice, TSE Systems, Hesse, Germany). From 
approximately 85-90 days of age, mice were acclimatised to the Rotarod (three once-
daily sessions of 5 minutes, with the drum rotating at 3 revolutions per minute [rpm]); 
and subsequently trained to stay on the accelerating drum (at least two once-daily 
sessions where the drum accelerated from 3rpm to 16rpm over 3 minutes).  
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On the day preceding the weekly Rotarod test, mice were given a practice session where 
the drum rotated at 3rpm for 1 minute, then accelerated from 3rpm to 16rpm over 3 
minutes. On the day of the test, mice were given a 5-minute warm up session on the 
Rotarod at 3rpm, then had a 10-minute break, then went through the acceleration 
protocol where the speed was increased from 3rpm to 16rpm over 3 minutes. The speed 
at which mice could not stay on the rotating drum was recorded. Mice which could not 
stay on the Rotarod due to advancing disease were given the minimum score of falling 
at 3rpm. Average speeds at which falls occurred were compared separately for female 
and male mice, with Gemals-treated and vehicle-treated mice compared by T-tests at 
each week of age, with appropriate corrections for unequal variances where necessary.       
3.2.3.4 Grip strength 
Hindlimb grip strength was measured using a grip strength (force) meter (Columbus 
Instruments, OH, USA). A single grip strength meter, with a triangular bar for mice, 
was mounted above bench level on a spacer arm and platform. Mice were scruffed and 
were allowed to grab the bar with their hind paws, then moved away from the grip 
strength apparatus until they let go of the bar, with the maximum force of three attempts 
recorded in newtons (N). Grip strengths were analysed separately for male and female 
mice, and experimental groups were compared by T-tests with appropriate correction 
for unequal variances where necessary. 
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3.3 Results 
3.3.1 Adverse effects 
3.3.1.1 Reaction to drug 
Most mice injected with the Gemals compound showed an adverse reaction within 5-10 
minutes of injection. Affected mice showed reduced mobility within the cage, tending 
to stay in one corner and sometimes adopting a hunched position. The drug appears to 
cause irritation, with mice sometimes scratching at the injury site and in the worst cases 
giving continuous shudders / shrugs of the shoulders while maintaining the hunched 
position. None of these symptoms were seen in vehicle-treated mice. Some particulate 
matter remained following resuspension of Gemals in PBS. A batch of Gemals was 
therefore centrifuged to remove particulates which might cause irritation after injection; 
however, the particulate-free Gemals elicited the same reaction as seen with 
resuspended Gemals, indicating a soluble component was causing the adverse reaction.  
Topical application of lignocaine and bupivacaine, either with Gemals injection or at 90 
minutes prior to Gemals injection, was not effective at reducing the adverse reaction, 
nor was injection of meloxicam together with Gemals effective at reducing the reaction; 
however, injecting meloxicam 60-90 minutes prior to Gemals injection suppressed most 
of the adverse response (Data from Dr Bill Bennett). Subcutaneous injection of 
meloxicam (5mg/kg, 40-60µL of 1:1 meloxicam:saline) was therefore performed 
approximately 60 minutes prior to injection with either Gemals or vehicle.      
3.3.1.2 Development of skin lesions   
In some Gemals-treated mice, the skin around the injection site appeared to become 
tough and fibrotic. A number of mice also developed isolated open wounds or lesions, 
which were initially observed on male mice and were attributed to fighting, but also 
appeared in female mice. Lesions occurred almost exclusively in Gemals-treated mice 
(6/14 female and 6/15 male Gemals-treated mice); lesions were rarely seen in vehicle-
treated mice (1/14 female and 0/16 male vehicle-treated mice). Lesions occurred on the 
skin of the flanks, back, or shoulders/neck, although one female mouse showed a lesion 
on the forelimb, and one male mouse showed a lesion at the base of the tail, both 
located far from any sites of drug injection. To treat these lesions, mice were placed 
under light isoflurane anaesthesia; the lesion was swabbed with sterile saline and had 
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betadine (Sanofi-Aventis, povidone-iodine antiseptic ointment) applied. If the skin 
surrounding the lesion site appeared irritated, imflamol (Apex Laboratories, broad 
spectrum anti-bacterial, anti-inflammatory, anti-fungal ointment) was applied. 
Treatment was applied daily while the lesion was present. Most lesions healed within 
4±1 days of appearance; two mice developed a lesion at 2-3 days before disease 
endpoint, which did not resolve by disease endpoint. Three mice developed a lesion on 
two separate occasions; in these mice, the first lesion was small and healed quickly, 
while on the second occasion the lesion was larger. The lesion appeared severe in two of 
these mice developing a second lesion, and these two mice were culled, along with their 
respective paired littermates (Table 3.4).  
The aetiology of these lesions is unclear. While some lesions may be possibly 
attributable to fighting between mice, lesions developed primarily in Gemals-treated 
mice, and were most common on the flanks, back and shoulders where Gemals 
injections took place. It is possible that the meloxicam injection did not completely 
relieve the irritant effect of Gemals injections, so the lesion may have been caused by 
excessive grooming or scratching of the injection site. Even more so, the analgesic 
effects of the meloxicam may have removed painful stimuli from excessive scratching, 
leading to more scratching and exacerbation of the lesion.     
 
3.3.2 Survival 
3.3.2.1 Kaplan-Meier analysis 
Kaplan-Meier was used to assess the effect of a single variable, such as Gemals 
treatment vs. vehicle treatment, or male vs. female gender, on survival outcomes.  
3.3.2.1.1 Kaplan-Meier analysis: Loss of righting reflex 
The average age at which righting reflex was lost was not different between Gemals-
treated and vehicle-treated mice (Gemals 171.2±2.9 days vs. vehicle 172.8±2.9 days, 
p=0.762) (Figure 3.1A), nor between female and male mice (female 172.4±2.8 days vs. 
male 171.1±3.0 days, p=0.706) (Figure 3.1B). Gemals treatment did not affect survival 
time in either female or male mice when each gender was considered separately (males: 
Gemals 167.7±1.6 days vs. vehicle 175.6±5.5 days, p=0.156; females: Gemals 
173.1±4.9 days vs. vehicle 171.8±3.0 days, p=0.307) (Figure 3.1C,D).  
__________________________________Chapter 3 – Gemals treatment in SOD1 mice 
______________________________________________________________________ 
______________________________________________________________________ 
 
105 
 
 
 
 
 
Figure 3.1 Kaplan-Meier survival curves for loss of the righting reflex 
The loss of the righting reflex reflects the age at which mice were no longer able to right 
within 30 seconds of being placed on their side. Kaplan-Meier survival curves were not 
significantly different between Gemals-treated mice and vehicle-treated mice (A), nor 
between female mice and male mice (B). Gemals treatment did not substantially alter 
retention of the righting reflex in male (C) or female (D) mice. Vertical dashes represent 
censored data points.   
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Figure 3.2 Kaplan-Meier survival curves for loss of 20% from peak body weight 
The survival curves for the age at which SOD1 mice had lost 20% from their pre-
disease maximum body weight were not significantly different between Gemals-treated 
mice and vehicle-treated mice (A). Female mice showed significantly longer times to 
loss of 20% body weight than male mice (B). No significant effect of Gemals treatment 
was seen in either male (C) or female (D) mice. Vertical dashes represent censored data 
points. BW, body weight.  
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3.3.2.1.2 Kaplan-Meier analysis: Loss of 20% body weight 
The age at which mice had lost 20% of their body weight was not different between 
Gemals-treated mice and vehicle-treated mice (Gemals 178.7±3.8 days vs. 172.2±1.8 
days, p=0.132) (Figure 3.2A). However, female mice displayed a delayed loss of 20% 
body weight compared to male mice (females 179.0±2.8 days vs. males 169.2±1.9 days, 
p=0.023) (Figure 3.2B). Considering male and female mice separately, Gemals showed 
no effect on the loss of 20% body weight compared to the vehicle control (females: 
Gemals 181.2±4.5 days vs. vehicle 175.5±2.1 days, p=0.228; males: Gemals 171.1±3.0 
days vs. vehicle 168.2±2.7 days, p=0.294) (Figure 3.2C,D).  
3.3.2.2 Cox proportional hazards regression analysis 
CPH regression was used to assess the effects of gender, Gemals treatment and possible 
covariates (copy number ΔCT, starting body weight, maximum body weight, and access 
to Nutragel cubes) on survival.  
3.3.2.2.1 Cox proportional hazards regression: Loss of righting reflex 
In univariable analyses, none of the factors and covariates tested (gender, Gemals 
treatment, copy number, starting and maximum body weights, and access to Nutragel 
cubes) showed any significant effect on the loss of the righting reflex (Table 3.5). 
Multivariable analysis including both gender and Gemals treatment also revealed no 
significant effects on loss of the righting reflex (Table 3.5). However, inclusion of an 
interaction term between gender and Gemals treatment revealed a significant interaction 
term (p=0.048, Table 3.5), indicating that the effect of Gemals on the loss of the 
righting reflex was different between male and female mice. Survival curves showing 
effects of Gemals treatment in male mice reveal a higher percentage of Gemals-treated 
male mice than vehicle-treated male mice surviving between 150-170 days of age, and a 
higher percentage of vehicle-treated than Gemals-treated male mice surviving between 
170-190 days of age (Figure 3.1C). This pattern is indeed reversed for female mice 
(Figure 3.1D), with a higher percentage of Gemals-treated female mice than vehicle-
treated female mice surviving between 150-170 days of age, and fewer Gemals-treated 
than vehicle-treated female mice surviving between 170-190 days of age. Thus, while 
Gemals did not show an increase in survival in either gender, Gemals treatment exerted 
different effects on the survival curves of female and male mice. However, this 
interaction drifted out of statistical significance when adjusted for other covariates 
which may influence survival (p=0.056, Table 3.5).  
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Table 3.5 Cox proportional hazards regression model for reaching disease 
endpoint: Righting reflex endpoint 
Factor(s) in the CPH model 
Loss of Righting Reflex 
HR (95% CI), p-value 
Univariable analyses
1
  
    Gender (female) 0.888 (0.471, 1.675), p=0.714 
    Treatment (Gemals) 1.097 (0.589, 2.043), p=0.769 
    Copy number (ΔCT) 1.066 (0.278, 4.093), p=0.926 
    Starting body weight 1.010 (0.919, 1.110), p=0.832 
    Maximum body weight  1.004 (0.915, 1.102), p=0.927 
    Access to Nutragel 1.141 (0.259, 5.018), p=0.861 
  
Multivariable analysis
2
  
    Gender (female) 0.860 (0.447, 1.657), p=0.653 
    Treatment (Gemals) 1.137 (0.599, 2.159), p=0.695 
  
Multivariable analysis, including interaction
3
 
    Gender (female) 1.659 (0.653, 4.216), p=0.288 
    Treatment (Gemals) 2.603 (0.927, 7.310), p=0.069 
    Gender*Treatment 0.243 (0.060, 0.990), p=0.048 
  
Multivariable analysis, including interaction, adjusted
4
 
    Gender (female) 0.255 (0.017, 3.884), p=0.325 
    Treatment (Gemals) 2.406 (0.833, 6.955), p=0.105 
    Gender*Treatment 0.239 (0.055, 1.035), p=0.056 
1
Univariable analyses were carried out with models containing only one of the following factors: Gender 
(male/female), Treatment (Gemals/vehicle), or access to Nutragel (yes/no); or with one of the following 
covariates: copy number (ΔCT), starting body weight, or maximum body weight. 2Multivariable analysis 
includes both Gender and Treatment as factors.  
3
Multivariable analysis includes Gender, Treatment, and 
a Gender*Treatment interaction term as factors. 
4
Adjusted multivariable analysis contains Gender, 
Treatment, Gender*Treatment, copy number, starting body weight, maximum body weight, and access to 
Nutragel; HRs for Gender, Treatment, and Gender*Treatment are therefore adjusted for copy number, 
starting body weight, maximum body weight, and access to Nutragel. 
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3.3.2.2.2 Cox proportional hazards regression: Loss of 20% body weight 
In contrast to the loss of the righting reflex, univariable analysis found that gender 
(p=0.030), starting body weight (p=0.037), maximum body weight (p=0.021), and 
access to Nutragel (p<0.001) influenced the loss of 20% from peak body weight (Table 
3.6). In multivariable analysis, the survival-promoting effect of female gender persisted 
upon adjustment for Gemals treatment (HRfemale=0.383, 95% CI 0.154-0.951, p=0.039) 
(Table 3.6). When a gender*treatment interaction was included in the multivariable 
analysis for body weight endpoints, the interaction term was not significant (p=0.777, 
Table 3.6), indicating that Gemals affected survival time no differently in female mice 
than in male mice. When the multivariable analysis (excluding the non-significant 
gender*treatment interaction term) was adjusted for other covariates, the only factor 
independently associated with increased survival times was access to Nutragel cubes 
(HRNutragel=0.060, 95% CI 0.013-0.268, p<0.001) (Table 3.6).  
These data indicate that mice with access to Nutragel cubes showed a slower loss of 
body weight than mice without access to Nutragel cubes. Interestingly, access to 
Nutragel cubes had no effect on the loss of righting reflex (Table 3.5) – perhaps 
indicating that access to continued easy nutrition maintained body weight but did not 
maintain muscle function, and suggesting that a major component in body weight 
survival analysis is hydration status which is maintained by the use of Nutragel cubes. 
Alternatively, the correlation may be due to changes in trial design at the early stages – 
the mice enrolled earliest in the trial did not have access to Nutragel cubes, and also had 
their survival times measured solely under the weight loss endpoint.  
Overall, survival data indicate that Gemals-treated mice showed no significant increase 
in survival time compared to that of vehicle-treated mice, as measured by either the loss 
of 20% body weight or the loss of the righting reflex.  
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Table 3.6 Cox proportional hazards regression model for reaching disease 
endpoint: Body weight endpoint 
Factor(s) in CPH model 
Loss of 20% Body Weight 
HR (95% CI), p-value 
Univariable analyses
1
  
    Gender (female) 0.365 (0.146, 0.909), p=0.030 
    Treatment (Gemals) 0.516 (0.213, 1.252), p=0.143 
    Copy number (ΔCT) 1.229 (0.222, 6.083), p=0.813 
    Starting body weight 1.152 (1.008, 1.317), p=0.037 
    Maximum body weight  1.168 (1.023, 1.334), p=0.021 
    Access to Nutragel 0.064 (0.018, 0.221), p<0.001 
  
Multivariable analysis
2
  
    Gender (female) 0.383 (0.154, 0.951), p=0.039 
    Treatment (Gemals) 0.548 (0.224, 1.335), p=0.185 
  
Multivariable analysis
3
  
    Gender (female) 0.417 (0.141, 1.235), p=0.115 
    Treatment (Gemals) 0.619 (0.183, 2.099), p=0.442 
    Gender*Treatment 0.771 (0.128, 4.311), p=0.777 
  
Multivariable analysis, adjusted
4
  
    Gender (female) 0.601 (0.010, 36.438), p=0.808 
    Treatment (Gemals) 0.538 (0.214, 1.353), p=0.188 
    Access to Nutragel 0.066 (0.016, 0.280), p<0.001 
1
Univariable analyses were carried out with models containing only one of the following factors: Gender 
(male/female), Treatment (Gemals/vehicle), or access to Nutragel (yes/no); or with one of the following 
covariates: copy number (ΔCT), starting body weight, or maximum body weight. 2Multivariable analysis 
includes both Gender and Treatment as factors.  
3
Multivariable analysis includes Gender, Treatment, and 
a Gender*Treatment interaction term as factors.  
4
Adjusted multivariable analysis contains Gender, 
Treatment, copy number, starting body weight, maximum body weight, and access to Nutragel; HRs for 
Gender, Treatment, and Access to Nutragel are therefore adjusted for copy number, starting body weight, 
and maximum body weight. 
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3.3.3 Body weights 
Weekly body weight averages were calculated for all mice. As expected, male mice 
showed higher body weights than female mice at all ages (Figure 3.3). Average body 
weights were not different between Gemals-treated mice and vehicle-treated mice at any 
age, for either male or female mice (Figure 3.3A,B). When body weights were 
expressed as a percentage of maximum attained by each mouse, there was a slight trend 
for higher percentage body weights in Gemals-treated female mice than vehicle-treated 
female mice between 23-27 weeks of age (Figure 3.4A). Body weight percentages did 
not differ between Gemals-treated and vehicle-treated male SOD1 mice (Figure 3.4B).  
As an aside, a transient stabilisation of body weight was seen in all mice at 20-21 weeks 
of age (Figure 3.3, Figure 3.4), corresponding to the age at which mice first had access 
to bacon-flavoured Nutragel cubes in addition to their normal ad libitum food; this 
temporary attenuation of body weight loss may be due to increased overall food intake. 
 
3.3.4 Rotarod performance 
Mice were trained on the Rotarod one to two weeks prior to testing; most mice never 
attained the maximum possible rotarod performance of 16rpm, so future studies should 
commence Rotarod training well before the onset of disease symptoms.  
Rotarod performance was similar between Gemals-treated and vehicle-treated mice at 
most time points. Female Gemals-treated mice showed better Rotarod performance than 
vehicle-treated female mice at 23 weeks of age (speed at fall: Gemals 8.9±1.2 rpm vs. 
vehicle 5.4±0.9 rpm, p=0.033) and showed a trend towards better Rotarod performance 
at 24 weeks of age (speed at fall: Gemals 8.1±1.5 rpm vs. vehicle 4.7±0.9 rpm, p=0.086) 
(Figure 3.5A). Male Gemals-treated mice showed a slightly better Rotarod performance 
at 16-18 weeks of age; this tended towards significance at 17 weeks of age (speed at 
fall: Gemals 10.5±0.7 rpm vs. vehicle 8.6±0.6 rpm, p=0.050) (Figure 3.5B).  
Gemals treatment produced some transient improvements in Rotarod performance for 
both male and female mice at certain time points mentioned above. Gemals treatment 
may help to maintain Rotarod performance and therefore retain motor function in 
female mice at 23 and 24 weeks of age; however, these effects were not continued out 
past 24 weeks of age and additionally were not observed in male mice. 
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Figure 3.3 Average body weights for Gemals-treated and control mice over time 
Body weight declined with disease progression over time in all SOD1 mice. No 
significant changes were observed in the body weights of female mice (A) or male mice 
(B) when treated with Gemals compared to vehicle alone. Bacon-flavoured Nutragel 
cubes were placed in cages from 20 weeks of age (arrow, A,B), leading to a slight 
increase or temporary stabilisation in body weight at 21 weeks of age, likely due to 
increased food intake. Error bars represent standard error of the mean. 
__________________________________Chapter 3 – Gemals treatment in SOD1 mice 
______________________________________________________________________ 
______________________________________________________________________ 
 
113 
 
 
 
 
Figure 3.4 Percentage body weights in Gemals-treated and vehicle mice 
Percentage of maximum body weight was calculated for both female (A) and male (B) 
mice. Percentage body weight was not significantly different between Gemals-treated 
and vehicle-treated female mice, although Gemals-treated female mice appeared to have 
slightly higher body weights than vehicle-treated female mice at 25-26 weeks of age 
(A). Body weight percentages were not different between Gemals-treated and vehicle-
treated male mice (B). A temporary stabilisation of body weight percentage was noted 
at 21 weeks of age, following the introduction of Nutragel cubes to the home cages at 
20 weeks of age (arrow, A,B). Error bars represent standard error of the mean.  
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Figure 3.5 Rotarod performance in Gemals-treated and control mice 
Rotarod performance, measured as the speed at which mice could not stay on the 
Rotarod drum during acceleration from 3rpm to 16rpm, declined with time in all SOD1 
mice. Gemals-treated female mice showed better Rotarod performance than vehicle-
treated female mice at 23-24 weeks of age (A), while  Gemals-treated male mice 
showed better Rotarod performance than vehicle-treated mice at 16-18 weeks of age 
(B). However, these improvements were not continued throughout the disease course in 
either female or male Gemals-treated mice. *p<0.05, t-test. Error bars represent 
standard error of the mean.  
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3.3.5 Grip strength 
Hindlimb grip strength showed high variability in both male and female mice (Figure 
3.6A,B), and did not demonstrate a clear decrease over time as the disease progressed. 
In female SOD1 mice, vehicle-treated mice had a stronger grip strength than Gemals-
treated mice at 21 weeks of age (Gemals 0.022±0.007N vs. vehicle 0.036±0.007N, T-
test p=0.010), while Gemals-treated mice had a stronger grip strength than vehicle-
treated mice at 22 weeks of age (Gemals 0.034±0.010N vs. vehicle 0.021±0.008N, T-
test p=0.045) (Figure 3.6A). In male SOD1 mice, Gemals treatment did not significantly 
affect grip strength (Figure 3.6B).  
Grip strength was measured sporadically throughout the study, at constant dates rather 
than constant ages in the SOD1 mice; therefore, not all mice were measured at each 
weekly time point. In order to reduce the amount of variability in the data set, grip 
strength data were collected into age bins (13-15 weeks, 16-18 weeks, 19-21 weeks, 22-
24 weeks, 25-27 weeks; Figure 3.6C,D) for analysis, averaging data from the same 
animal where necessary to avoid pseudoreplication. However, similar to the weekly age 
data (Figure 3.6A,B), binned grip strength data showed no substantial decrease over 
time for either male or female Gemals-treated or vehicle-treated SOD1 mice (Figure 
3.6C,D). 
The lack of a substantial change over time, in any group of SOD1 mice, indicates that 
grip strength as measured here may not be a reliable indicator of decreasing muscle 
strength due to disease progression. Mice were not pre-trained in this muscle strength 
test, as it was thought to be a natural response of mice to grip the bar. However, it is 
possible that the mice habituated to the testing procedure over the course of the disease, 
and that increased technique and ability to grip the bar compensated for a lack of muscle 
strength. This may explain the lack of decline in grip strength over time. As with the 
Rotarod, earlier habituation to this grip strength test may allow more accurate recording 
of change in muscle strength over time in SOD1 mice.  
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Figure 3.6 Grip strength in Gemals-treated and control mice over time 
Grip strength measurements (in newtons, N) varied over time and showed no clear 
pattern for either female (A) or male (B) mice. The only differences between Gemals-
treated and vehicle-treated SOD1 mice occurred in female mice; vehicle-treated mice 
showed a higher grip strength at 21 weeks of age, while Gemals-treated mice showed a 
higher grip strength at 22 weeks of age (A). Grouping of data into categories each 
spanning three weeks (C,D) did not reveal any differences in grip strength between 
Gemals-treated and vehicle-treated female (C) or male (D) mice. *p<0.05. Error bars 
represent standard error of the mean.  
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3.4 Discussion 
3.4.1 Summary of results 
Male and female SOD1 mice were treated with Gemals compound or a control vehicle, 
with treatment commencing at 100 days of age, after the onset of disease symptoms. 
Gemals treatment did not significantly affect survival time for either male or female 
SOD1 mice (Figure 3.1, Figure 3.2); nor did Gemals treatment show substantial effects 
on the decline of body weight and rotarod performance over time (Figure 3.3, Figure 
3.4, Figure 3.5). However, the Gemals treatment was not well tolerated, with irritation 
after administration and the gradual development of skin lesions (see section 3.3.1), and 
these issues may have confounded any beneficial effects of the drug.  
 
3.4.2 Comparison of the present study with previous Endotherapia studies 
A previous study of Gemals in ALS rodent models tested the pre-symptomatic effects of 
Gemals in the SOD1
G93A
 rat model (Nicaise et al. 2008). Three experimental groups 
were used – a control group, a low-dose Gemals group, and a high-dose Gemals group, 
each containing 8-11 animals. Nicaise and colleagues found that pre-symptomatic 
Gemals treatment significantly delayed onset of disease symptoms (hindlimb paresis) 
and increased survival time in a dose-dependent manner, with survival time extended by 
up to 18% by the higher dosage (Nicaise et al. 2008). Additionally, a Gemals-like 
compound has been tested in a small open clinical trial of ALS patients – this small trial 
reported positive outcomes in the ALS functional rating score (ALSFRS) of treated 
patients compared against a worldwide reference ALSFRS score (Geffard et al. 2010). 
In contrast, the present study found no significant effect on survival time when Gemals 
was administered after disease onset in SOD1 mice (Figure 3.1, Figure 3.2).  
There are two main possibilities as to why Gemals showed no survival effects in the 
present study. The first possibility is that the administration of an antioxidant therapy 
after the onset of disease is ineffective at halting disease processes. The second 
possibility is that the presence of several confounding factors in this study, such as the 
irritation following injection and the need to administer an analgesic, may have 
obscured any beneficial effect of Gemals treatment on survival.  
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3.4.3 Antioxidants as a therapeutic strategy for ALS 
Oxidative stress appears to be a convergence point for several ALS-related pathologies, 
as discussed in Chapter 1. The components of Gemals are designed to limit oxidative 
stress and neuroinflammation (Nicaise et al. 2008; Geffard et al. 2010). The 
administration of Gemals to pre-symptomatic SOD1 rats increased survival time 
(Nicaise et al. 2008), but Gemals treatment after the onset of disease symptoms did not 
increase survival time in the current study. This discrepancy could indicate that the 
timing of antioxidant therapy is important in the treatment of SOD1-mediated ALS.  
Disease processes in SOD1 motor neurons are generally accepted to start long before 
the onset of disease symptoms (Vinsant et al. 2013); indeed, the results of Chapter 2 
showed that ubiquitinated inclusions were present 8 weeks prior to the earliest disease 
symptoms. Oxidative stress may be a key disease process in ALS, and signs of 
oxidative stress are present in SOD1 mice before the development of disease symptoms 
(Hall et al. 1998a). Oxidative stress is linked into several other pathologies, such as 
protein aggregation, mitochondrial dysfunction, excitotoxicity, and glial activation 
(Barber & Shaw 2010); see section on convergent pathology (section 1.3.9). It may be 
the case that the downstream effects of oxidative stress, such as the formation of protein 
aggregates and the dysfunction of mitochondria, cannot be remedied by the amelioration 
of the oxidative stress itself. In line with this theory, antioxidant compounds such as 
vitamin E and N-acetyl-L-cysteine have shown benefits when administered before 
symptom onset in SOD1 mice, but showed no effects on survival in ALS patients 
(Gibson & Bromberg 2012). It is possible that Gemals reduced oxidative stress but did 
not protect motor neurons from degeneration. 
The amelioration of oxidative stress early in the disease course may have beneficial 
effects for the survival of motor neurons; however, in the absence of biochemical 
markers for pre-symptomatic testing for ALS, therapies which can be used after the 
onset of disease symptoms in ALS patients are required. Treatment of oxidative stress 
should be incorporated as part of a multi-action therapy targeting multiple cellular 
pathways, with the aims of simultaneously reducing oxidative stress, increasing 
clearance of aggregated proteins, attenuating glial activation, and increasing motor 
neuron survival. The data generated from this study may not be a true reflection of the 
potential of Gemals to ameliorate disease due to the presence of confounding factors, as 
explained in the following section.  
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3.4.4 Confounding effects in the current study 
3.4.4.1 Lesions and irritation 
Gemals did not appear to be well tolerated in this study, with mice showing irritation at 
the injection site and adopting a hunched demeanour, usually indicative of pain or 
illness, within minutes of the Gemals injection. These symptoms were not observed in 
mice injected with vehicle alone. Some Gemals-treated mice also developed skin 
lesions. The positioning of the skin lesions, mostly seen on the flank or shoulders but in 
some instances occurring at the base of the tail or on the forelimb, indicates that the 
lesions may have been a result of scratching at the lesion site, or possibly a result of 
excessive grooming due to stress in these animals. Both restraint stress and elevated 
corticosterone levels are associated with accelerated disease progression and shortened 
survival times in SOD1 mice (Fidler et al. 2011), and thus, any stressful effects of 
irritation and/or lesion development in Gemals-treated mice may have masked 
neuroprotective effects of Gemals.  
The source of irritation in the Gemals mixture has not been determined. The study by 
Nicaise and colleagues in 2008 reported no such irritation or adverse response to 
subcutaneous injection of Gemals in SOD1 rats, and sublingual Endotherapia 
compounds are reported to have few side effects in humans (Geffard et al. 2010). The 
concentration of injected Gemals compound in the present study was 2.5mg/mL, while 
the highest concentration injected in the Nicaise study was 3.75mg/mL, which was 
reported to be well tolerated (Nicaise et al. 2008).  
Mice and rats may show different tolerance doses for specific Gemals components, 
which may help to explain the irritation seen in mice in the current study but not 
reported in the Nicaise (2008) study. Additionally, it is possible that the dosage of 
Gemals may have been slightly higher in the present study than in the Nicaise (2008) 
study of Gemals in SOD1 rats. Nicaise and colleagues used a dose of 1.87mg/rat/day, 
equivalent to 9.4mg/kg for a 200g rat, and 7.5mg/kg for a 250g rat. If the body weight 
of SOD1 rats was generally greater than these estimates, the 10mg/kg dosage for mice 
in the current study may result in a greater dose compared to the Nicaise (2008) study.  
A difference between the Nicaise (2008) study and the present study was the choice of 
vehicle – saline in the study by Nicaise and colleagues, and phosphate-buffered saline in 
the present study. However, as the same irritation was observed when saline was used 
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as a vehicle in the present study (data not shown), it is unlikely that the choice of 
vehicle contributes to the irritation. The Gemals compound is mostly soluble, with a few 
suspended particles. However, centrifugation to remove these insoluble particles did not 
remove the irritation caused by Gemals treatment, indicating that the responsible 
component was soluble (data from Dr Bill Bennett). It is unclear whether the irritation 
seen in this study is a phenomenon specific to mice, or whether some kind of 
contamination had occurred in the preparation of the Gemals compound for injection. 
Future work with the Gemals compound in mice should carefully monitor mice for 
symptoms of irritation, and examine whether the dosage or concentration of specific 
components in the Gemals mixture requires adjustments for use in mice.    
3.4.4.2 Administration of meloxicam 
Administration of meloxicam at 60-90 minutes prior to administration of Gemals was 
effective at ameliorating Gemals-induced irritation. Meloxicam preferentially inhibits 
cyclooxygenase2 (COX2), resulting in decreased COX2-mediated synthesis of the 
inflammatory mediators prostaglandins (Engelhardt et al. 1996), and relief from 
inflammatory pain (Hilario et al. 2006). Importantly in the context of this study, COX2 
may play a role in neuroinflammation in ALS. COX2 is upregulated in the spinal cord 
of both ALS patients (Yasojima et al. 2001; Kiaei et al. 2005) and SOD1 mice (Almer 
et al. 1999; McGeer & McGeer 2002; Okuno et al. 2004). Pre-symptomatic treatment 
with COX2 inhibitors delays disease onset and extends survival in SOD1 mice 
(Drachman et al. 2002; Pompl et al. 2003; Klivenyi et al. 2004); it is therefore possible 
that inhibition of COX2 activity by meloxicam in this study affected disease 
progression in our cohort of mice. Drachman (2002), Pompl (2003), and Klivenyi 
(2004) all studied the effects of diet-based COX2 inhibition in SOD1 mice. Drachman 
used  the COX2-selective inhibitor celecoxib at 1500ppm (1500mg/kg) in feed, 
“equivalent to 400-800mg/day in humans” (Drachman et al. 2002) (approximately 5-
10mg/kg/day for a 75kg adult) and saw a reduction in prostaglandin E2 (PGE2) 
production (a marker of COX2 activity) in the SOD1 spinal cord down to the levels of 
the WT spinal cord (Drachman et al. 2002). Similarly, Pompl used nimesulide at 
1500ppm in feed and reduced SOD1 spinal PGE2 production down to WT levels 
(Pompl et al. 2003). Klivenyi used 0.012% (120ppm) celecoxib or 0.005% (50ppm) 
rofecoxib in feed, and saw reduced PGE2 production in the SOD1 spinal cord, although 
the levels were still slightly higer than those of WT mice (Klivenyi et al. 2004). SOD1 
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mice in the present study were administered meloxicam, a COX2-selective inhibitor, 
subcutaneously at 5mg/kg body weight. This would be at least equivalent to, if not 
greater than, the same milligram dosage given for celecoxib in the study by Drachman 
(2002), with the meloxicam likely more bioavailable given its subcutaneous rather than 
oral delivery in the present study. If Gemals were to act through a COX2-dependent 
pathway, any Gemals-mediated protective effects may have been masked by the use of 
meloxicam in both Gemals-treated and vehicle-treated SOD1 mice. In this situation, the 
dose of meloxicam used in the present study would be sufficient to reduce COX2 
activity levels in the SOD1 spinal cord back down to those of WT mice. Therefore, 
there may be no scope for the components of Gemals to further reduce COX2 activity 
beyond the reduction carried out by meloxicam. This may explain why no survival 
effects were observed with Gemals treatment in the current study.  
In line with this theory, several Gemals components are saturated or unsaturated fatty 
acids (Table 3.1), which have the capacity to modulate COX2 activity (Lee et al. 2001; 
Ringbom et al. 2001). Saturated fatty acids increase COX2 activity, whereas 
unsaturated fatty acids inhibit COX2 activity (Lee et al. 2001; Ringbom et al. 2001). 
Although COX2 inhibition appears beneficial for SOD1 mice as described above, 
downstream prostaglandin products of COX2 activity can also show neuroprotective 
effects (Bilak et al. 2004; Consilvio et al. 2004). As Gemals contains both kinds of fatty 
acids, it is unclear whether Gemals would inhibit COX2 activity via unsaturated fatty 
acids, reducing the production of inflammatory prostaglandins; or instead promote 
COX2 activity via saturated fatty acids, potentially increasing the production of 
neuroprotective prostaglandins (Bilak et al. 2004); the former is the more likely option. 
Regardless of the direction of the effects of Gemals on COX2 activity, COX2 inhibition 
by meloxicam administration could have masked any neuroprotective effects of Gemals 
from being detected in the current study.  
3.4.4.3 Nutritional supplementation 
Bacon-flavoured Nutragel cubes were given to SOD1 mice from 18 weeks of age, to 
ensure easy access to nutrition and hydration as disease progressed and functional 
ability declined. As the Nutragel only became available after the trial had started, some 
mice did not have access to Nutragel during the trial period. Access to Nutragel 
influenced the time at which mice reached their body weight endpoint (20% loss from 
peak body weight), but had no effect on the ability of SOD1 mice to right themselves 
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(Table 3.5). While this effect can be accounted for in statistical analyses, any dietary 
supplementation needs to be kept constant between all mice in future studies.  
3.4.5 Species differences 
The absence of a Gemals-mediated survival increase in this study is likely due to the 
post-onset treatment and confounding factors discussed above, and less likely due to 
differences between mouse models of ALS, rat models of ALS, and human ALS 
patients. Both SOD1 mice and SOD1 rats over-express SOD1
G93A
 protein, such that 
SOD1 activity increases four-fold in SOD1 mice (Gurney et al. 1994) and three-fold in 
SOD1 rats (Nagai et al. 2001), and the pathogenic processes and disease course are 
similar between rat and mouse models. It therefore seems unlikely that Endotherapia 
compounds should show robust increased survival when used pre-symptomatically in 
SOD1 rats, and appear to show positive effects in an open clinical trial of ALS patients, 
but not influence survival in SOD1 mice as observed in the present study. It is possible 
that the higher SOD1 expression and activity (Gurney et al. 1994; Nagai et al. 2001) 
results in a more aggressive disease process in SOD1 mice than SOD1 rats, and may 
indicate that the pathogenic processes in SOD1 rats are a closer echo of those seen in 
ALS patients.  
It is possible that Endotherapia, a multi-action mixture, has different effects in the ALS 
patients and in rodent models. While the evidence for chronic bacterial infection as a 
causative factor in ALS is not comprehensive (Nicolson 2008), the fatty acid 
components of Endotherapia are intended to sequester bacterial cell wall moieties which 
would normally be used for attachment to cell membranes (Geffard et al. 2010). If such 
chronic infections were present in some, or all, of the small ALS patient cohort used for 
the open clinical trial, the putative anti-infection, antioxidant, and anti-inflammatory 
properties of Endotherapia may contribute to the positive outcome observed (Geffard et 
al. 2010). It seems unlikely that such environmentally-acquired infections would occur 
in SOD1 animal models, considering that most laboratory animals are kept in sterile 
environments, and therefore the effects of Gemals compounds in SOD1 animals are 
limited to its antioxidant and anti-inflammatory properties. Once again, the differing 
effects of Gemals in rats and mice may come down to the differences in disease severity 
and timing of administration in relation to the dynamics of oxidative stress.  
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3.4.6 Summary and conclusions  
In conclusion, this study found no survival effect of Gemals in SOD1 mice when 
administered after symptom onset. This may be due to oxidative stress in the pre-
symptomatic phase setting up pathogenic pathways such as protein aggregation which 
cannot be ameliorated by treating oxidative stress alone; or may be due to the presence 
of confounding factors such as the administration of meloxicam to alleviate irritation 
caused by Gemals injection.  
The fact that we also administered meloxicam and in this study saw no change in 
disease outcome measures that could be attributed to Gemals treatment, hints that the 
beneficial effect of Gemals seen in the previous study (Nicaise et al. 2008) may involve 
a COX2-dependent mechanism of action. Future work on this compound should include 
identification of the component causing irritation to mice, and further investigation of 
the mechanism of action in the SOD1 rat spinal cord.  
Endotherapia has previously shown promise in an open clinical trial of ALS patients; 
yet without a control group, the results of the open trial cannot be distinguished from 
any drift in the ALSAQ-40 reference rate over time (Geffard et al. 2010). For its further 
development as a potential therapeutic for ALS, Endotherapia should be trialled using a 
traditional clinical trial design series: first, a safety trial to ensure no adverse events 
occur in human ALS patients; and second, a double-blind, randomised clinical trial to 
look at drug efficacy.  
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The effects of metallothionein-2 treatment  
and treadmill exercise in SOD1 mice 
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4.1 Background  
Multiple pathologies are present in ALS, and thus multi-action drugs are needed to 
address multiple aspects of the disease process. Oxidative stress has already been 
addressed as a key pathology (see Chapter 1, section 1.3.9). The protein 
metallothionein-1/2 (MT-1/2), which is upregulated in SOD1 mice (see Chapter 2), 
plays multiple roles in neuronal protection and response to oxidative stress, and may be 
an appropriate multi-action therapeutic compound for the treatment of ALS.  
 
4.1.1 Metallothioneins 
4.1.1.1 Structure and function of metallothioneins 
Metallothioneins (MTs) are a highly conserved family of small, metal-binding proteins 
(Hamer 1986; Aschner 1996). There are four mammalian MT isoforms, MT-1 to MT-4, 
which share a similar structure comprising two metal-binding domains and a central 
linker region (Figure 4.1) (Hamer 1986). MT proteins are rich in cysteine residues, used 
for the coordination of zinc, copper, and cadmium in vivo, as well as iron, lead, silver, 
gold, platinum, arsenic, and bismuth in vitro (Kagi & Valee 1960; Good & Vasak 1986; 
Ngu & Stillman 2006). The cysteine residues can also bind reactive oxygen species in 
preference to metal ions under conditions of oxidative stress, conferring potent 
antioxidant properties on MT proteins (Thornalley & Vasak 1985).  
The MT-1 and MT-2 isoforms, considered to be functionally similar and sometimes 
referred to as a single ‘MT-1/2’ isoform, are expressed at low levels in most body 
tissues but are absent from neurons (Chung et al. 2003). MT-3 is expressed only in the 
central nervous system (Palmiter et al. 1992), while MT-4 is expressed only in stratified 
squamous epithelia (Quaife et al. 1994). MT-1/2 is the most well-characterised isoform 
of the MT family, and shows neuroprotective properties in a range of contexts as will be 
discussed below. Expression of MT-1/2 is increased in response to high levels of metal 
ions such as zinc and copper (Richards et al. 1984; Suzuki & Koizumi 2000), oxidative 
stress (Campagne et al. 2000), glucocorticoids (Richards et al. 1984), and the presence 
of inflammatory cytokines such as IL-1 (Cousins & Leinart 1988). Astrocytes are the 
major source of MT-1/2 within the central nervous system, and can rapidly induce MT-
1/2 expression in response to neuronal damage, and secrete MT-1/2 to act 
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extracellularly on surrounding neurons (Chung et al. 2004; Chung et al. 2008b). The 
expression of MT-1/2 in response to these cellular stresses implicates MT-1/2 in metal 
homeostasis, cellular defenses against oxidative stress, and neuroprotection (Michalska 
& Choo 1993; Aschner 1996; West et al. 2008; Blindauer & Leszczyszyn 2010).  
4.1.1.2 Growth-promoting and neuroprotective roles of MT-1/2 
MT-1/2 shows growth-promoting and neuroprotective roles in both in vitro and in vivo 
paradigms. MT-1/2 promotes neurite outgrowth when applied to cultured cortical, 
dopaminergic, hippocampal, and cerebellar granule neurons; and promotes reactive 
sprouting in response to axon bundle transection (Chung et al. 2003; Kohler et al. 2003; 
Asmussen et al. 2009b). In vivo, MT-1/2 promotes regenerative axonal sprouting after a 
focal brain injury (Chung et al. 2003), and optic nerve regeneration following axonal 
transection (Fitzgerald et al. 2007). In terms of neuroprotection, MT-1/2 promotes 
survival of dopaminergic and hippocampal neurons from 6-hydroxydopamine and β-
amyloid toxicity, respectively (Kohler et al. 2003). MT-1/2 promotes neuronal survival 
in mice following ischaemia/reperfusion injury (van Lookeren Campagne et al. 1999; 
Trendelenburg et al. 2002) and focal brain injury, as well as reduction of the glial scar 
and increased wound healing in the latter injury (Chung et al. 2003). MT-1/2 also 
promotes neuronal survival in mouse models of Parkinson’s disease (Ebadi et al. 2005) 
and Alzheimer’s disease (Manso et al. 2011).   
4.1.1.3 Mechanisms of MT-1/2-mediated neuroprotection 
Extracellular MT-1/2 interacts with neurons via the low-density lipoprotein receptor-
related proteins, LRP1 and LRP2, on neuronal cell bodies (Fitzgerald et al. 2007; 
Ambjorn et al. 2008; Chung et al. 2008b). The interactions between MT-1/2 and LRPs 
promote neurite outgrowth and neuronal survival via activation of the intracellular 
growth-promoting and pro-survival PI3K, MAPK, Akt, and CREB pathways (Fitzgerald 
et al. 2007; Ambjorn et al. 2008; Asmussen et al. 2009b). MT-1/2 may also be 
internalised into neurons by its interaction with LRPs (Chung et al. 2008b), and if able 
to avoid lysosomal degradation, could play an intracellular role in ROS scavenging and 
intracellular metal homeostasis. Internalised MT-1/2 may additionally protect against 
apoptosis via an interaction of the apo-MT protein with the tumour suppressor protein 
p53 (Ostrakhovitch et al. 2006; Ruttkay-Nedecky et al. 2013). MT-1/2 also shows a role 
in modulating glial cell activation and neuroinflammation, by suppressing astrogliosis 
and microglial reactivity following cortical needlestick injury (Chung et al. 2003).  
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Figure 4.1 The structure and sequence of MT2 
 (A) A stylised diagram of MT2 protein, binding seven divalent metal ions in two 
clusters, is shown here. All MT proteins share the same basic structure: a C-terminal 
metal-binding domain (α domain) and an N-terminal metal-binding domain (β domain), 
joined by a short linker region (Hamer 1986). The abundant cysteine residues in MT, 
shown as blue circles, coordinate metal-binding in thiolate clusters. One MT molecule 
may bind up to seven divalent metal ions (as shown above) or twelve monovalent metal 
ions. Amino acids are labelled with standard single-letter notation. (B) A schematic 
diagram (adapted from Fischer and Davie 1998) showing the coordination of divalent 
metal ions in two thiolate clusters through bonds from direct (blue) and bridging (green) 
cysteine sulfur (S) ligands.  
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4.1.1.4 MT-1/2 in ALS 
Alterations in CNS levels of MT-1/2 in ALS patients are unclear. An early study 
indicated increased MT-1/2 immunoreactivity in ALS patient spinal cord (Sillevis Smitt 
et al. 1994), while a subsequent study indicated no consistent change in mRNA levels 
for several MT-1/2 genes in ALS patients (Blaauwgeers et al. 1996). A more recent 
study indicated that MT-1/2 protein levels were reduced in ALS spinal cord at end-stage 
(Hozumi et al. 2008). However, MT-1/2 protein levels are consistently reported as 
increased in the spinal cord of SOD1 mouse models of ALS compared with controls 
(Gong & Elliott 2000; Tokuda et al. 2007; Tokuda et al. 2013), and this is consistent 
with the results from Chapter 2 of this thesis. Upregulation of MT-1/2 with disease 
progression may be in response to oxidative stress in ALS tissue, but also may play a 
role in protecting motor neurons from toxicity. Genetic ablation of MT-1/2 in SOD1 
mice shortened survival times and hastened disease progression (Nagano et al. 2001; 
Puttaparthi et al. 2002), while SOD1 mice over-expressing MT-1/2 showed delayed 
disease onset and lengthened survival times (Tokuda et al. 2013). Thus, MT-1/2 appears 
to play a protective role in ALS and is a suitable candidiate therapeutic for testing in 
SOD1 mice. Although our laboratory previously showed minimal CNS entry of injected 
MT2 through the intact BBB (Lewis et al. 2012b), the SOD1 mouse BBB is known to 
be compromised from early in the disease course (Garbuzova-Davis et al. 2007), 
increasing the likelihood of successful CNS delivery of injected therapeutic compounds.  
4.1.2 Exercise in ALS 
The relationship between exercise and ALS is complex, with exercise having been 
implicated as both a cause and a potential therapy for ALS. Some epidemiological 
studies have indicated that increased vocational and leisure-time or sport-related 
physical activity has been linked with an increased ALS risk (Beghi et al. 2010; 
Huisman et al. 2013), and clusters of ALS have been observed amongst those with high 
occupational levels of physical activity, such as athletes (Chio et al. 2009; Lehman et al. 
2012) and military personnel (Weisskopf et al. 2005). However, it is unclear whether 
these increased risks are due to physical activity itself, genetic factors predisposing to 
fitness, or shared environmental exposures (Cox et al. 2009; Chio & Mora 2012). 
Conversely, a number of small studies indicate a therapeutic benefit of exercise in ALS 
patients (Drory et al. 2001; Dal Bello-Haas et al. 2007; Sanjak et al. 2010), although 
any positive effects of exercise on slowing disease progression are yet to be confirmed 
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by a large, randomised controlled trial (Dal Bello-Haas et al. 2008). The potential for 
exercise to modulate survival of SOD1 mice has been explored with wheel running, 
treadmill running and swimming paradigms, but consensus on the effects of exercise is 
still lacking within the literature. Daily wheel running showed a non-significant increase 
in survival times of SOD1 mice (Liebetanz et al. 2004), while most studies on 
moderate-intensity treadmill exercise showed increased survival times (Kirkinezos et al. 
2003; Kaspar et al. 2005; Carreras et al. 2010). However, an alternate study found 
increased survival in SOD1 mice undergoing swimming exercise, but no benefit from 
treadmill running (Deforges et al. 2009). In addition, high-intensity treadmill running 
showed a detrimental effect on SOD1 mouse survival times (Mahoney et al. 2004). 
Thus, the duration, intensity, and type of exercise appeared to affect how exercise 
modulates survival in SOD1 mouse models of ALS. 
4.1.3 Aims and hypothesis 
As described in section 4.1.1.3, MT-1/2 appears neuroprotective via a range of 
mechanisms which could include ROS scavenging, preventing apoptosis, modulating 
glial reactivity, and activating neuronal signalling pathways; MT-1/2 protein is therefore 
a suitable candidate therapeutic for ALS. Interestingly, moderate-intensity treadmill 
running exercise has been shown to upregulate MT-1/2 in the spinal cord of non-
transgenic mice (Hashimoto et al. 2009). It is possible that the protective effects of 
treadmill exercise in SOD1 mice may be due to increased production of the 
neuroprotective MT-1/2 protein in the spinal cord. This study aims to test the protective 
effects of MT-1/2 in SOD1 mice, via administration of exogenous MT-2A protein (the 
most common MT-1/2 isoform), or via upregulation of endogenous MT-1/2 by exercise.  
Hypothesis: Pre-symptomatic administration of exogenous MT-2A protein, and/or 
treadmill running exercise, will improve functional and survival outcomes in SOD1 
mice compared with untreated controls.  
This longitudinal study was designed to monitor disease onset, disease progression, and 
survival time in a cohort of female SOD1 mice. The cohort was split into 4 treatment 
groups in a 2x2 design, with mice receiving either: treadmill exercise alone; MT-2A 
treatment alone; treadmill exercise and MT2 treatment; or no treatment 
(vehicle/sedentary control). A factorial approach was used in order to identify any 
synergistic effects of concurrent MT-2A treatment and treadmill running. 
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4.2 Methods 
4.2.1 Animals 
All procedures and protocols involving animals were approved by the University of 
Tasmania’s Animal Ethics Committee (permit number A10995). SOD1 mice were 
housed and genotyped according to the protocols in Chapter 2.  
4.2.2 Treatments 
Female SOD1 mice were assigned to one of four treatment groups in a 2x2 design 
(n=13-16/group). Mice received two simultaneous treatments: 1) administration of MT2 
protein, or saline control; and 2) treadmill exercise, or sedentary control. The treatment 
groups were MT2+Exercise, Saline+Exercise, MT2+Sedentary, and Saline+Sedentary. 
All treatments started at 6 weeks of age, during the pre-symptomatic stage of disease, 
and stopped after 16 weeks of age (Figure 4.2). Copy number, age at start of treatment, 
and starting body weight did not differ between treatment groups (Table 4.1). 
 
Table 4.1 Characteristics of SOD1 mice at start of treatment 
Treatment Group n Copy number 
(ΔCT) 
Age at start 
(days) 
Starting 
weight (g) 
MT2/Exercise 14 5.33 ± 0.07 46.7 ± 1.2 17.7 ± 0.4 
MT2/Sedentary 14 5.33 ± 0.08 46.9 ± 1.2 17.6 ± 0.3 
Saline/Exercise 14 5.31 ± 0.05 47.7 ± 1.1 17.4 ± 0.2 
Saline/Sedentary 16 5.31 ± 0.05 48.6 ± 1.2 17.3 ± 0.3 
Omnibus one-way ANOVA: Copy number, p=0.994; Age at start, p=0.665; Starting weight, p=0.790.  
 
4.2.2.1 MT2 administration 
Lyohilised, purified rabbit-liver Zn7-metallothionein-2A (MT2; >98% purity by HPLC, 
Bestenbalt LLC, Tallinn, Harjumaa, Estonia), was dissolved in 0.9% sterile saline 
solution for injection. MT2 treatment consisted of twice-weekly intramuscular 
injections of 10mg MT2/kg body weight, giving a weekly total dose of 20mg MT2/kg. 
MT2 solution, or sterile saline for control mice, was injected into the caudal thigh 
musculature via a 31-gauge needle, with a maximum volume of 30µL per injection, 
under light isoflurane (Attane) anaesthesia (3.5% isoflurane in 2L/min oxygen flow). 
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4.2.2.2 Treadmill running exercise 
Exercised mice were exercised five days per week on a mouse treadmill (Exer 3/6, 
Columbus Instruments, OH, USA). Daily sessions consisted of a warm-up (5min, 
0m/min to 10m/min) followed by constant speed exercise (25min, 10m/min), and a 
cool-down (1min, 10m/min to 0m/min), performed between 9am and 12noon as much 
as practicable. Sedentary controls spent 25 minutes on the stationary treadmill, to try to 
control any effects of environmental enrichment due to a novel treadmill environment.       
4.2.3 Outcome measures 
4.2.3.1 Functional assessments 
Stride pattern testing and wire hang duration (Chapter 2) were tested weekly, and body 
weight at least twice weekly, in all mice throughout the treatment period, and in those 
mice followed through to disease endpoint (Figure 4.2). Weekly average stride length, 
uniformity, body weight, percentage body weight, and wire hang duration ability were 
compared using two-way ANOVA, with MT2/saline and exercise/sedentary as factors. 
All data are reported as mean ± standard error of the mean; F tests of fixed effects in the 
two-way ANOVA are also reported. Linear mixed modelling was also used to model 
body weight trajectories over time (see Chapter 2), and the non-linear combination of 
estimators (nlcom) procedure in StataIC was used to estimate age at which maximum 
body weight was attained (mean ± standard error for each group). Point estimates of age 
at maximum body weight were compared between treatment groups using Z scores. 
p<0.05 was considered significant in all analyses. 
4.2.3.2  Histological and immunostaining analyses 
At 17 weeks of age, 3-4 mice per group were sacrificed for histological analysis 
(MT2/Exercise n=3, MT2/Sedentary n=3, Saline/Exercise n=4, Saline/Sedentary n=4) 
(Figure 4.2), and perfused with 4% PFA (see Chapter 2). The lumbar spinal cord was 
decalcified, embedded in paraffin, and microtome-sectioned at 5µm; the hindlimb calf 
musculature was post-fixed in 4% w/v PFA in PBS at 4°C, cryoprotected in 10% and 
30% w/v sucrose (Sigma-Aldrich) in PBS, embedded in OCT cryomatrix (Sakura 
Finetek, Tokyo, Japan) and cryostat-sectioned (Leica) at 80µm onto slides; excess 
cryomatrix was removed with PBS prior to immunolabelling. Spinal cord sections were 
dewaxed in xylene and rehydrated through graded alcohols prior to labelling, and also 
quenched with 3% H2O2 in PBS (20 minutes) prior to DAB immunohistochemistry. 
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Figure 4.2 Experimental design for the MT2 and/or exercise trial 
Female SOD1 mice were divided into 4 treatment groups at 6 weeks of age. Treatment 
with MT2 (MT-2A 10mg/kg i.m., twice per week) or treadmill running exercise 
(10m/min, 30min, 5 days per week), or both, was carried out from 6 to 16 weeks of age 
(n=13-16 per group). Body weight, stride pattern testing, and wire hang duration were 
measured at least weekly from 6 weeks of age through to disease endpoint. At 17 weeks 
of age, at least 3 mice in each treatment group were sacrificed for histological analysis 
of spinal cord motor neuron, microglia, and astrocyte numbers, spinal cord MT-1/2 
levels, and  neuromuscular junction innervation. Ten mice in each treatment group were 
followed for survival analysis, with disease endpoint measured as a loss of 20% from 
peak body weight. 
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4.2.3.2.1 Nissl stain 
Eight to ten sections per spinal cord, each separated by a minimum distance of 40µm, 
were incubated with cresyl violet solution (1% w/v cresyl fast violet, acidified with 
0.25% v/v acetic acid [both Sigma-Aldrich]) for 30 minutes, then washed in slowly-
running water until dye no long leached from the sections. Slides were then passed 
through 95% ethanol for 4 minutes, 100% ethanol for 2 minutes, incubated in xylene, 
passed through 100% ethanol and incubated with cajeput oil for 3 minutes, then rinsed 
twice in xylene and coverslipped using Pertex mounting medium (Leica).  
4.2.3.2.2 MT-1/2 immunohistochemistry 
Immunolabelling for MT-1/2 was performed as described in Chapter 2, with the 
exception that the primary mouse anti-MT-1/2 antibody was used at 1:750. MT-1/2-
positive cells were counted in the lumbar spinal cord ventral horn, dorsal horn, dorsal 
white matter, corticospinal tract, and ventral/lateral white matter (see Figure 4.10A). 
4.2.3.2.3 Tomato lectin labelling 
Tomato lectin (TL) labelling was performed to label microglial cells. Three lumbar 
spinal cord sections from each mouse, each separated by a minimum distance of 80µm, 
were blocked and incubated with biotinylated TL as described in Chapter 2. TL was 
detected with stretapvidin-HRP (Life Technologies, 1:1000 for 1 hour in PBS) and 
DAB substrate (Vector Laboratories, 1 minute); sections were counterstained with 
nuclear fast red, dehydrated and coverslipped using Pertex.  
4.2.3.2.4 GFAP immunohistochemistry 
Three lumbar spinal cord sections from each mouse, each separated by a minimum 
distance of 80µm, were blocked and incubated with anti-GFAP antibody as described in 
Chapter 2. The primary antibody was detected with HRP-conjugated goat anti-rabbit 
antibody (1:1000 for 1 hour, Dako) and DAB substrate (Vector Laboratories) for 1 
minute. All sections were counterstained and coverslipped as above.  
4.2.3.2.5 Neuromuscular junction counts 
To examine neuromuscular junction (NMJ) innervation, colocalisation between 
nicotinic acetylcholine receptors and neuronal markers was examined. Cryosections of 
calf and gastrocnemius musculature (80µm) were incubated with α-bungarotoxin-
AF594 (αBTx [Life Technologies], 1:200 for 45 minutes), washed with PBS, then fixed 
with ice-cold methanol for 5 minutes. After 2 PBS washes, the tissue was permeabilised 
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by a 2-hour incubation with 0.3% TritonX-100 in PBS, then washed twice in PBS. A 
cocktail of primary antibodies against neuronal markers (mouse anti-dephosphorylated 
neurofilament SMI32 1:500, mouse anti-phosphorylated neurofilament SMI312 1:750 
[Covance], mouse anti-synaptophysin 1:500 [Santa Cruz Biotechnology] and mouse 
anti-tau 1:500 [Santa Cruz Biotechnology]) was applied O/N at RT. Primary antibodies 
were detected with goat anti-mouse-AF488 (1:500 for 2 hours); nuclei were stained 
with Nuclear Yellow (1:10000 for 15 minutes). Muscle sections were coverslipped in 
aqueous mounting medium and examined under a fluorescence microscope (Olympus) 
for colocalisation between αBTx and neuronal markers. An innervated NMJ was scored 
as having any colocalisation between neuronal markers and αBTx labelling. For each 
animal, the innervation status of at least 100 NMJs was scored.  
4.2.3.2.6 Counts and statistical analysis 
DAB-stained slides were imaged under bright field microscopy (Leica Biosystems). 
Cell counts for motor neurons, MT-1/2-positive cells, and TL-positive cells were carried 
out in ImageJ (NIH). GFAP labelling was thresholded in the HSB colour space (hue, 
stop 83-84; saturation, pass 0-112; brightness, pass 170-255) in ImageJ, and quantified 
as a percentage area showing positive immunoreactivity in each region (see Figure 
4.12F). Statistical analysis of all histological markers was carried out in SPSS, using 
one-way and two-way ANOVA to check for differences between treatment groups. 
4.2.3.3 Survival 
Survival time, measured as the earliest of either a loss of 20% from maximum recorded 
body weight or inability of a mouse to right within 30 seconds of being placed on its 
side, was analysed in SPSS using Kaplan-Meier analysis and Cox proportional hazards 
regression. Of 58 treated mice (Table 4.1), four mice died prior to disease endpoint – 
two Saline+Sedentary mice died under anaesthesia, and one MT2+Exercise mouse and 
one MT2+Sedentary mouse were found deceased in their cages unexpectedly. 
Examination by the animal welfare officer was unable to isolate a cause of death, but it 
is possible that these two mice died due to complications from intramuscular injections. 
These four unexpected deaths in the cohort represent a rate of 7%, a rate slightly lower 
than the 10% observed in previous SOD1 studies (Scott et al. 2008). After removing 
mice for histological analyses, and accounting for unexpected deaths, ten mice per 
treatment group (40 of the original 58) provided data for survival analysis.   
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4.3 Results 
4.3.1 Survival 
Survival time was recorded as the earliest of either the mouse losing 20% from its pre-
disease maximum body weight, or the inability to right within 30 seconds. Four SOD1 
mice (10%) reached their righting endpoint prior to their weight endpoint; 34 SOD1 
mice (85%) displayed a 20% loss of peak body weight while still able to right within 30 
seconds. Two SOD1 mice (5%) were culled just prior to disease endpoint due to 1) a 
mistake with ear ID clips and 2) an eye infection; data from these mice were censored 
appropriately in the survival analyses. Kaplan-Meier survival curves were plotted, and 
interactions between MT2 treatment and exercise were analysed using CPH analysis.   
4.3.1.1 Kaplan-Meier survival analysis 
Kaplan-Meier survival curves, with each treatment group plotted separately, indicate 
that MT2-treated mice (red lines) showed a more right-shifted survival curve with 
longer survival times than saline-treated mice (blue lines) (Figure 4.3A). Survival 
curves for exercised mice (solid lines) and sedentary mice (dashed lines) were 
approximately equal, although a very slight right-shift for exercised mice could be 
observed (Figure 4.3A). Average survival time estimates from Kaplan-Meier analysis 
were Saline+Sedentary 165.6±2.7 days, Saline+Exercise 168.0±2.3 days, 
MT2+Sedentary 170.5±1.8 days, and MT2+Exercise 172.7±1.8 days. Differences 
between the four individual treatment groups did not reach statistical significance (Log 
Rank test, p=0.146). Kaplan-Meier analysis was also used to split the mice on the basis 
of MT2 treatment or exercise treatment; MT2-treated mice showed longer survival 
times than saline-treated mice (Log-Rank test p=0.070; Figure 4.3B), whereas exercised 
and sedentary mice showed similar survival times (Log-rank test p=0.147; Figure 4.3C). 
4.3.1.2 Cox proportional hazards regression 
Cox proportional hazards regression (CPH) was used to examine the effects of exercise 
and MT2 treatment separately. Univariable CPH modelling showed that the hazard rate 
for MT2-treated mice was reduced compared to saline-treated mice, and the hazard rate 
for exercised mice was slightly reduced compared to sedentary mice (Table 4.2). Copy 
number, age at start of treatment, starting body weight, maximum body weight, and age 
at maximum body weight had negligible effects on survival (Table 4.2).   
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Figure 4.3 Kaplan-Meier survival curves for MT2-treated and exercised SOD1 
mice  
Comparing all four treatment groups (A) revealed that MT2-treated mice (red lines) 
showed right-shifted survival curves compared to saline-treated mice (blue lines), while 
exercised mice (solid lines) showed slightly right-shifted survival curves compared to 
sedentary mice (dashed lines); there were no significant differences between the four 
treatment groups. When MT2 treatment was compared with saline, regardless of 
exercise status (B), MT2-treated mice showed longer survival times than saline-treated 
mice. When exercise was compared with remaining sedentary, regardless of MT2 status 
(C), the survival curves showed few differences between exercised and sedentary mice. 
Vertical dashes represent censored data points. 
100
S…
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Multivariable CPH regression, including both MT2 and exercise treatment, indicated 
that the hazard rate for MT2-treated mice was reduced by approximately 45% compared 
to saline-treated mice, and this effect approached statistical significance (HRMT2=0.556, 
95% CI 0.284-1.091, p=0.088). The hazard rate for exercise-treated mice was reduced 
by approximately 35% compared to sedentary mice, although this was not significant 
(HRexercise=0.626, 95% CI 0.318-1.230, p=0.174) (Table 4.2). The associations between 
MT2 treatment and reduced hazard ratio, and exercise and reduced hazard ratio, became 
stronger when the multivariable model was adjusted for possible confounders copy 
number, age at start of treatment, starting body weight, maximum body weight, and age 
at maximum body weight (Table 4.2). The results of survival analyses show that MT2 
treatment increases survival time by approximately 5 days (around 3% of SOD1 mouse 
lifespan), and that these effects approach statistical significance.       
 
Table 4.2 Cox proportional hazards regression model for disease endpoint 
Factor(s) in CPH model HR (95% CI) p-value 
Univariable analysis
1
   
            MT2 0.555 (0.283, 1.089) 0.087 
            Exercise 0.624 (0.318, 1.226) 0.171 
            Copy number (ΔCT) 0.911 (0.271, 3.065) 0.880 
            Age at start 1.009 (0.933, 1.092) 0.817 
            Starting weight 1.096 (0.836, 1.436) 0.506 
            Maximum body weight 1.067 (0.825, 1.380) 0.624 
            Age at maximum body weight
#
 0.992 (0.975, 1.009) 0.342 
Multivariable analysis
2
   
            MT2 0.556 (0.284, 1.091) 0.088 
            Exercise 0.626 (0.318, 1.230) 0.174 
Multivariable analysis, adjusted
3
   
            MT2 0.351 (0.149, 0.828) 0.017 
            Exercise 0.531 (0.259, 1.088) 0.084 
1
Univariable analysis contains the listed factor/covariate. 
2
Multivariable analysis contains both exercise 
and MT2. 
3
Multivariable analysis contains exercise, MT2, and possible confounders copy number, age at 
start of treatment, starting body weight, maximum body weight and age at maximum body weight. 
#
If 
maximum body weight was achieved on more than one occasion, the largest age was used in the analysis.  
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4.3.2 Body weight 
4.3.2.1 Average body weight per week 
The body weight trajectories of SOD1 mice were curved, with all SOD1 mice showing 
weight gain from 6 to approximately 18 weeks of age, and weight loss therafter (Figure 
4.4A). MT2-treated mice appeared to have higher average body weight than saline-
treated mice at 17-22 weeks of age (Figure 4.4A); however, body weights differences 
between treatment groups were not significant by one or two-way ANOVA.  
4.3.2.2 Linear mixed modelling of body weight 
The MT2/saline treatment and the exercise/sedentary status of SOD1 mice both 
contributed to the fit of the model, such that the model fit the raw data better when these 
factors were included rather than excluded (Supplementary Data 3). The model fit was 
not improved by including interaction terms (MT2*exercise) (Supplementary Data 3); 
thus, the final model, with parameters outlined in Table 4.3, contained no interaction 
term (for full model specification, see Model 3, Supplementary Data 3). 
The results of the linear mixed model give a set of parameters for the equation  
Body weight = β0 + β1*Age + β2*Age
2
 + β3*Age
3
, where each β coefficient has a unique 
value for each SOD1 treatment group (listed in Table 4.3). The β coefficients for MT2-
treated mice were significantly different from those of saline-treated mice, whereas the 
β coefficients for exercised mice were not significantly different from those of 
sedentary mice (Supplementary Data 3). When graphed, the body weight trajectory 
curves indicated that MT2-treated mice (red lines) showed slightly higher body weights 
than saline-treated control mice (blue lines) at 120-140 days of age (Figure 4.4B).  
 
Table 4.3 Parameter estimates from linear mixed modelling of body weight 
Fixed effects 
parameter
1
 
Saline + 
Sedentary 
Saline + 
Exercise 
MT2 + 
Sedentary 
MT2 +  
Exercise 
Intercept (β0) 17.36 17.39 17.78 17.81 
Age (β1)  2.10 x 10
-2
  1.89 x 10
-2
 -4.33 x 10
-3
 -6.40 x 10
-3
 
Age
2
 (β2)  4.78 x 10
-4
  4.30 x 10
-4
  9.88 x 10
-4
  9.39 x 10
-4
 
Age
3
 (β3) -5.55 x 10
-6
 -4.74 x 10
-6
 -8.13 x 10
-6
 -7.32 x 10
-6
 
1
For equation: Body weight = β0 + β1*Age + β2*Age2 + β3*Age3, where Age = Age, centered at 42 days.   
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Figure 4.4 Body weight averages and modelled body weight trajectories in MT2-
treated and exercised SOD1 mice over time 
Average body weight at each age week (A) was not significantly different between 
treatment groups. Linear mixed model body weight trajectories (B) for MT2-treated (red 
lines), saline-treated (blue lines), exercised (solid lines), and sedentary (dashed lines) 
SOD1 mice are shown, corresponding to parameter estimates from Table 4.3. Model-
based nlcom estimates of maximum body weight did not differ between treatment 
groups (C). Model-based nlcom estimates of the age at maximum body weight (D; 
arrows in B) showed later age at maximum body weight in MT2-treated mice than in  
saline-treated mice. *p<0.05 **p<0.01 ***p<0.001. Sed., sedentary; Ex., exercise. Error 
bars represent standard error of the mean (A) or of the nlcom point estimate (C,D). 
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4.3.2.3 Estimation of maximum body weight, and age at maximum body weight, 
from mixed model parameters using nlcom 
From the mixed model parameters for each group, point estimates of the maximum 
body weight and the age at maximum body weight were calculated. MT2-treated mice 
had a slightly higher peak body weight than saline-treated mice, although this was not 
significant (Figure 4.4C). The age at which mice reached maximum body weight (point 
estimate ± standard error) was 116.4±1.4 days in Saline+Sedentary mice, 119.6±1.5 
days in Saline+Exercise mice, 120.8±1.1 days in MT2+Sedentary mice, and 124.0±1.2 
days in MT2+Exercise mice (Figure 4.4D; arrows in Figure 4.4B).  
MT2+Exercise and MT2+Sedentary mice reached maximum body weight at a later age 
than Saline+Sedentary mice (p<0.05). MT2+Exercise mice also reached maximum body 
weight at a later age than Saline+Exercise and MT2+Sedentary mice (p<0.05) (Figure 
4.4D). This indicated that MT2-treated mice reached their maximum body weight, a 
proxy of disease onset, slightly later than saline-treated mice. This was not due to 
differences in maximum body weight attained (Figure 4.4), nor due to differences in the 
amount of weight gained between starting treatment and reaching maximum body 
weight (weight gains: Saline+Sedentary 2.5±0.3g, Saline+Exercise 2.6±0.3g, 
MT2+Sedentary 2.7±0.3g, MT2+Exercise 2.4±0.2g; p>0.4 by one-way and two-way 
ANOVA). Thus, it would appear that MT2 treatment slightly delays disease onset.  
4.3.2.4 Percentages body weight by week. 
Interestingly, the body weight trajectories for exercised mice (solid lines) appeared to 
decline less steeply than those of sedentary mice (dashed lines) (Figure 4.4B). To 
determine whether any treatment had an effect on body weight decline over time, the 
ages at which mice reached 95, 90, and 85% of their maximum body weight were 
examined. Body weights were converted to a percentage of each mouse’s maximum 
body weight, and percentage body weights were compared at each week using two-way 
ANOVA, including an MT2*exercise interaction term. At 22 weeks of age, exercise and 
MT2 treatment appeared to act together to produce the highest percentage of maximum 
body weight remaining (MT2+Exercise 92±1%, MT2+Sedentary 88±1%, 
Saline+Exercise 89±1%, Saline+Sedentary 90±1%; while main effects were not 
significant, FMT2*exercise(1,34)=5.065, p=0.031). At 24 weeks of age, exercised mice 
showed higher percentage body weights than sedentary mice (MT2+Exercise 83±1%, 
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MT2+Sedentary 82±1%, Saline+Exercise 85±1%, Saline+Sedentary 81±2%;  
Fexercise(1,20)=5.655, p=0.027) (Figure 4.5A). However, these changes were not 
consistent throughout the disease course (Figure 4.5A).  
The ages at which mice reached 95%, 90% and 85% of their maximum body weight 
were also examined using survival analysis; Kaplan-Meier survival curves are provided 
in Figure 4.5B, while CPH regression was used for statistical analysis. Exercised mice 
had a reduced hazard ratio for reaching 95% body weight compared to sedentary mice 
(HR(95%BW)Exercise=0.468, 95% CI 0.238-0.918, p=0.027, adjusted for MT2 
treatment), indicating that exercised mice stayed above 95% of their maximum body 
weight for longer than sedentary mice (Figure 4.5B, left panel). MT2-treated mice 
tended towards a reduced hazard ratio for reaching 90% of peak body weight compared 
to saline-treated mice (HR(90%BW)MT2=0.511, 95% CI  0.255-1.021, p=0.057, adjusted 
for exercise), indicating that MT2-treated mice stayed above 90% of their maximum 
body weight for slightly longer than saline-treated mice. Examination of the Kaplan-
Meier survival curves indicates this effect is driven mainly by maintenance of >90% 
body weight in MT2+Exercise mice (Figure 4.5B, middle panel). There were no 
differences between treatment groups for the age at reaching 85% body weight (Figure 
4.5B, right panel).     
In summary, MT2 treatment appears to affect the body weight of SOD1 mice, with a 
slightly later age at disease onset compared to saline-treated mice.  
 
4.3.3 Stride pattern 
The stride pattern parameters, stride length and uniformity measurement (see Figure 
2.11A,B), were measured weekly in all treatment groups.   
4.3.3.1 Stride length 
Stride length decreased over time in all SOD1 mice (Figure 4.6A). Stride lengths were 
similar between treatment groups at most weekly time points, although 
Saline+Sedentary mice tended to have shorter stride lengths than other treatment groups 
at 16, 18, 19 and 20 weeks of age (Figure 4.6A). At 12 and 14 weeks of age, exercised 
mice showed longer stride lengths than sedentary mice (12 weeks: Fexercise(1,50)=6.153, 
p=0.017); 14 weeks: Fexercise(1,48)=6.356, p=0.014).  
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Figure 4.5 Percentage body weights of MT2-treated and exercised SOD1 mice 
MT2+Exercise mice showed slightly higher retention of percentage body weight at 22 
weeks of age, while exercised mice displayed higher body weight percentages than 
sedentary mice at 24 weeks of age (A). Kaplan-Meier curves for falling below 95%, 
90%, and 85% percent of maximum body weight (B) show that exercised mice appeared 
to drop below 95% of maximum body weight later than sedentary mice (B, left panel), 
and MT2+Exercise mice appeared the last to drop below 90% of maximum body weight 
(B, middle panel). *p<0.05 MT2+Exercise mice vs. all other groups, #p<0.05 exercised 
mice vs. sedentary mice. BW, body weight; MT+Ex, MT2+Exercise; MT+Sed, 
MT2+Sedentary; S+Ex, Saline+Exercise; S+Sed, Sedentary+Saline. Vertical dashes in 
B represent censored data. Error bars represent standard error of the mean. 
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At 16 weeks of age, exercised mice had a slightly longer stride length than sedentary 
mice (Fexercise(1,39)=3.951, p=0.054); although the main effect for MT2 was not 
significant (FMT2(1,39)=0.486, p=0.490), there was a significant interaction between 
MT2 and exercise (FMT2*exercise(1,39)=4.179, p=0.048), indicating that the effect of 
exercise was not the same for mice receiving MT2 and mice receiving saline. 
Examining stride length averages confirmed that at 16 weeks of age, Saline+Exercise 
mice had a longer stride length than Saline+Sedentary mice, but there was no difference 
in stride length between MT2+Exercise mice and MT2+Sedentary mice. However, this 
effect was not maintained at 17 or 18 weeks of age. At 19 weeks of age, exercised mice 
again showed longer stride lengths than sedentary mice (Fexercise(1,36)=7.864, p=0.008).  
At 20 weeks of age, MT2-treated mice showed longer stride lengths than saline-treated 
mice (FMT2(1,32)=5.833, p=0.022), and exercised mice showed longer stride lengths 
than sedentary mice (Fexercise (1,32)=6.453, p=0.016). However, the interaction term was 
also significant (Fexercise*MT2(1,32)=5.175, p=0.030), with average values indicating that 
MT2+Exercise mice had no further increase in stride length above that seen by either 
treatment applied individually, i.e. MT2+Exercise stride length was no different to 
either Saline+Exercise or MT2+Sedentary stride length. At 23 weeks of age, exercised 
mice showed longer stride lengths than sedentary mice (Fexercise (1,24)=8.060, p=0.009) 
4.3.3.2 Uniformity: 
Uniformity measurements increased over time in SOD1 mice (Figure 4.6B). Uniformity 
measurements were relatively constant between treatment groups (Figure 4.6B), 
although slight differences were noted at 19 and 20 weeks of age where MT2-treated 
mice (red lines) appeared to have smaller uniformity measures than saline-treated mice 
(blue lines). At 9 weeks of age, exercised mice showed increased uniformity measures 
compared to sedentary mice (Fexercise(1,51)=11.971, p=0.001), although uniformity 
measures between all mice subsequently remained similar until 19 weeks of age. At 19 
weeks of age, MT2-treated mice showed lower uniformity measures than saline-treated 
mice (FMT2(1,36)=4.675, p=0.037). A similar trend for decreased uniformity in MT2-
treated mice was present at 20 weeks of age, but this did not reach statistical 
significance (p=0.077). Thus, both exercise and MT2 treatment appear to have slight 
effects on stride pattern – at select time points, exercise and MT2 both appeared to 
maintain stride length, while MT2 treatment appeared to promote lower uniformity 
values, although these effects were not consistent throughout disease progression. 
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Figure 4.6 Stride pattern in MT2-treated and exercised SOD1 mice 
Stride length, the distance between consecutive hind paw prints (A), and uniformity 
measure, the distance between placement of the front paw and subsequent hind paw 
placement when passing over the same spot (B), were similar between treatment groups. 
Stride length appears shortest in Saline+Sedentary mice at 18-20 weeks, while 
uniformity appears longer in saline-treated mice than MT2-treated mice at 19-20 weeks 
of age. *p<0.05 exercised mice vs. sedentary mice; #p<0.05 Saline+Exercise mice vs. 
Saline+Sedentary mice;†p<0.05 Saline+Sedentary vs. all other groups; ‡p<0.05 MT2-
treated mice vs. saline-treated mice. Error bars represent standard error of the mean.    
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4.3.4 Wire hang duration 
The wire hang duration testing revealed a large amount of variation within treatment 
groups (Figure 4.7A). Two-way ANOVA revealed only a significant interaction 
between exercise and MT2 at 17 weeks of age (Fexercise*MT2(1,35)=6.502, p=0.015), 
indicating that the effect of MT2 treatment on wire hang duration varied depending on 
whether the mice were exercised or not. Specifically, the average wire hang values 
indicated that MT2+Exercise mice had a slightly longer wire hang duration than 
Saline+Exercise mice at 17 weeks of age, but MT2+Sedentary mice in fact had a shorter 
wire hang duration than Saline+Sedentary mice at 17 weeks of age (Figure 4.7A).   
From the 40 mice which were measured from 6 weeks of age until endpoint, 32 
recorded the maximum wire hang duration of 60 seconds on at least one time point. 
Eight of the 40 mice (20%) were unable to hang on for 60 seconds at any time point; by 
group, these were 1 x MT2+Exercise, 2 x Saline+Exercise, 4 x MT2+Sedentary, and 1 x 
Saline+Sedentary. Amongst the 32 mice which attained a wire hang duration of 60 
seconds, there were no differences between treatment groups for 1) the age at mice were 
no longer able to consistently hold on for 60 seconds (Figure 4.7B), 2) the age at which 
mice were no longer able to consistently hold on for 30 seconds (Figure 4.7C), and 3) 
the age at which mice were unable to grip the bars, i.e. wire hang duration = 0 seconds 
(Figure 4.7D). Amongst all 40 mice, even those which did not attain a wire hang 
duration of 60 seconds at any time point, there was no difference between treatment 
groups in the age at which mice were able to hold on for less than 50% of their 
maximum attained hang duration (Figure 4.7E).    
 
4.3.5 Nissl staining 
The number of Nissl-stained motor neurons present in the lumbar spinal cord ventral 
horn at 17 weeks of age, after the 10 weeks of MT2 and/or exercise treatment, was 
counted and compared between treatment groups. The number of motor neurons 
remaining at 17 weeks of age was not different between the four treatment groups 
(Figure 4.8). The number of large, vacuolated, degenerating motor neurons present in 
the ventral horn was likewise not different between treatment groups (data not shown). 
These data indicate that neither exercise nor MT2 treatment were particularly effective 
at preventing motor neuron degeneration in the pre-symptomatic period.   
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Figure 4.7 Wire hang duration in MT2-treated and exercised SOD1 mice 
Average wire hang durations were similar between experimental groups at all time 
points (A). In mice which recorded the maximum of 60 seconds’ hang duration at any 
time point, no between-group differences were seen in the age at which mice were 
subsequently unable to hang on for 60 seconds (B), unable to hang on for 30 seconds 
(C), or unable to grip bars at all (D). Amongst all mice, including those which did not 
record 60 seconds’ grip duration at any time point, there was no difference in the age at 
which mice were unable to hang on for 50% of their maximum time (E). WH, wire hang 
duration. Error bars represent standard error of the mean. 
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Figure 4.8 Nissl-stained motor neurons in the ventral horn of MT2-treated and 
exercised SOD1 mice 
The number of motor neurons (MNs) remaining in the spinal cord ventral horn of 
Saline+Sedentary (A), Saline+Exercise (B), MT2+Sedentary (C), and MT2+Exercise 
(D) mice was not different at 17 weeks of age (E). Scale bar 50µm for A-D. Error bars 
in E represent standard error of the mean. 
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4.3.6 MT-1/2 immunostaining 
MT-1/2 was observed within glial cells in both the white and grey matter of all SOD1 
mice (Figure 4.9A-D). The number of MT-1/2-positive cells in the different spinal cord 
regions (Figure 4.10A) was compared between treatment groups. The numbers of MT-
1/2-positive cell bodies in both the dorsal and ventral/lateral white matter columns 
appeared to increase slightly with exercise but not with MT2 treatment (Figure 
4.10B,C). In the ventral horn grey matter, Saline+Exercise mice showed the largest 
number of MT-1/2-positive cells, although MT2+Exercise mice showed no increase in 
MT-1/2-positive cells compared to MT2+Sedentary mice (Figure 4.10D). However, 
there were no significant changes as assessed by two-way ANOVA. Few MT-1/2-
positive cells were observed in the corticospinal tract white matter and in the dorsal 
horn grey matter (Figure 4.10E,F). 
4.3.7 GFAP immunostaining 
Quantification of GFAP immunolabelling in different spinal cord regions (Figure 
4.11A-D, Figure 4.12F) revealed that that percentage area of the ventral horn grey 
matter, dorsal horn grey matter, corticospinal tract white matter, and dorsal column 
white matter occupied by GFAP immunoreactivity appeared to be increased by exercise 
(Figure 4.12A-E). The exercise-mediated increase in percentage area occupied by 
GFAP immunoreactivity was only significant in the dorsal column (Fexercise(1,9)=5.881, 
p=0.038) (Figure 4.12D). In contrast, MT2 treatment did not affect GFAP 
immunoreactivity in any region. 
4.3.8 Tomato lectin labelling 
Quantification of ventral horn microglial cells revealed a slight, but not significant, 
increase in Saline+Exercise mice compared to Saline+Sedentary mice (Figure 4.13). 
Neither MT2 nor exercise treatment appeared able to attenuate microglial activation.  
 
4.3.9 Neuromuscular junction innervation 
The percentage of innervated neuromuscular junctions in skeletal muscle from each 
treatment group was compared. No treatment appeared to significantly change the 
percentage of neuromuscular junctions innervated by motor axons (Figure 4.14). 
Neither MT2 treatment nor exercise was able to prevent muscle denervation in SOD1 
mice (Figure 4.14).  
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Figure 4.9 Representative images of MT-1/2 immunoreactivity in the spinal cord of 
MT2-treated and exercised SOD1 mice.  
Representative images of the MT-1/2 immunoreactivity (DAB chromogen, positive 
immunoreactivity gives a brown precipitate). Representative images are shown from the 
spinal cord of Saline+Sedentary (A), Saline+Exercise (B), MT2+Sedentary (C) and 
MT2+Exercise (D) mice. Black lines denote region dividers (see Figure 4.10A). Scale 
bar is 150µm in A-D. Quantitation of MT-1/2-positive cells is presented in Figure 4.10.  
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Figure 4.10 MT-1/2 immunostaining in MT2-treated and exercised SOD1 mice 
MT-1/2-positive (‘MT-positive’) cells in different regions of the spinal cord (line 
drawing, A) were counted. The number of MT-1/2-positive cells in the white matter 
increased slightly with exercise but not with MT2 treatment (B,C). In the grey matter, 
exercise appeared to increase the number of MT-1/2-positive cells in saline-treated mice 
only (D). Few MT-1/2-positive cells were seen in the corticospinal tract or in the dorsal 
horn (E,F). dwm, dorsal column white matter; cst, corticospinal tract; dh, dorsal horn; 
vh, ventral horn; vlwm, ventral and lateral white matter; Ex., exercise; Sed., sedentary. 
Error bars represent standard error of the mean. 
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Figure 4.11 Representative images of GFAP immunoreactivity in the spinal cord of 
MT2-treated and exercised SOD1 mice.  
Representative images of GFAP immunostaining with DAB chromogen are shown here 
for Saline+Sedentary (A), Saline+Exercise (B), MT2+Sedentary (C) and MT2+Exercise 
(D) treatment groups of SOD1 mice. Quantitation was performed and is presented in 
Figure 4.12. Scale bar is 150µm in A-D. Magenta lines denote regions in which GFAP-
positive immunoreactivity was quantitated (see Figure 4.12F). 
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Figure 4.12 GFAP immunoreactivity in MT2-treated and exercised SOD1 mice 
The astrocyte marker, GFAP, was detected by immunolabelling, and the amount of 
GFAP immunoreactivity (GFAP IR) was quantified using ImageJ and expressed as a 
percentage area of each spinal cord region (line drawing, F) displaying positive 
immunoreactivity. The percentage area displaying GFAP IR appeared to increase 
slightly with exercise in the ventral horn (A) and dorsal horn (B) grey matter, and in the 
dorsal (D) and corticospinal tract (E) white matter; no differences were seen in the 
ventral and lateral white matter with exercise (C). *p<0.05. dwm, dorsal column white 
matter; cst, corticospinal tract; dh, dorsal horn; vh, ventral horn; vlwm, ventral and 
lateral white matter; Ex., exercise; Sed., sedentary. Error bars represent standard error of 
the mean. 
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Figure 4.13 Tomato lectin labelling in MT2-treated and exercised SOD1 mice 
Representative images of tomato lectin staining, labelling both blood vessels and 
microglia, are shown for the lumbar spinal cord of SOD1 mice in all four treatment 
groups (A-D). The number of microglial cells in the ventral horn was not significantly 
different between treatment groups at 17 weeks of age (E). However, the number of 
microglia did appear to increase slightly in response to exercise in saline-treated mice 
only. Error bars represent standard error of the mean. Scale bar is 150µm in A-D. 
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Figure 4.14 Neuromuscular junction innervation in MT2-treated and exercised 
SOD1 mice 
Innervation was examined as colocalisation between α-bungarotoxin (“BT”) and a 
cocktail of neuronal antibodies (synaptophysin, SMI32, SMI312, and tau, “Axon”). 
Examples of co-localisation between the axonal markers and α-bungarotoxin are given 
in panels A-C. Neuromuscular junctions either showed full or partial innervation via 
colocalisation between the two markers (A,B) or showed no colocalisation (C). Neither 
MT2 treatment nor exercise were able to significantly prevent denervation at the 
neuromuscular junction (NMJ) by 17 weeks of age (D). Error bars represent standard 
error of the mean. 
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4.4 Discussion 
In this study, pre-symptomatic treatment with metallothionein-2A (MT2) and/or 
treadmill exercise were examined as potential therapies for delaying disease onset, 
ameliorating functional decline and increasing survival time in SOD1 mice. Pre-
symptomatic MT2 treatment delayed disease onset as measured by the timing of peak 
body weight, and showed positive but non-significant effects on survival time (Figure 
4.3, Figure 4.4). In contrast, pre-symptomatic treadmill exercise did not alter disease 
onset or survival time. Neither treatment substantially ameliorated disease progression 
as measured by stride pattern and wire hang duration (Figure 4.6, Figure 4.7). The 
mechanism of action for the MT2-mediated delay in disease onset and increase in 
survival remains as yet unknown, with no overt differences in motor neuron numbers, 
glial activation, or neuromuscular junction innervation as measured in this study (Figure 
4.8, Figure 4.12, Figure 4.13, Figure 4.14). Potential mechanisms by which MT2 could 
maintain motor units, and strategies to maximise the protective effect of MT2 in future 
studies, are discussed below.   
 
4.4.1 Metallothionein-2 as a potential therapeutic for ALS 
The results of the current study show a delayed disease onset for MT2-treated mice, and 
a slight increase in survival time. These results are consistent with genetic studies 
showing that ablation of MT-1/2 leads to an accelerated disease progression and 
reduced survival in SOD1 mice (Nagano et al. 2001; Puttaparthi et al. 2002), while 
global over-expression of MT1 protein delayed the onset of disease symptoms and 
increased survival time in SOD1 mice (Tokuda et al. 2013). MT-1/2 has multiple 
putative functions as an antioxidant, a response to metal dyshomeostasis, and as a 
neuroprotectant following neuronal injury (West et al. 2008). 
An advantageous feature of MT2 protein as a therapeutic for ALS is its multiple actions, 
which could counter multiple possible pathogenic processes in ALS. Conversely, this 
same feature makes it difficult to elucidate the exact mechanism of action by which 
MT2 may confer therapeutic benefits in SOD1 mice. As MT-1/2 can be internalised into 
cortical neurons (Chung et al. 2008b), the known intracellular and extracellular 
neuroprotective roles of MT-1/2, and how these properties may confer a protective role 
in ALS, will be discussed in the following sections.   
_________________________Chapter 4 – MT2 and exercise treatments in SOD1 mice 
______________________________________________________________________ 
______________________________________________________________________ 
 
156 
 
4.4.1.1 Possible intracellular neuroprotective functions of MT2 in neurons 
4.4.1.1.1 The antioxidant role of MT2 
Oxidative stress appears to be central to ALS pathology (Barber & Shaw 2010). MT-1/2 
shows potent antioxidant activity, and is able to release its metal ions in order to bind 
and sequester reactive oxygen species such as superoxide and hydroxyl radicals 
(Thornalley & Vasak 1985; Abel & de Ruiter 1989). MT-1/2 is also able to bind NO 
and peroxynitrite in vitro, but as this interaction is suppressed by physiological levels of 
reduced glutathione, it is as yet unclear whether MT-1/2 can sequester harmful NO and 
peroxynitrite species in vivo (Khatai et al. 2004). An MT2-mediated reduction of 
oxidative stress in the pre-symptomatic phase of SOD1 mice may delay the 
accumulation of oxidatively-damaged proteins and mRNA, preventing the development 
of downstream disease-related pathologies such as protein aggregation. The putative 
role of MT2 in scavenging NO and peroxynitrite would be very interesting to examine 
in more detail in ALS, due to the observed induction of iNOS in SOD1 spinal cord 
microglia with disease progression (see Chapter 2), and the reports of protein tyrosine 
nitration in ALS (Sasaki et al. 2000).     
4.4.1.1.2 The role of MT2 in metal homeostasis 
MT2 is a metal-binding protein, with each MT2 molecule capable of binding up to 7 
divalent metal ions or up to 12 monovalent metal ions, through thiol linkages on 
cysteine residues (Hamer 1986) (Figure 4.1). Sporadic ALS has been associated with 
exposure to heavy metals in epidemiological studies (Trojsi et al. 2013), while 
laboratory studies have showed higher levels of heavy metals in the spinal cord motor 
neurons of ALS patients than non-ALS controls (Pamphlett & Kum Jew 2013). 
Elevated levels of copper, zinc, magnesium, iron, cadmium, lead, aluminium, 
manganese, vanadium and uranium have been identified in the CSF and serum of ALS 
patients in various studies (Hozumi et al. 2011; Roos et al. 2013), suggesting that 
environmental exposures to metals, or dyshomeostasis of physiological metals such as 
zinc and copper, may contribute to the development of ALS.  
Elevated levels of redox-active metals, such as copper, are particularly damaging in the 
nervous system via the aberrant production of reactive oxygen species (Scheiber et al. 
2014). The presence of elevated copper levels may also apply to familial ALS, with 
SOD1 mice showing a shift towards copper accumulation in the spinal cord by 
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alteration of copper-trafficking pathways (Tokuda et al. 2009). One potential 
neuroprotective role of MT2 may be to sequester free copper ions and prevent metal-
mediated production of ROS; a previous study has shown a similar MT isoform, MT-3, 
is able to exchange its bound zinc ions for copper ions, silencing the redox-active 
copper ions (Meloni et al. 2007). Indeed, over-expression of MT1 in SOD1 mice 
normalises elevated levels of copper in the SOD1 spinal cord (Tokuda et al. 2013).  
An alternative, more speculative, action for MT2 may be ensuring correct metallation of 
mutant SOD1 protein. The metallation status of SOD1 modulates its neurotoxic 
properties (Banci et al. 2008), with mutant SOD1 proteins and zinc-deficient wild-type 
SOD1 protein showing similar propensity for aggregation and activation of ER stress 
responses (Rakhit et al. 2002; Homma et al. 2013). Zinc-loaded MT-1/2 is thought to be 
involved in the supply of zinc ions for zinc-binding proteins such as the MTF-1 
transcription factor (Zhang et al. 2003); if MT2 were able to facilitate the constitution of 
nascent mutant SOD1 with zinc, the aggregation of mutant SOD1 may be attenuated 
(Lelie et al. 2011).  
Thus, the metal-binding abilities of MT2 may mediate its beneficial effects in SOD1 
mice (Tokuda et al. 2013). This result would be in line with other copper-modulating 
compounds also having shown beneficial effects in the SOD1 mouse model of ALS 
(Soon et al. 2011; Parker et al. 2012).  
4.4.1.1.3 Internalisation via low-density lipoprotein receptor related proteins 
In order for MT2 to elicit intracellular effects, MT2 must be internalised into motor 
neurons. MT-1/2 is known to be internalised by transmembrane low-density lipoprotein 
receptor-related proteins (LRP1 and LRP2) by endocytosis in both kidney tubule cells 
(Erfurt et al. 2003; Klassen et al. 2004) and cultured cortical neurons (Chung et al. 
2008b). Preliminary data indicates that motor neurons in the mouse spinal cord express 
LRP2 (Nicholas Blackburn, unpublished observations). LRP1- and LRP2-mediated 
endocytosis is thought to be mostly clathrin-dependent, leading to lysosomal 
degradation of endosome contents (Harasaki et al. 2005; Buchackert et al. 2012). The 
metals bound to endosomal MT2 may become liberated upon the fusion with 
lysosomes, due to the drop in pH; these free metals may enter the cytosol (Hao et al. 
2007) and may stimulate the synthesis of new MT-1/2 molecules (Richards et al. 1984), 
with the overall effect of raising cellular MT-1/2 levels.  
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More speculatively, LRP1 can be recruited for caveolae-mediated endocytosis in 
adipocytes and hepatocytes (Zhang et al. 2004; Kanai et al. 2014); if these mechanisms 
are also present in motor neurons, it may be possible that an LRP1-MT2 complex could 
be internalised via non-classical endocytosis involving caveolae or lipid rafts (Hao et al. 
2007), potentially avoiding the lysosomal degradation pathway (Kiss & Botos 2009). 
Regardless of whether MT2 enters the cell intact, or releases its metals upon lysosomal 
degradation to stimulate de novo MT-1/2 synthesis, the intracellular level of MT-1/2 is 
likely to be increased upon LRP-mediated internalisation of MT2.  
4.4.1.2 Possible extracellular neuroprotective action of MT2 on neurons  
MT-1/2 is known to act extracellularly on neuronal cell bodies to induce neurite 
outgrowth through interaction with LRP1 and LRP2 (Fitzgerald et al. 2007; Chung et 
al. 2008b). The cytoplasmic portion of LRP1 protein contains signal transduction 
motifs, and is potentially involved in both endocytosis and intracellular signalling 
(Boucher & Gotthardt 2004). Thus, the interaction between MT2 and LRPs may induce 
neuroprotection via the activation of downstream signalling pathways, in addition to the 
intracellular roles for LRP-internalised MT2 discussed above.  
In cerebellar granule neurons, MT-1/2-LRP interactions activate pro-survival and pro-
outgrowth PI3K/Akt and MAPK/ERK pathways (Dudek et al. 1997; Chang & Karin 
2001), activate the pro-survival transcription factor CREB (Walton & Dragunow 2000), 
and dephosphorylate the pro-apoptotic factor Jun (Ham et al. 2000). Hence, LRP-
mediated activation of pro-survival and pro-outgrowth pathways upon MT2 binding 
may represent a possible pathway for maintaining neuronal function in ALS.  
4.4.1.3 A role for MT2 at the neuromuscular junction? 
The combined intraneuronal and extracellular actions of MT-1/2 provide a putative 
mechanism by which motor neurons are protected, and disease onset is delayed, by 
MT2 treatment in SOD1 mice. However, no differences in the number of Nissl-stained 
motor neurons were seen between MT2-treated and control SOD1 mice at 17 weeks of 
age (Figure 4.8), indicating that the actions of MT2 did not prevent death of motor 
neuron cell bodies, or indicating that little data about neuronal health can be gleaned 
from the Nissl stain alone. Markers of neuronal apoptotic status, such as the presence of 
cleaved caspases, should also be examined in MT2-treated and exercised SOD1 mice, in 
order to give more detail about the potential mechanism of action of MT2.  
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Given no obvious protection of motor neuron cell bodies, it is possible that MT2 
affected the motor unit at the neuromuscular junction (NMJ). The stimulation of LRPs 
by MT-1/2 induces neurite outgrowth in cultured neurons, and reactive sprouting in 
injured neurons (Chung et al. 2003; Fitzgerald et al. 2007). Motor neurons in ALS 
demonstrate compensatory plasticity at the NMJ, with re-innervation of denervated 
NMJs by neighbouring motor units in order to maintain function (Stalberg et al. 1975; 
Gurney et al. 1994). Any MT2-mediated increase in sprouting at the distal motor axon 
might enhance compensatory re-innervation, maintaining muscular connections and 
delaying the loss of body weight caused by denervation and muscle atrophy.  
The current study showed no difference in the percentage of innervated neuromuscular 
junctions between treatment groups (Figure 4.14), which would argue against increased 
re-innervation by MT2 treatment. However, this study only looked at the percentage of 
NMJs showing any neuronal innervation; a more detailed assessment of the degree of 
colocalisation between pre- and post-synaptic NMJ components in individual NMJs 
may help to detect differences between treatment groups. Intriguingly, another member 
of the LRP family, LRP4, is involved in neuromuscular junction formation and 
maintenance through agrin and Musk signalling (Kim et al. 2008; Zhang et al. 2008); 
one could speculate that MT2, if found to be a ligand of LRP4, might play a direct role 
in neuromuscular junction dynamics at the muscle. 
4.4.1.4 A role for MT2 in regulating glial phenotype? 
Activation of astrocytes and microglia is a pathological feature of ALS (see Chapter 1 
and Chapter 2). MT-1/2 may play a role in modulating astrocytic activation in cell 
culture and in response to focal brain injury (Chung et al. 2003; Leung et al. 2010). 
MT-1/2 may also modulate microglial activation and attenuate development of a 
neurotoxic microglial phenotype (Potter et al. 2007; Chung et al. 2009), and affect the 
phenotype of circulating monocytes (Pankhurst et al. 2011). Over-expression of MT1 in 
SOD1 mice has been reported to ameliorate astrocytic pathology (Tokuda et al. 2013). 
While there were no differences between astroglial and microglial numbers measured in 
MT2-treated and control SOD1 mice at the conclusion of treatment in the current study 
(Figure 4.12, Figure 4.13), markers of M1 and M2 microglial phenotypes were not 
examined in MT2-treated mice, and might provide clues as to the action of MT2 in 
SOD1 mice.  
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4.4.1.5 Timing and delivery of MT 
In this study, pre-symptomatic MT2 treatment delayed disease onset and slightly 
increased survival time. However, the magnitude of the MT2-induced changes was 
small: disease onset was delayed by approximately 4%, while survival time was 
increased by approximately 3%. The small effect of MT2 may be due to the timing of 
treatment in this study, or due to insufficient delivery of MT2 to the CNS. Had MT2 
treatment been maintained until disease endpoint, rather than stopping after 16 weeks of 
age, the effects of MT2 treatment on survival time may have been more pronounced. In 
particular, it was recently reported that the over-expression of MT1 in SOD1 mice was 
particularly effective in extending the duration of the later phase of disease; measured 
between the loss of 10% from peak body weight and disease endpoint (Tokuda et al. 
2013). Therefore, continued MT2 injections during the symptomatic stage of disease 
may have resulted in significant improvements in SOD1 survival.  
Alternatively, intramuscular injection may not efficiently deliver MT2 to the CNS. MT2 
rapidly enters the circulation after intramuscular injection, but does not readily enter the 
CNS when the BBB is intact, and is cleared through the renal system (Lewis et al. 
2012b). SOD1 mice show evidence of compromised BBB integrity in both pre-
symptomatic and symptomatic stages of disease (Garbuzova-Davis et al. 2007; Zhong 
et al. 2008), potentially facilitating the CNS entry of systemically-administered 
therapeutics such as MT2. The number of MT-1/2-positive cells in the spinal cord was 
not significantly greater after MT2 administration (Figure 4.10); however, the diffuse 
immunoreactivity thought to be extracellular MT-1/2 was not quantified in this study, 
and future work will determine whether MT2 administration increases extracellular MT-
1/2 levels. The beneficial survival effects seen by Tokuda (2013) upon MT1 over-
expression in SOD1 mice, where spinal cord MT1 levels were consistently elevated, 
were not seen to the same extent in the current study; exogenous MT2 injection may 
provide only transient elevations in spinal cord MT2 levels.  
Given that the number of MT-1/2-positive cells was not drastically increased following 
intramuscular MT2 treatment in this study, yet some positive effects on survival and 
disease onset were seen, the non-CNS activity of MT2 may need further exploration. As 
disease onset and survival parameters are both linked to body weight, it could be 
suggested that MT2 has some effect on body weight which is independent of CNS 
motor neuron counts or muscular innervation and mass. However, this is unlikely to be 
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the case, as Figure 4.4 shows that MT2-treated mice had virtually identical body 
weights compared with saline-treated mice between 6 and 14 weeks of age, during the 
treatment window in which MT2 was administered – this argues against a generalised 
body weight increase caused by MT2. Rather, after 14 weeks of age, MT2-treated mice 
retained their body weight slightly longer than saline-treated mice, delaying the muscle 
mass loss caused by disease processes (Figure 4.4). MT-1/2 expression is known to 
protect cardiac muscle after ischaemia/reperfusion injury (Wang et al. 2006); we may 
speculate that the injected MT2 in this study did have some direct protection on the 
skeletal muscles in the SOD1 hindlimb, but whether the protective mechanisms in 
cardiac muscle are also present in skeletal muscle are unknown.        
To avoid the issue of insufficient MT2 delivery to the CNS, it may be possible to use 
small peptides based on the sequence of human MT2 as therapeutics for ALS. These 
peptides, termed ‘Emtins’, show effects on the outgrowth of cortical neurons similar to 
those seen with MT-1/2, and have the added advantage of being BBB-permeable 
(Ambjorn et al. 2008; Asmussen et al. 2009a; Sonn et al. 2010). The use of Emtin 
peptides in SOD1 mice will be explored in Chapter 5.  
 
4.4.2 Exercise as a potential therapy for ALS 
The role of exercise in ALS is controversial – on one hand, high levels of physical 
activity are correlated with the development of ALS in epidemiological studies (Beghi 
et al. 2010; Huisman et al. 2013), and on the other hand there are numerous case studies 
and small trials showing that exercise therapy may help to ameliorate disease 
progression to a small extent in ALS patients (Bohannon 1983; Johnson 1988; Dal 
Bello-Haas et al. 2007; Sanjak et al. 2010). In the current study, pre-symptomatic 
treadmill exercise had no significant impact on disease onset and survival time in 
female SOD1 mice, showing neither beneficial nor detrimental effects. However, 
exercised mice did show slightly increased stride length compared to sedentary mice at 
a few select time points in disease progression (Figure 4.6). Although this increase in 
stride length is not clear evidence of a protective effect, this suggests that moderate 
treadmill exercise is, at least, not detrimental to SOD1 mice.  
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4.4.2.1 Previous exercise studies in ALS mice 
Previous studies of exercise in SOD1 mice have shown varying outcomes, depending on 
the type of exercise, the intensity of the exercise, mouse gender, and whether or not the 
effects of environmental enrichment were controlled for. Generally, moderate-intensity 
treadmill exercise has shown marginal to moderate beneficial effects on survival time, 
disease onset, and functional parameters when started pre-symptomatically in SOD1 
mice (Kirkinezos et al. 2003; Veldink et al. 2003; Liebetanz et al. 2004; Sorrells et al. 
2009; Carreras et al. 2010).  
Wheel-running exercise and swimming exercise have also shown beneficial effects for 
survival of SOD1 mice (Kaspar et al. 2005; Deforges et al. 2009; Sorrells et al. 2009), 
with wheel-running mice showing increased survival even when exercise was started 
around the onset of disease symptoms (Kaspar et al. 2005). In contrast, high-intensity or 
forced exercise has shown detrimental effects on survival in SOD1 mice (Mahoney et 
al. 2004). The exercise intensity in the present study was designated as ‘moderate’ – 
similar to that used in two previous studies which showed beneficially effects of 
exercise in SOD1 mice (Kirkinezos et al. 2003; Carreras et al. 2010). However, mindful 
that forced running had a detrimental effect on SOD1 mouse survival (Mahoney et al. 
2004), mice in the current study were encouraged but not forced to keep running on the 
treadmill – thus, the exercise intensity may not have been high enough to elicit 
protective effects. 
Environmental enrichment may also contribute to the apparent effects of exercise seen 
in previous studies – SOD1 mice exposed to a novel exercise environment, without 
undergoing exercise, showed longer survival times than mice not exposed to the novel 
environment (Sorrells et al. 2009; Gerber et al. 2012). In a treadmill exercise study 
which controlled for environmental enrichment by placing mouse on a stationary 
treadmill, no effect of exercise was seen on survival of SOD1 mice (Deforges et al. 
2009). The current study also controlled for effects of environmental enrichment by 
placing mice on a stationary treadmill, and saw no significant effects of exercise on 
survival times. Thus environmental enrichment may play some role in determining 
survival time, although the biochemical mechanisms behind these effects remain to be 
elucidated.   
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Gender and background strain, and interactions between the two, are known to affect 
SOD1 mouse survival time (Heiman-Patterson et al. 2005). Most previous studies on 
exercise in SOD1 mice involved mice with expression of the SOD1 transgene on a 
hybrid B6SJL genetic background, and most studies looked at the effects of exercise in 
male mice alone, with a few looking at a mix of male and female mice. Previous studies 
involving both female and male SOD1 mice have shown differing responses to exercise 
between the genders: three studies indicate male SOD1 mice respond more strongly to 
exercise than their female counterparts, regardless of whether exercise has a beneficial 
effect (Kirkinezos et al. 2003; Kaspar et al. 2005) or a detrimental effect (Mahoney et 
al. 2004). In contrast, another study showed exercise had a beneficial effect on survival 
in female but not male SOD1 mice (Veldink et al. 2003). To the best of my knowledge, 
the current study is the first to examine the effect of exercise in female SOD1 mice on a 
congenic B6 genetic background. As male mice were not tested in the present study, 
there may be an unknown effect of gender, or an interaction between gender and genetic 
background, which results in female SOD1 mice on a congenic B6 background being 
unresponsive to exercise treatment.   
To further examine the effects of exercise in female SOD1 mice on a congenic B6 
background, adaptations of the skeletal muscle to exercise should be examined in detail. 
As mentioned previously, the percentage innervation of neuromuscular junctions in the 
muscle was not significantly different between treatment groups (Figure 4.14). 
However, one of the beneficial effects of swimming exercise in SOD1 mice is the 
conversion of muscle fibre types from fast-twitch fibres to slow-twitch fibres (Deforges 
et al. 2009); slow-twitch fibres are more resistant to denervation and atrophy in SOD1-
mediated ALS than fast-twitch fibres (Hegedus et al. 2008). Analysis of the muscle 
fibre type profile of exercised and non-exercised female SOD1 mice might help to 
determine whether moderate-intensity treadmill exercise does induce a protective 
conversion of muscle fibre types in SOD1 muscle.  
4.4.2.2 Exercise and MT-1/2 induction 
Part of the original rationale for examining exercise was the apparent upregulation of 
MT-1/2 in response to exercise in wild-type mouse spinal cord (Hashimoto et al. 2009). 
In the present study, the number of spinal cord MT-1/2-positive cells appeared slightly 
higher in the ventral/lateral and dorsal white matter compared to sedentary controls, but 
these changes were not significant and were not present in the ventral horn (Figure 
_________________________Chapter 4 – MT2 and exercise treatments in SOD1 mice 
______________________________________________________________________ 
______________________________________________________________________ 
 
164 
 
4.10). While the quantitative level of MT-1/2 expression was not directly tested in this 
study (for example, with western blotting or RT-PCR), Hashimoto and colleagues 
(2009) saw a widespread increase in both the total spinal cord MT-1/2 levels and in the 
number of cells displaying strong MT-1/2 immunoreactivity following a two week 
treadmill exercise program in WT mice (Hashimoto et al. 2009). Although it cannot be 
definitively stated that exercise failed to increase MT-1/2 levels in the current study due 
to the lack of direct testing by western blot, the fact that the number of MT-1/2-positive 
cells did not drastically increase with exercise hints that exercise at the intensity used in 
the current study may not be sufficient to increase the production of MT-1/2 in the 
spinal cord above that seen with increased duration of disease (Chapter 2, Figure 2.7). 
The lack of MT-1/2 upregulation with exercise in the current study may correlate with 
the minimal effects of exercise on survival time; however, MT-1/2 is unlikely to be the 
sole factor responsible for any exercise-mediated increase in SOD1 survival. Several 
other factors, indcluding muscle fibre type switching (Deforges et al. 2009), or the 
production of BDNF and IGF1 (Kaspar et al. 2005; Carreras et al. 2010) are likely 
responsible for the exercise-mediated increase in survival time seen in previous studies 
(McCrate & Kaspar 2008).  
Interestingly, a possible interaction might exist between MT2 and exercise which does 
not involve upregulation of MT-1/2 in the spinal cord. The age at disease onset, as 
calculated from linear mixed modelling, was later in exercised MT2-treated mice than 
in sedentary MT2-treated mice, but was not affected by exercise in saline-treated mice 
(Figure 4.4D). Exercise has been reported to enhance LRP2 expression at the choroid 
plexus, to transport circulating IGF1 into the brain (Carro et al. 2005). As LRP2 is also 
a receptor for MT2 protein (Klassen et al. 2004), exercise may also facilitate the entry 
of MT2 into the central nervous system. As mentioned previously, examination of the 
spinal cord diffuse MT-1/2 immunolabelling, thought to represent extracellular MT-1/2, 
may determine whether exercise facilitates spinal cord entry of circulating MT2.  
4.4.2.3 Exercise in ALS patients 
The majority of studies in SOD1 mouse models of ALS show slight beneficial effects of 
moderate-intensity exercise. These correspond well with several small studies showing 
slight delays in disease progression in ALS patients treated with exercise-based 
therapies, with few adverse effects (Drory et al. 2001; Dal Bello-Haas et al. 2007; Lui 
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& Byl 2009; Sanjak et al. 2010). Exercise and physical therapy have been implicated as 
an important component of multidisciplinary care for ALS patients, in order to 
strengthen remaining muscles, maintain range of motion, and help combat stiffness and 
cramping in affected muscles (de Almeida et al. 2012; Skalsky & McDonald 2012; 
Arbesman & Sheard 2014).  
The potential beneficial effects of exercise in ALS patients are in contrast to 
epidemiological studies implicating high levels of physical activity as a risk factor for 
ALS (Beghi et al. 2010; Lehman et al. 2012; Huisman et al. 2013). However, the 
absence of a dose-response effect for increasing levels of exercise somewhat attenuates 
direct causality between physical activity and ALS (Huisman et al. 2013). An alternate 
theory proposes that the genetic profiles which naturally confer some higher level of 
body fitness may also predispose to ALS (Chio & Mora 2012; Mattsson et al. 2012). 
Thus, rather than physical activity directly causing ALS, it may be that those with a 
genetic risk profile conferring susceptibility to ALS are also more likely to engage in 
exercise-based leisure-time activities, or lean towards careers involving physical 
exertion such as professional sports (Lehman et al. 2012) or military service (Weisskopf 
et al. 2005).  
 
4.4.3 Summary and conclusions 
In summary, this proof-of-concept study reports that pre-symptomatic MT2 treatment 
resulted in a slight delay in disease onset and tended to increase survival time in female 
SOD1 mice, while exercise failed to show significant effects on disease onset or 
survival. No consistent synergistic effects were observed between MT2 treatment and 
exercise in SOD1 mice.  
The current study showed no detrimental effects of moderate-intensity treadmill 
exercise on SOD1 mice, and is consistent with the concept that physical exercise is not 
causative of ALS; rather, as-yet-unknown genetic factors may predispose to both a 
lifestyle involving high levels of physical activity, and the development of ALS. In this 
context, low-intensity to moderate-intensity exercise may be beneficial for ALS patients 
by providing a minor neuroprotective effect, and for maintaining strength and range of 
motion around affected muscle groups. However, caution should be used to avoid 
strenuous exercise which could potentially accelerate disease progression.  
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While MT2 has a solid theoretical basis for attenuating multiple pathological pathways 
present in ALS, the small magnitude of the effects may be due to the timing and 
delivery method of MT2 administration. Administration of MT2 directly to the central 
nervous system through intracerebroventricular injection or intrathecal pump, or via 
viral delivery, to deliver a consistent amount of MT2, may produce more pronounced 
effects on SOD1 mouse survival. Additionally, treatment beginning after the onset of 
disease symptoms is needed to confirm the survival-extending properties of MT2 and 
evaluate the use of MT2 as a potential therapeutic molecule for human ALS. To this 
end, the effects of a peptide analogue of MT2 will be discussed in Chapter 5.  
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Chapter 5  
 
Emtin peptides as therapeutic molecules  
in SOD1 mice – a pilot study 
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5.1 Background 
5.1.1 Emtin peptides 
Metallothionein-2 (MT2) provides a promising therapeutic candidate for extending 
survival when administered pre-symptomatically to SOD1 mice, as discussed in the 
previous chapter. However, MT2 does not readily access the CNS when injected either 
intraperitoneally or intramuscularly (Lewis et al. 2012b). Emtin peptides, synthetic 
derivatives of MT2, are able to cross the BBB and have similar in vitro effects to MT2 
protein (Ambjorn et al. 2008; Asmussen et al. 2009a; Sonn et al. 2010). Thus, Emtin 
peptides may present a therapeutic alternative to MT2 protein.  
5.1.1.1 Emtin structure 
Each of the Emtin peptide monomers consists of 14 amino acids, with the sequence 
derived from the human MT2A protein (Swiss Protein Database P02795). Four Emtin 
peptides have been synthesised (Schafer-N, Copenhagen, Denmark) to date: EmtinBn, 
based on the MT2 β-domain N-terminal sequence; EmtinB, based on the MT2 β-domain 
C-terminal sequence; EmtinAn, based on the MT2 α-domain N-terminal sequence; and 
EmtinAc, based on the MT2 α-domain C-terminal sequence (Table 5.1) (Ambjorn et al. 
2008; Asmussen et al. 2009a). Some of the cysteine residues in the parent MT2 protein 
sequence have been replaced with serine residues in the corresponding Emtin peptide, 
as indicated in Table 5.1, to prevent cysteine/disulphide-mediated crosslinking of Emtin 
peptides in solution (Asmussen et al. 2009a).  
 
Table 5.1 Amino acid sequences of human MT2A protein and Emtin peptides 
 Human MT2A sequence Monomeric Emtin sequence 
EmtinAc* 45-AQGCICKGASDKCS AQGSICKGASDKSS 
EmtinAn 30-KKSCCSCCPVGCAK KKSSCSCSPVGSAK 
EmtinB* 15-CAGSCKCKECKCTS SAGSCKCKESKSTS 
EmtinBn 1-MDPNCSCAAGDSCT MDPNCSCAAGDSST 
*EmtinAc and EmtinB were tested in the present study. The portion of human MT2A isoform protein 
sequence (Swiss Protein Database P02795) on which each Emtin peptide sequence was based is provided 
for comparison; replacement of cysteine residues in the MT2A sequence with serine residues in the Emtin 
sequence is denoted by bold, underlined text.  
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Emtin peptides can be synthesised either as monomers, dimers (two identical monomers 
coupled to a lysine residue) or tetramers (four identical monomers coupled to a lysine 
backbone) (Figure 5.1). The probable structure of Emtin tetramers, as predicted by 
PROFASI protein folding simulation, appeared to be unstructured (Ambjorn et al. 
2008). The currently-published literature relates solely to tetrameric Emtin peptides; 
hereafter, the generic term ‘Emtin’ relates to tetrameric Emtin peptides unless otherwise 
specified.    
5.1.1.2  Properties of Emtin peptides 
Due to the replacement of cysteine residues with serine residues, the Emtin peptides 
may be less able to bind metals and sequester reactive oxygen species than the MT2 
protein from which their sequence is derived (Ambjorn et al. 2008). Despite these 
differences, the Emtins exhibit similar neuroprotective properties to the MT2 protein. 
All four Emtin peptides prevent cultured cerebellar granule neurons (CGNs) from 
undergoing apoptosis in response to potassium withdrawal from the medium (Ambjorn 
et al. 2008; Asmussen et al. 2009a). EmtinB also protected cultured hippocampal 
neurons from kainic acid excitotoxicity in vitro, and attenuated seizure severity and 
hippocampal neuron death induced by kainic acid treatment of mice (Sonn et al. 2010). 
In addition, EmtinAc, EmtinAn, and EmtinB were able to induce neurite outgrowth in 
cultured CGNs (Ambjorn et al. 2008; Asmussen et al. 2009a). These data show that 
Emtin peptides, like MT-1/2, can increase survival of neurons exposed to toxic insults 
and can also promote neurite outgrowth.  
Extracellular MT-1/2 exerts its growth-promoting and survival effects via the LRP 
proteins low-density lipoprotein receptor-related proteins (LRP1 and LRP2) (Fitzgerald 
et al. 2007; Chung et al. 2008b). The outgrowth and survival effects of EmtinAc, 
EmtinBn, and EmtinB, but not of EmtinAc, were blocked by receptor-associated protein 
(RAP), a chaperone and competitive inhibitor of LRPs, and EmtinB binding to both 
LRP1 and LRP2 has been demonstrated in vitro (Ambjorn et al. 2008; Asmussen et al. 
2009a). The binding of EmtinB, EmtinAc, and EmtinAn to LRPs induces the 
downstream activation of MAPK, Akt, and CREB (Ambjorn et al. 2008; Asmussen et 
al. 2009a); these are the same neuroprotective pathways activated by MT2-LRP 
interactions, indicating common neuroprotective mechanisms between MT2 and Emtins 
(Asmussen et al. 2009b).   
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Figure 5.1 Structure of monomeric, dimeric and tetrameric Emtin peptides 
A schematic diagram of the structure of monomeric, dimeric, and tetrameric emtin 
peptides is given. Monomeric Emtin peptides consist of a single peptide chain, here 
labelled ‘Emtin’, with the amino acid sequence of EmtinAc, EmtinAn, EmtinB, or 
EmtinBn as shown in Table 5.1. Dimeric Emtin peptides consist of two identical 
monomeric Emtin peptides joined to a single lysine. Tetrameric Emtin peptides consist 
of four identical monomeric Emtin peptides joined to a three-lysine backbone, or can be 
thought of as two dimeric Emtin peptides joined together via a third lysine. Tetrameric 
EmtinAc and tetrameric EmtinB were used in the current study. This diagram is based 
on the molecular structure of dendrimeric peptides reported by Pankratova and 
colleagues (Pankratova et al. 2010).  
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5.1.2 Aims and hypothesis 
The ability of EmtinB to penetrate the CNS after subcutaneous injection (Sonn et al. 
2010), makes Emtin peptides suitable as CNS-targeted therapeutic molecules. Given 
that the Emtin peptides display similar neuroprotective properties to MT2, and act 
through the same receptors, the Emtin peptides may also exert protective effects in a 
mouse model of ALS. The aim of this study was to examine survival in Emtin-treated 
and control SOD1 mice, to determine whether Emtin administration after disease onset 
could increase survival time in SOD1 mice.  
Hypothesis: Administration of EmtinAc or EmtinB from the age of symptom onset 
until disease endpoint will increase survival time in female SOD1 mice.  
In this pilot study, a small cohort of female SOD1 mice were divided into three 
treatment groups, receiving either EmtinAc, EmtinB, or vehicle control injections from 
95 days of age until disease endpoint. Survival time and functional outcomes were 
measured as the primary outcomes of this pilot study. Additionally, a preliminary screen 
of post-injection Emtin distribution was carried out. 
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5.2 Methods 
All procedures and protocols involving animals were approved by the University of 
Tasmania’s Animal Ethics Committee (ethics permit numbers A10995 and A11958). 
SOD1 mice were genotyped and maintained as described in Chapter 2.  
 
5.2.1 Pilot study for survival in the SOD1 mice with tetrameric Emtin 
5.2.1.1 Administration of emtins 
Tetrameric Emtin peptides (EmtinAc or EmtinB) were dissolved in filter-sterilised 
MilliQ water at 4mg/mL for injection. Eighteen female SOD1 mice were split into three 
treatment groups (n=6/group): one group received EmtinAc; one group received 
EmtinB; and one group received vehicle (MilliQ water) alone. Treatment with Emtin or 
vehicle commenced at approximately 95 days of age (Table 5.2), with treatment 
continuing until the mice reached disease endpoint. The dosage was 10µg Emtin per 
gram body weight three times weekly, giving a total dosage of 30mg/kg/week (approx. 
600µg/20g mouse/week); injections of 4mg/mL Emtin solution were given 
subcutaneously via insulin syringes with 31-gauge needles, with control mice receiving 
the equivalent volume of filter-sterilised MilliQ water. No differences in copy number 
(ΔCT), age at start of treatment, or starting body weight, were observed between 
treatment groups (Table 5.2). 
 
Table 5.2. Cohort characteristics at start of treatment 
Treatment n Copy number (ΔCT) Age (days) Starting Weight (g) 
Control 6 5.29 ± 0.11 94.8 ± 0.2 19.5 ± 0.3 
EmtinAc 6 5.29 ± 0.07 94.7 ± 0.7 19.3 ± 0.4 
EmtinB 6 5.27 ± 0.03 96.0 ± 0.7 19.5 ± 0.5 
No significant difference in cohort parameters at the start of treatment (copy number, age at start). 
 
5.2.1.2 Outcome measures and statistical analyses 
Body weight and neurological score were recorded at least twice weekly, and more 
frequently towards disease endpoint. Survival time was assessed as the loss of 20% 
from peak body weight, and was analysed using Kaplan-Meier survival curves and Cox 
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proportional hazards regression. Stride pattern (see Figure 2.11A-D) was recorded 
weekly until mice could no longer provide a measureable pattern. Body weight and 
stride pattern were also examined in age-matched non-transgenic (WT) littermates 
receiving subcutaneous injections of vehicle only (n=6).  
Body weight and stride pattern were averaged per week per animal and analysed by 
ANOVA and Tukey’s post-hoc test with adjustments for inequality of variance (Welch 
ANOVA omnibus test with Tamhane’s post-hoc test) or non-normality (Kruskal Wallis 
non-parametric test with Bonferroni-corrected Mann Whitney U as a post-hoc test) as 
appropriate. Additionally, body weight was analysed using the linear mixed modelling 
method outlined in Chapter 2.  
During the course of the experiment, three mice received one dosage of the incorrect 
drug (e.g. EmtinAc instead of EmtinB). Data for these three mice (two in the EmtinAc-
treatment group and one in the vehicle-treatment group) recorded after the age of 
incorrect treatment were not used for statistical analyses of stride length or body weight, 
and were censored for survival analysis.    
5.2.1.3 Nissl Stain for motor neuron number at endpoint: 
Upon reaching disease endpoint, mice were transcardially perfused with PBS and 4% 
PFA as described in Chapter 2 – briefly, the lumbar spinal cord (T12-L1 vertebrae) was 
removed, decalcified, embedded in paraffin and sectioned at 5µm. As some mice were 
censored prior to disease endpoint (see above), and some mice could not be perfused 
upon disease endpoint due to time constraints, spinal cords were collected from five 
vehicle-treated SOD1 mice, three EmtinAc-treated SOD1 mice, and five EmtinB-treated 
mice. 
Nissl staining was performed as per Chapter 4, with slight modifications – briefly, 
sections were immersed in Cresyl violet solution for 30 minutes, passed through 70%, 
95% and 100% ethanol, cleared in xylene and coverslipped with DPX mounting 
medium. Images were captured on a light microscope with attached camera (Leica). The 
number of α-motor neurons remaining in the lumbar spinal cord was counted in three 
5µm sections from the lumbar spinal cord of each animal; these were averaged to give 
one measurement per mouse to avoid pseudoreplication.  
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5.2.2 Distribution of injected biotinylated dimeric EmtinB 
To determine whether the Emtin peptides were acting upon the central nervous system, 
the presence or absence of dimeric EmtinB (d-EmtinB) in serum and cortical brain 
parenchyma was examined after subcutaneous injection.  
5.2.2.1 Preparation of biotinylated d-EmtinB 
d-EmtinB peptide was biotinylated using the ImmunoProbe biotinylation kit (Sigma-
Aldrich) as per the manufacturer’s instructions (performed by Ms Emma Eaton) and 
reconstituted at 2.5mg/mL in sterile PBS.  
5.2.2.2 d-EmtinB administration and sample collection 
 Biotinylated d-EmtinB was administered at 10mg/kg body weight to two SOD1 and 
two WT mice at 14 weeks of age; one SOD1 and two WT mice received an equivalent 
volume of vehicle alone. All subcutaneous injections were performed using an insulin 
syringe with 31-gauge needle, under light isoflurane anaesthesia.  
At 1 hour post-injection, a urine sample was able to be collected from 2 of 7 mice (two 
SOD1 mice: one d-EmtinB-injected, and one PBS-injected); all mice were then deeply 
anaesthetised with sodium pentobarbitone (100mg/kg, i.p.). When all reflexes were 
absent, the thoracic cavity was opened for transcardiac perfusion with PBS alone. Prior 
to insertion of the perfusion line, approximately 100uL whole blood was withdrawn 
from the left ventricle via an insulin syringe and 22-gauge needle under gentle pressure 
so as not to collapse the chamber walls; the collected blood was transferred to a 
microcentrifuge tube (Axygen Maxymum Recovery, Corning Life Science, MA, USA) 
and left to clot at room temperature. The mouse was then perfused with PBS until the 
liver paled and the foot-pads became white. The spinal cord and the cerebral cortices 
were dissected out and snap-frozen in liquid nitrogen, then stored at -80°C. The serum 
sample was prepared by removal of clotted proteins by centrifugation at 16060g for 10 
minutes at 4°C in a benchtop microcentrifuge (Heraeus Biofuge Pico), and the 
supernatant (serum) was stored at -20°C until analysis.  
5.2.2.3 Sample prepration and western blotting 
Tissue lysates were prepared by homogenisation using an Ultra-Turrax rotor-stator 
homogenisation device (IKA Werke GmbH & Co, BW, Germany). Cortex and spinal 
cord tissues were immersed in 1mL ice-cold tissue lysis buffer (50mM Tris-HCl, 
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150mM NaCl, 1% v/v Igepal CA630, 0.5% w/v sodium deoxycholate, 1mM EDTA, 
0.1% w/v sodium dodecyl sulphate [all Sigma-Aldrich], pH 7.4, with 1 protease 
inhibitor tablet added to each 10mL lysis buffer [cOmplete Mini, EDTA-free, Roche 
Applied Science, IN, USA]) and homogenised with 3 x 10 second pulses using the 
Ultra-Turrax at setting 4, each separated by 30-60 seconds on ice, then centrifuged at 
16060g for 10min in a benchtop microcentrifuge. The supernatant, containing cytosolic 
proteins, was retained for analysis and stored at -20°C.  
A BCA assay for total protein concentration (Pierce BCA Protein Assay Kit, Thermo 
Scientific, IL, USA) was performed according to the manufacturer’s instructions, to 
ensure equal amounts of total protein were loaded for each sample. Following the BCA 
assay, cortical tissue homogenate samples were made up to 21µL with MilliQ water and 
were combined with 9µL reducing sample buffer (0.45M Tris-HCl pH 6.8, 3.5% w/v 
SDS, 18% v/v glycerol, 0.02% w/v bromophenol blue, 18% v/v β-mercaptoethanol [all 
Sigma-Aldrich]). One microliter of each urine sample was added to 20µL MilliQ water 
and combined with 9µL reducing sample buffer. To avoid possible coagulation of high-
concentration serum proteins, serum samples were mixed 1:1 with reducing sample 
buffer; all samples were heated to 60°C for 5 minutes and then to 90°C for 5 minutes to 
solubilise proteins.  
Western blotting was performed using the NuPAGE X-Cell system (Life Technologies); 
the protein samples and 5µL SeeBlue Plus2 protein ladder (Life Technologies) were 
loaded onto pre-cast NuPAGE 10% bis-tris acrylamide gels, and subjected to gel 
electrophoresis at 150V for 45 minutes in 1X NuPAGE MES running buffer with 
500µL NuPAGE antioxidant added to the upper chamber. The proteins were then 
transferred to nitrocellulose membrane (Thermo Scientific) at 30V for 45 minutes in 
transfer buffer (25mM Trizma base [Sigma-Aldrich], 190mM glycine [Sigma-Aldrich], 
20% v/v methanol [Merck Millipore]). The membrane was blocked with 5% non-fat 
milk powder in PBS-T for 1 hour with shaking at room temperature, washed, and 
incubated with HRP-conjugated streptavidin (1:2000) for 1 hour. Biotinylated d-EmtinB 
was visualised with SuperSignal West Dura chemiluminescent substrate (Thermo 
Scientific) using a Chemi-Smart 5000 imaging system (Vilber Lourmat, IDF, France).        
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5.3 Results 
5.3.1 Treatment of SOD1 mice with Emtin 
5.3.1.1 Emtin treatment slightly delays disease endpoint 
All SOD1 mice reached endpoint between 152 and 177 days of age. Kaplan-Meier 
analysis revealed a slight right-shift in the survival curves of EmtinAc- and EmtinB-
treated mice, indicating delayed endpoint ages compared with vehicle-treated mice 
(Figure 5.2A), although these curves were not significantly different (p=0.105, Log 
Rank test in Kaplan-Meier analysis). On average, mice receiving either EmtinAc or 
EmtinB reached endpoint approximately 5% later than mice receiving vehicle alone 
(EmtinAc 170.5±2.8 days, EmtinB 169.3±2.7 days, control 161.2±2.9 days; Figure 
5.2B). Similarly, EmtinAc- and EmtinB-treated mice displayed a longer median 
survival time compared with vehicle-treated mice (EmtinAc 168.0±4.5 days, EmtinB 
169.0±3.7 days, control 162.0±8.0 days, data not shown). However, these differences in 
mean and median survival times were not significantly different between treatment 
groups.  
CPH regression revealed that the hazard ratio for reaching disease endpoint was reduced 
for mice receiving either EmtinAc treatment or EmtinB treatment compared with 
vehicle controls, indicating an increased survival time for Emtin-treated mice (Table 
5.3). These hazard ratios (HR) approached, but did not reach, statistical significance 
(HREmtinAc=0.226, 95% CI 0.044-1.155, p=0.074; HREmtinB=0.253, 95% CI 0.055-1.164, 
p=0.078).  
In order to examine whether any other factors were affecting survival in this cohort, the 
age at start of treatment, weight at start of treatment, and copy number were analysed 
with CPH analysis; none of these covariates had a significant effect on survival time 
(Table 5.3). Accordingly, the association of Emtin treatment with reduced odds ratio of 
reaching endpoint persisted when the model was adjusted for age at the start of 
treatment, weight at the start of treatment and copy number (Table 5.3).  
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Figure 5.2 Survival in Emtin-treated and control SOD1 mice 
Treatment with EmtinAc or EmtinB from symptom onset shifted Kaplan-Meier survival 
curves to the right (A). The average survival times for EmtinAc-treated or EmtinB-
treated mice were slightly longer than vehicle-treated control mice (B). Vertical dashes 
represent censored data. Error bars represent standard error of the mean. 
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Table 5.3 Cox proportional hazards regression for reaching disease endpoint 
Factor HR (95% CI) p-value 
Univariable analysis   
         Emtin treatment
1
  0.152 
                      EmtinAc
2
 0.226 (0.044-1.155) 0.074 
                      EmtinB
2
 0.253 (0.055-1.164) 0.078 
         Age at start 0.951 (0.617-1.464) 0.818 
         Copy number 0.352 (0.005-27.118) 0.637 
         Weight at start 1.442 (0.776-2.681) 0.247 
   
Multivariable analysis
3
   
         Emtin treatment
1
  0.126 
                      EmtinAc
2
 0.193 (0.035-1.059) 0.058 
                      EmtinB
2
 0.237 (0.048-1.165) 0.076 
1
Multi-level categorical variable, overall p-value given; 
2Subgroups of categorical variable ‘Emtin’. 
3
Adjusted for age at start of treatment, weight at start of treatment, and copy number. 
 
5.3.1.2 Body weight 
Body weight was measured at least twice per week throughout the experiment. As 
previously mentioned, starting body weight did not differ between Emtin-treated and 
vehicle-treated mice (Table 5.2). Maximum body weight, weekly averages, and body 
weight trajectory over time are discussed below. 
5.3.1.2.1 Maximum body weight 
The average maximum body weight attained by these mice was not different between 
treatment groups, although vehicle-treated mice showed a slightly higher maximum 
body weight compared with Emtin-treated mice (EmtinAc 20.0±0.3g, EmtinB 20.6±0.7, 
vehicle 21.0±0.4g, ANOVA omnibus p=0.37). The age at which maximum body weight 
was reached was not different between treatment groups (EmtinAc 116.2±6.3 days, 
EmtinB 122.5±6.8 days, vehicle 124.7±5.4 days, ANOVA omnibus p=0.61). As 
treatment was only started at 95 days of age (approximately 14 weeks of age), large 
changes in disease onset as measured by the age of maximum body weight were not 
expected between treatment groups.  
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Figure 5.3 Body weight averages and body weight mixed model trajectories in 
Emtin-treated and control SOD1 mice  
Weekly body weight averages (A) were not significantly different between Emtin-
treated and control SOD1 mice. EmtinB and control SOD1 mice showed lower body 
weights than WT mice from 19 weeks of age, whereas all SOD1 mice showed lower 
body weights than WT mice from 20 weeks of age onwards (A). Body weight 
trajectories (B) for each treatment group of SOD1 mice were plotted from linear mixed 
modelling parameters (Table 5.4), showing a wider, flatter trajectory curve for Emtin-
treated SOD1 mice compared to control SOD1 mice. *p<0.05 EmtinAc vs WT, #p<0.05 
EmtinB vs. WT, †p<0.05 vehicle vs. WT. Error bars represent standard error of the 
mean. 
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5.3.1.2.2 Average body weight per week 
Average body weight increased over time in WT mice, while the body weight of SOD1 
mice peaked at approximately 17 weeks of age regardless of treatment, and declined 
thereafter (Figure 5.3). Average body weight was not different between SOD1 treatment 
groups at any of the time points measured (p>0.05) (Figure 5.3). However, EmtinAc-
treated mice appeared to have the lowest body weights of any group from 14-17 weeks 
of age (14wks: EmtinAc 19.0±0.3g vs. WT 20.3±0.3g, Tamhane p=0.032; 15wks: 
EmtinAc 19.1±0.3g vs. WT 20.4±0.3g, Tamhane p=0.047) (Figure 5.3A). At 19 weeks 
of age, EmtinAc-treated and EmtinB-treated SOD1 mice showed lower body weights 
than WT mice (WT 21.2±0.3g; WT vs. EmtinAc 19.0±0.4g, Tukey p=0.003; WT vs. 
EmtinB 19.6±0.5g, Tukey p=0.034); while from 20 weeks onwards, all groups of SOD1 
mice showed lower body weights than WT mice (Figure 5.3A).  
5.3.1.2.3 Linear mixed modelling of body weight 
Body weight trajectories of Emtin-treated and control SOD1 mice were examined by 
linear mixed modelling. In the absence of pre-symptomatic body weight measures, a 
quadratic curve was fitted, as a cubic curve could not be reliably modelled. The model 
included the intercept, Age and Age
2
 as fixed factors, and a random intercept and slope 
as random factors (for full model specification, see Supplementary Data 4). The linear 
mixed model gives a set of parameters for the equation Body weight = β0 + β1*Age + 
β2*Age
2
, where each β coefficient has a unique value for the control, EmtinAc-treated, 
and EmtinB-treated groups (listed in Table 5.4). The body weight trajectory parameters 
differed significantly between Emtin-treated mice and control mice (Supplementary 
Data 4). When graphed, the body weight curves showed a wider, flatter body weight 
trajectory for Emtin-treated mice than control mice (Figure 5.3), possibly indicating that 
Emtin-treated mice lose body weight at a slower rate than control mice. 
 
 Table 5.4 Parameter estimates from linear mixed model of body weight trajectory 
Fixed effects 
parameter
1
 
Vehicle EmtinAc EmtinB 
Intercept (β0) -4.449 3.095 3.585 
Age (β1) 4.20 x 10
-1
 2.77 x 10
-1
 2.80 x 10
-1
 
Age
2
 (β2) -1.80 x 10
-3
 -1.20 x 10
-3
 -1.22 x 10
-3
 
1
Parameter estimates for the equation Body weight = β0 + β1*Age + β2*Age
2
, where Age = age in days 
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5.3.1.2.4 Percentage body weights 
As the three treatment groups of SOD1 mice showed no significant differences in 
average weekly body weights (Figure 5.3A), the percentage body weights were 
examined. Percentage body weights were not significantly different between Emtin-
treated and vehicle-treated SOD1 mice, although vehicle-treated mice showed the 
lowest percentage body weight at 21 weeks of age of any group (Figure 5.4A).  
As the disease endpoint, measured as reaching 80% of peak body weight, was slightly 
delayed in Emtin-treated SOD1 mice (Figure 5.2), the age at which SOD1 mice reached 
95%, 90%, and 85% of their maximum body weight was also examined (Figure 5.4B). 
Although Kaplan-Meier analysis revealed no significant differences between treatment 
groups, survival curves showed that vehicle-treated mice reached 85% of their 
maximum body weight slightly earlier than Emtin-treated mice (Figure 5.4B). The mean 
age at which Emtin-treated mice reached 90% and 85% of maximum body weight was 
slightly later than those of vehicle-treated mice; the same was true for the median age of 
reaching 95%, 90%, and 85% of maximum body weight (Table 5.5), however these 
changes were not statistically significant. 
 
Table 5.5 Average and median ages at which 95, 90, and 85% of maximum body 
weight were reached  
 Treatment 95% BW 90% BW 85% BW 
 Vehicle 140.8 ± 2.7 151.3 ± 2.0 158.2 ± 2.6 
Mean age 
(days) 
EmtinAc 140.8 ± 1.2 156.5 ± 1.6 164.3 ± 0.9 
 EmtinB 142.2 ± 3.7 156.0 ± 2.6 165.2 ± 3.2 
     
 Vehicle 136.0 ± 2.0 149.0 ± 2.0 156.0 ± 5.5 
Median age 
(days) 
EmtinAc 140.0 ± 1.8 155.0 ± 2.5 164.0 ± 1.5 
 EmtinB 140.0 ± 6.7 153.0 ± 3.1 164.0 ± 1.2 
 
Thus, both linear mixed modelling of Emtin-treated and control SOD1 mouse body 
weight trajectories, and analysis of the age at which 95%, 90%, and 85% of maximum 
body weight were reached, suggested that Emtin-treated mice may retain body weight 
slightly longer than control mice. These differences did not reach statistical 
significance, which may be due to the small cohort size used in this study.  
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Figure 5.4 Percentage body weights in Emtin-treated and control SOD1 mice 
Vehicle-treated (control) SOD1 mice showed the lowest percentage body weight at 21 
weeks of age, although there were no significant differences in percentage body weight 
weekly averages (A). Kaplan-Meier analysis was carried out on the age at which mice 
reached  95% (B, left-hand panel), 90% (B, middle panel), and 85% (B, right-hand 
panel) of their maximum body weight. There appeared to be a slight tendency for 
vehicle-treated mice to reach 90% and 85% of their maximum body weight slightly 
earlier than EmtinAc-treated or EmtinB-treated mice (B). maxBW, maximum body 
weight; LR, Log-Rank test in Kaplan-Meier analysis. Error bars represent standard error 
of the mean. 
60
95
E
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5.3.1.3 Stride Test 
Stride length and uniformity were measured weekly. As expected, the stride length and 
uniformity of WT mice did not change substantially over time, whereas SOD1 mice 
showed decreasing stride length and increasing uniformity with age (Figure 5.5). The 
stride length and uniformity of SOD1 mice did not differ by treatment group at the start 
of treatment (Table 5.6). 
5.3.1.3.1 Stride length 
Average stride length did not differ between Emtin-treated and control SOD1 mice 
throughout the experiment (Figure 5.5A). Compared to WT mice, control SOD1 mice 
were the first to show a significantly lower stride length, at 17 weeks of age (control 
6.0±0.1cm vs. WT 7.0±0.4cm, Tukey p=0.023). Control and EmtinB-treated SOD1 
mice had shorter stride lengths than WT mice at 18 weeks of age (WT 6.8±0.2cm: vs. 
control 5.5±0.3cm, Tukey p=0.002; vs. EmtinB 5.8±0.2cm, Tukey p=0.017), and all 
SOD1 mice showed a shorter stride length than WT mice thereafter (Figure 5.5A), 
although this was not significant for any group at 19 weeks of age due to larger 
variances at this time point (ANOVA omnibus p=0.103). The maximum stride length 
attained by SOD1 mice was not different between treatment groups, although EmtinAc-
treated mice attained their maximum stride length later than control mice (Tukey 
p=0.043, Table 5.6); these results suggest that EmtinAc, but not EmtinB, was able to 
delay the onset of functional deficits as measured by maintenance of stride length to a 
greater age than control SOD1 mice.  
 
Table 5.6 Starting and maximal stride pattern measurements 
 
Treatment 
 
n 
Starting 
stride length 
(cm) 
Maximum 
stride length 
(cm) 
Age at maximum 
stride length 
(days) 
Starting 
uniformity 
(cm) 
Vehicle 6 6.0 ± 0.2 6.8 ± 0.2 114.7 ± 2.4 0.2 ± 0.1 
EmtinAc 6 6.1 ± 0.2 6.6 ± 0.2   126.2 ± 3.9* 0.3 ± 0.1 
EmtinB 6 6.0 ± 0.3 6.7 ± 0.2 116.7 ± 2.6 0.3 ± 0.1 
*Significantly different from vehicle, Tukey p=0.043. 
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To examine the loss of stride length from the recorded maximum, the percentage of 
maximum stride length attained over time was calculated. WT mice show a slight 
decrease in percentage stride length over time, from an average of 93±3% of maximum 
at 15 weeks of age to 77±4% of maximum at 24 weeks of age (Figure 5.5B). SOD1 
mice showed a far more substantial decrease in percentage stride length, from 
approximately 95% of maximum at 15 weeks of age down to just above 30% of 
maximum at 24 weeks of age (Figure 5.5B).  
There were no significant differences between SOD1 treatment groups throughout the 
time course; however, at 20 weeks of age, only control SOD1 mice showed a 
significantly lower percentage stride length than WT mice (WT 88±3% vs. control 
67±6%, Tukey p=0.044) (Figure 5.5B). At 21 weeks of age, both control mice and 
EmtinB-treated mice displayed a lower percentage stride length than WT mice (WT 
86±5%; vs. control 51±5%, Tukey p=0.002; vs. EmtinB 53±7%, Tukey p=0.003) 
(Figure 5.5B). By 22 weeks of age, the percentage of maximum stride length was lower 
than WT for all SOD1 treatment groups (WT 82±5%; vs. control 47±5%, Tukey 
p<0.001; vs. EmtinA 50±5%, Tukey p=0.002; vs. EmtinB 43±5%, Tukey p<0.001) 
(Figure 5.5B). Treatment with EmtinAc, but not EmtinB, appeared to slightly delay the 
loss of stride length as a percentage of maximum.   
5.3.1.3.2 Uniformity 
Uniformity measurements at the start of treatment did not differ between SOD1 
treatment groups (Table 5.6). Average uniformity measurement was not significantly 
different between SOD1 treatment groups over time (Figure 5.5C). At 18 weeks of age, 
only vehicle-treated SOD1 mice showed a larger uniformity measurement than WT 
mice (WT 0.3±0.1cm vs. vehicle 0.7±0.1cm, Tukey p=0.017). At all successive time 
points, all SOD1 mice showed a larger uniformity measurement than WT mice (Figure 
5.5C). As a larger uniformity measurement indicates increasing dysfunction and 
inability to move the hind limbs in a forward motion, the slightly earlier increase in the 
control mice may indicate that treatment with EmtinAc or EmtinB resulted in initially 
slightly better maintenance of hindlimb function than control SOD1 mice. However, as 
disease progressed, neither EmtinAc nor EmtinB treatment was able to significantly 
delay the increase in uniformity measure.    
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Figure 5.5 Stride pattern measurements in Emtin-treated and control SOD1 mice  
Stride length (A), percentage of maximum stride length (B), and uniformity (C) were 
not significantly different between EmtinAc-treated, EmtinB-treated, and control SOD1 
mice over time. SOD1 treatment groups varied at the age which they diverged from WT 
mice in stride length (A; control at 17 weeks of age, EmtinB at 18 weeks of age, 
EmtinAc at 20 weeks of age), percentage stride length (B; control at 20 weeks of age, 
EmtinB at 21 weeks of age, EmtinAc at 22 weeks of age), and uniformity measure (C; 
control at 18 weeks of age, EmtinAc and EmtinB at 19 weeks of age). *p<0.05 EmtinAc 
vs WT, #p<0.05 EmtinB vs WT, †p<0.05 vehicle vs WT mice. Error bars represent 
standard error of the mean. 
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5.3.1.4 Neurological Score 
Neurological scoring (NS) was conducted according to the guidelines laid out in 
Chapter 2 (Table 2.3). As SOD1 mice were already displaying early disease symptoms 
upon arrival at the facility, the age of onset (NS=1) could not be determined. 
Additionally, most SOD1 mice reached disease endpoint (80% of maximum body 
weight) before reaching hindlimb paralysis (NS=3), so the age at paralysis could not be 
determined.  
To examine disease progression in Emtin-treated and vehicle-treated SOD1 mice, the 
age at which SOD1 mice reached NS=2 (foot-dragging, Table 2.3) was analysed using 
Kaplan-Meier analysis. Survival curves for NS=2 showed a slight right-shift for 
EmtinB-treated mice compared to vehicle-treated mice (Figure 5.6A), indicating that 
EmtinB-treated mice show profound gait abnormalities at a slightly later age than 
vehicle-treated mice.  
Accordingly, the average age at reaching NS=2 was slightly higher for EmtinAc-treated 
mice (164.7±3.7 days) and EmtinB-treated mice (168.0±5.9 days) than for vehicle-
treated mice (158.0±5.3 days), although these differences were statistically significant 
(ANOVA omnibus p=0.407).   
 
5.3.2 Endpoint Motor Neuron Numbers 
At endpoint (20% loss from peak body weight), spinal cord samples were taken from 
SOD1 mice to count the number of motor neurons remaining in the ventral horn. There 
were no significant differences between treatment groups, although EmtinAc-treated 
mice showed the lowest number of motor neurons remaining (Figure 5.7).  
To account for any variation in size of the ventral horn between sections, the number of 
motor neurons within a single field of view within the ventral horn was also counted, 
and showed the same pattern as shown in Figure 5.7 (data not shown).  
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Figure 5.6 Age at which Emtin-treated and control SOD1 mice reach neurological 
score NS=2  
Figure 5.6 Age at which Emtin-treated and control SOD1 mice reach neurological score 
NS=2. Using Kaplan-Meier survival curves to measure time-to-event data for SOD1 
mice reaching NS=2 (Toes curl under at least twice during walking of 12 inches, or any 
part of foot is dragging along cage bottom/table, Table 2.3), the survival curve for 
EmtinB-treated mice is lightly right-shifted compared to the survival curve for vehicle-
treated mice (A). EmtinAc-treated and EmtinB-treated mice reached NS=2 at a slightly 
higher average age than vehicle-treated mice (B). Vertical dashes represent censored 
data. Error bars represent standard error of the mean. 
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Figure 5.7 Motor neurons in the ventral horn at endpoint  
The number of motor neurons remaining in the ventral horn of Emtin-treated and 
vehicle-treated mice was examined. Panels A-C show Nissl-stained motor neurons 
remaining in the ventral horn at disease endpoint in vehicle-treated (A), EmtinAc-
treated (B) and EmtinB-treated (C) SOD1 mice. Quantitation of remaining motor 
neurons (D) showed that EmtinAc-treated mice had fewer motor neurons remaining 
than vehicle-treated and EmtinB-treated SOD1 mice at endpoint, however this was not 
significantly different between groups. Error bars represent standard error of the mean. 
Scale bar 40µm for A-C. 
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5.3.3 Distribution of biotinylated d-EmtinB 
Biotinylated dimeric EmtinB (d-EmtinB) was injected subcutaneously into SOD1 and 
WT mice to examine its distribution in the serum and in the brain. Western blotting to 
detect biotinylated d-EmtinB, using HRP-conjugated streptavidin, showed the presence 
of d-EmtinB in the serum of both WT and SOD1 mice within an hour of injection 
(Figure 5.8A). Mice injected with a vehicle control (PBS) showed no such bands 
(Figure 5.8A). In the brain, no clear d-EmtinB signal could be seen at 1 hour after 
injection (Figure 5.8B), although the multiple non-specific bands observed in the brain 
homogenates may prevent detection of d-EmtinB. Only two urine samples were able to 
be collected; both were from SOD1 mice, one injected with biotinylated d-EmtinB and 
one injected with vehicle alone. A strong signal was observed in the urine of the d-
EmtinB-injected SOD1 mouse (Figure 5.8B), and was absent from the vehicle-injected 
mouse (Figure 5.8A), indicating that at least some of the injected d-EmtinB may be 
cleared through the kidneys within one hour of subcutaneous injection. 
Biotinylated d-EmtinB, with an apparent molecular weight of approximately 4kDa 
(Figure 5.8A, B, arrow) also appears at approximately 6-8kDa (Figure 5.8A, B, 
arrowhead) and in serum samples, at approximately 20kDa (Figure 5.8A, asterisk). 
These higher molecular weight bands suggest that biotinylated d-EmtinB could form 
oligomeric species in solution or in vivo, or may form a complex with other proteins.  
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Figure 5.8 Distribution of biotinylated d-EmtinB in serum and brain samples 
Western blot assayed the presence of biotinylated EmtinB dimer (d-EmtinB) in serum 
(A) and brain homogenate (B) of wild type or SOD1 mice at one hour after 
subcutaneous injection of d-EmtinB injection (EB) or vehicle (-). A positive control 
(5ng biotinylated d-EmtinB, 5ng EB) was run on each gel (A,B), and resolved at an 
apparent molecular weight of approximately 4kDa (arrow, A, B), also showing a band 
around 6-8kDa (arrowhead, A, B). d-EmtinB was present in serum at one hour after 
injection in either WT or SOD1 mice (4kDa, arrow; 6-8kDa, arrowhead; ~20kDa, 
asterisk; A). d-EmtinB was not detected in the brain at one hour after injection in WT or 
SOD1 mice (B); however, multiple non-specific signals seen in all brain samples (B) 
may reduce the chance of identifying changes between d-EmtinB-injected and vehicle-
injected mice. One SOD1 mouse injected with d-EmtinB showed a strong positive 
signal in the urine at 1 hour after injection (SOD1 urine, B), compared to no signal in 
urine from a vehicle-injected SOD1 mouse (SOD1 urine, A). 
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5.4 Discussion 
5.4.1 Summary of effects of Emtin peptides 
Emtin peptides are tetrameric peptides based on the sequence of human metallothionein 
protein (Figure 5.1). In this study, EmtinAc or EmtinB peptides were administered to a 
small pilot cohort of female SOD1 mice, from 95 days of age until disease endpoint. 
Emtin treatment may delay the loss of body weight in SOD1 mice, as measured by 
survival time, body weight mixed modelling, and analysis of percentage body weights 
(Figure 5.2, Figure 5.3, Figure 5.4). EmtinAc treatment may delay the loss of stride 
length (Figure 5.5), while EmtinB appears to delay the onset of more severe 
neurological score rating (Figure 5.6). These effects indicate that administration of 
Emtin peptides may be able to increase survival time and maintain hindlimb function in 
a small cohort of SOD1 mice, despite treatment only starting around disease onset.  
 
5.4.2 Mechanism of action of Emtin peptides 
The delayed loss of body weight and maintenance of hindlimb function in Emtin-treated 
SOD1 mice may indicate that Emtin peptides play a role in maintaining neuromuscular 
connections and preventing muscular atrophy. Previous studies on the actions of Emtin 
peptides in cell culture may provide some insight into possible mechanisms for 
neuroprotection in the current study. In cerebellar granule neuron cultures, both 
EmtinAc and EmtinB are able to promote neurite outgrowth and prevent apoptosis in 
response to potassium withdrawal stress, via interaction with LRPs and activation of the 
MAPK and PI3K/Akt intracellular signalling pathways (Dudek et al. 1997; Chang & 
Karin 2001; Ambjorn et al. 2008; Asmussen et al. 2009a). In the current study, Emtin 
peptides may activate these same pathways in motor neurons in order to elicit motor 
neuron protection against cell death processes, or promote regenerative sprouting at the 
muscle. The number of motor neurons remaining at disease endpoint was not different 
between Emtin-treated and vehicle-treated mice (Figure 5.7); however, it is difficult to 
directly compare the number of motor neurons due to the different ages (endpoints) at 
which the spinal cord samples were obtained. Future examination of the neuromuscular 
junction architecture may determine whether increased sprouting or innervation at the 
muscle is responsible for the slight Emtin-mediated delay in disease endpoint (Figure 
5.2) and maintenance of muscle function (Figure 5.5).     
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5.4.3 Comparison of mechanism of action of Emtin and MT2 
In Chapter 4, pre-symptomatic treatment with MT2 was able to significantly delay 
disease onset and slightly delay disease endpoint, while in this chapter, treatment with 
Emtin from symptom onset onwards showed a trend for increasing survival time. The 
Emtin peptides are MT2 derivatives, and neuroprotective mechanisms of action utilising 
LRP receptors are shared between both MT-1/2 protein and Emtin peptides in cell 
culture (Ambjorn et al. 2008; Asmussen et al. 2009a). However, the replacement of 
cysteine residues in MT2 for serine residues in Emtin peptides (Table 5.1), performed to 
prevent intra- and inter-peptide cysteine linkages forming, may limit the metal-binding 
and antioxidant ability of Emtin peptides (Asmussen et al. 2009a). The MT-1/2 protein 
binds metal ions via its cysteine residues (Ruttkay-Nedecky et al. 2013), so although 
there is no published literature on the metal-binding capacity of Emtin peptides, it is 
likely that Emtins peptides will show reduced metal-binding ability due to the 
replacement of cysteine residues with serine residues. MT-1/2 also uses its cysteine 
residues for its antioxidant capacity (Ruttkay-Nedecky et al. 2013), so it is likely that 
Emtin peptides will display little ability to sequester reactive oxygen species. It is 
therefore likely that the protective effects of Emtin peptides seen in the current study are 
due to the interaction between Emtin peptides and their LRP receptors (Asmussen et al. 
2009a), whereas the protective effects of MT2 administration seen in Chapter 4 may be 
either due to interaction between MT2 and LRP receptors, or due to the metal-binding 
and antioxidant capacities of the MT2 protein.   
 
5.4.4 Delivery of EmtinB to the central nervous system 
After a single subcutaneous injection of biotinylated d-EmtinB, d-EmtinB was observed 
in the serum and urine but was not found in brain homogenate (Figure 5.8). These data 
may indicate that biotinylated d-EmtinB peptides do not enter the brain tissue of the 
central nervous system at one hour post-injection. A previous study showed the 
presence of biotinylated EmtinB in the cerebrospinal fluid at one hour after injection 
(Sonn et al. 2010). The differing results between the current study and that of Sonn and 
colleagues (2010) may be due to the peptide administered, the dosage, and differences 
in sampling the central nervous system, as discussed below.  
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Instead of administering EmtinB tetramer peptide at 20mg/kg (Sonn et al. 2010), 
dimeric EmtinB peptide at 10mg/kg was administered in the current study. It is possible 
that the dose of 10mg/kg is too low to be detectable in brain homogenate at one hour 
after injection, or that the kinetics of dimeric and tetrameric EmtinB delivery to the 
CNS are slightly different and thus entry to the CNS was not seen at the one hour 
timepoint in the current study.  
It is also possible that biotinylated d-EmtinB, with 2-3 molecules of biotin attached on 
spacer arms away from the peptide, may show altered steric interactions with 
mechanisms which may normally mediate the delivery of EmtinB across the blood-
brain barrier. Sonn (2010) used EmtinB containing a single biotinylated site, causing 
minimal alterations from the kinetics of non-biotinylated EmtinB. It is likely that LRPs 
at the choroid plexus (Carro et al. 2005) allow transport of EmtinB from the blood into 
the CSF (Sonn et al. 2010). Another option for differing results between the current 
study and the Sonn (2010) study is that dimeric EmtinB peptides may show a weaker 
interaction with LRPs than tetrameric EmtinB peptides, and therefore may not be 
transported as efficiently into the CNS.  
Additionally, Sonn and colleagues (2010) studied the presence of EmtinB in CSF, 
whereas the current study examined whole brain homogenates for the presence of 
EmtinB. As the contribution of CSF to protein levels in whole brain homogenate may 
be minimal, due to loss of CSF during perfusion and dissection, the absence of 
detectable levels of biotinylated d-EmtinB in brain homogenates do not directly rule out 
its presence in the CSF in the present study. As the neuroprotective actions of EmtinB 
can be triggered by extracellular interactions between EmtinB and its LRP receptors 
(Ambjorn et al. 2008), extracellular or CSF EmtinB may still elicit protective effects 
despite not being internalised into neurons.   
The presence of EmtinB in the urine at one hour after injection indicates that dimeric 
EmtinB is readily cleared from the circulation through the kidneys in the present study. 
The presence of EmtinB in the urine matches that of MT2, which is also present in the 
kidney and urine after i.p. injection (Lewis et al. 2012b). Future studies examining 
administration of either EmtinB or MT2 must determine how much of the active 
molecule is lost through the kidneys in order to determine strategies for successful CNS 
penetration.  
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Multiple d-EmtinB bands, possibly representing oligomeric or aggregated forms of the 
injected peptide, were observed in the serum at one hour after injection. Care must be 
taken in future studies to avoid the formation of high molecular weight aggregates of 
Emtin peptides in solution, for two reasons: first, these aggregates may not properly 
interact with LRP receptors and may not activate the correct intracellular pathways; 
second, delivery of aggregated peptides to the CNS may place undue stress on motor 
neurons in SOD1 mice which are already under stress due to aggregated proteins 
(Watanabe et al. 2001).   
 
5.4.5 Summary and conclusions 
In summary, Emtin peptides administered from symptom onset onwards appear to show 
increased survival times, and slight retention of hindlimb function, in a small cohort of 
female SOD1 mice. The effects of Emtin peptides approach statistical significance, 
despite the small numbers (n=6 for each group) involved in this pilot study, and despite 
the treatment only being started around the point of disease onset. Emtin peptides 
appear to be a promising candidate for further development as a therapeutic for human 
ALS. Future work should involve a larger cohort of SOD1 mice in accordance with 
consensus guidelines for pre-clinical SOD1 trials, and should also involve analysis of 
motor neuron protection and neuromuscular junction innervation in a subset of SOD1 
mice, to determine the mechanism of action of Emtin peptides.  
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6.1 The need for novel ALS therapeutics 
Amyotrophic lateral sclerosis is a neurodegenerative disease of the motor system, with a 
complex aetiology potentially involving many cellular pathways, with oxidative stress, 
neuroinflammation, RNA metabolism, and protein degradation dysfunction featuring 
most prominently amongst possible aetiologies. The search for an effective  therapeutic 
molecule for preventing motor neuron degeneration has so far not been successful, with 
the only approved drug treatment for ALS, Riluzole, only extending lifespan by a matter 
of months (Bensimon et al. 1994).   
The work contained within this thesis uses a mouse model of ALS to explore a link 
between microglial activation and oxidative stress via nitric oxide metabolism, and to 
trial the ability of three therapeutic compounds to extend lifespan in the mouse model. 
Here, the results of each chapter will be reviewed in the context of attempting to 
understand the disease mechanisms contributing to disease in the mouse model of ALS.  
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6.2 Microglial activation in ALS 
Microglial activation has been implicated in the progression of ALS, with SOD1 mice 
showing pre-symptomatic and post-symptom-onset microglial activation, and ALS 
patients showing microglial activation in post-mortem spinal cord (Hall et al. 1998b; 
Alexianu et al. 2001; Henkel et al. 2004). In Chapter 2, the temporal relationships 
between microglial activation, development of neuronal pathology, and functional 
decline in SOD1 mice were examined. Consistent with previous studies, it was shown 
that microglial activation coincided with disease onset, but preceded the development of 
overt functional deficits, indicating that microglial activation may accelerate disease 
progression.  
While previous studies have indicated a swing towards M1 neurotoxic microglia as 
disease progresses(Liao et al. 2012), examination of arginine-metabolising enzymes and 
putative M1/M2 markers in the current study, Arg1 and iNOS, indicated that both pro-
inflammatory and anti-inflammatory phenotypes of microglia are present in the lumbar 
spinal cord of symptomatic SOD1 mice. These data may represent ongoing conflict 
between neuroinflammatory states – M2 neuroprotective microglia may attempt to 
dampen inflammation to prevent further neuronal damage, while M1 neurotoxic 
microglia may induce motor neuron damage, in part through increased expression of 
iNOS and increased NO synthesis (Zhao et al. 2004). Slight changes in the 
inflammatory environment of the lumbar and cervical spinal cords, characterised by a 
slightly more M2-like environment in the cervical region, may account for the relative 
sparing of the cervical region compared to the lumbar region (Beers et al. 2011b).  
Therapeutics aimed at inhibiting neuroinflammation have been trialled with positive 
results in SOD1 mice, yet showed no effect, or had detrimental effects, when translated 
into human ALS clinical trials (Bowerman et al. 2013). The data from clinical trials 
reinforce the dual role of microglia in neurodegenerative disease, with ongoing 
neuroprotective functions in addition to neurotoxic functions; inhibiting microglial 
activation may deplete any neuroprotection provided to motor neurons by microglia 
with an M2-like phenotype. The ongoing expression of Arg1, as described in SOD1 
microglia in Chapter 2 of this thesis, correlates with ongoing neuroprotective functions 
of activated microglia in ALS. Additionally, the importance of microglial activation in 
ALS is underlined by a recent study implicating a mutation in the triggering receptor 
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expressed by myeloid cells 2 (TREM2) protein, involved in microglial phagocytosis of 
cellular debris, as a risk factor for sporadic ALS (Neumann & Takahashi 2007; Cady et 
al. 2014). It is therefore critical that more research into microglial activation in 
neuroinflammation is carried out, in order to determine how best to eliminate neurotoxic 
microglial function while retaining neuroprotective function. Future work should aim to 
identify mediators of the molecular switch between neuroprotective and neurotoxic 
microglial phenotypes, and examine the bidirectional signalling between activated 
microglia and motor neurons. Further elucidation of microglial-mediated disease 
mechanisms in ALS may identify novel targets for therapeutic intervention.  
 
_______________________________Chapter 6 – Concluding remarks and future work 
______________________________________________________________________ 
______________________________________________________________________ 
 
199 
 
6.3 Antioxidant treatments for ALS 
Oxidative stress is intricately linked to ALS, either as a potential primary cause of 
disease or as an effector of other upstream pathogenic mechanisms (see convergent 
pathology, section 1.3.9). 
Two of the potential ALS therapeutics used in this thesis, Gemals and MT2, are thought 
to act at least in part via antioxidant mechanisms. In Chapter 4, pre-symptomatic 
treatment with MT2 protein resulted in a slight delay in disease onset as measured by 
peak body weight, and tended to increase survival time. In Chapter 3, treatment with 
Gemals from after symptom onset until disease endpoint did not show a significant 
effect on survival time in a large cohort of SOD1 mice. However, it must be noted that 
several confounding factors in the Gemals trial, such as the development and treatment 
of irritation and skin lesions, may have prevented a protective effect of the Gemals 
compound from being detected.  
Setting aside confounding factors in the Gemals trial, the results from the Gemals trial 
and the MT2 trial suggest that oxidative stress-directed treatments may only be effective 
at slowing disease processes during the pre-symptomatic stage of disease. Indeed, the 
only other study examining the effect of Gemals in ALS rodent models showed an 
increase in survival time when Gemals was administered during the pre-symptomatic 
stage of disease (Nicaise et al. 2008).  
If treating oxidative stress in the pre-symptomatic stage is able to delay disease, but 
treatment of oxidative stress after symptom onset has little effect, it is possible that 
oxidative stress is a key mechanistic event in ALS pathogenesis, but may cause a 
cascade of downstream pathological mechanisms, such as mitochondrial dysfunction or 
protein aggregation, which cannot be reversed by removing the initial oxidative insult. 
To effectively treat such a situation, antioxidant compounds which slow the 
development of pathology would need to be used in conjunction with drugs which may 
provide neuronal protection or promote the degradation of damaged mitochondria and 
aggregated proteins, preventing the formation of downstream products and facilitating 
the removal of altered cellular components.   
In SOD1 mice, drugs with an antioxidant mechanism of action show the most promising 
effects for treatment after disease onset (Benatar 2007). However, a Cochrane review of 
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antioxidant therapies in ALS patients showed that antioxidants have little beneficial 
effect on survival (Orrell et al. 2007). More recently, an open trial of Gemals in a small 
group of ALS patients did indicate positive preliminary results of this compound in 
patients (Geffard et al. 2010). The Geffard (2010) study could indicate that Gemals 
exerts a protective effect due to its multiple putative mechanisms of action, rather than 
purely due to its antioxidant function (Geffard et al. 2010). If future work on Gemals is 
to take place in SOD1 mice, care should be taken to isolate the component/s causing 
irritation, to prevent the development of skin lesions and prevent the need for 
confounding analgesic treatment in further trials. Like Gemals, MT2 has multiple 
putative mechanisms by which it could induce protection of motor neurons, rather than 
a purely antioxidant mechanism.  
Oxidative stress is known to be present in sporadic and familial ALS cases (Ferrante et 
al. 1997), yet the treatments used in thesis that were based around the amelioration of 
oxidative stress did not show robust beneficial effects. Based on the common presence 
of oxidative stress in sporadic and familial disease (Ferrante et al. 1997), I would 
therefore have expected that, had the treatments shown robust effects in SOD1 mice, 
these treatments would have been translatable into potential therapies for human ALS 
patients. However, as these treatments showed no substantial effects in SOD1 mice, it is 
unclear whether these oxidation-targeted therapeutics in their current form would hold 
any benefit for ALS patients. More research into the mechanisms of oxidative stress-
mediated damage in motor neurons should be performed in order to determine whether 
oxidative stress is a primary factor causing neuronal degeneration, or purely a 
downstream byproduct of another degenerative process. It is possible that the pathology 
seen in SOD1 mice, including oxidative stress, is limited to animals and patients with 
SOD1-linked disease. Indeed, only SOD1-linked familial ALS cases show SOD1 
protein aggregation in spinal cord motor neurons; SOD1 aggregates are not found in 
non-SOD1-linked familial ALS, and only rarely seen in sporadic ALS cases (Bosco et 
al. 2010; Ravits et al. 2013).  
The targeting of other common pathologies in ALS, such as the presence of TDP43 in 
sporadic and virtually all non-SOD1 familial ALS cases, may provide more benefit in 
developing broad-spectrum therapeutics for ALS patients regardless of genetic or 
sporadic aetiology. 
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6.4 MT2 and its derivatives as putative ALS therapeutics 
The multipurpose neuroprotective protein metallothionein-1/2 (MT-1/2), and its 
derivatives, have been discussed in Chapters 2, 4, and 5. The amount of MT-1/2 in the 
spinal cord of SOD1 mice increases with disease progression, with the increased MT-
1/2 production mainly mediated by astrocytes. Pre-symptomatic treatment with MT2 
injections, but not with an exercise regime, delayed disease onset as measured by 
maximum body weight, and tended to increase survival times in SOD1 mice. A small 
pilot study of the MT2 derivative peptides, Emtins, showed a tendency for Emtin 
treatment to increase survival time even when administered after the onset of disease 
symptoms. Thus, it appears that MT-1/2 plays a neuroprotective role, and MT2 or its 
derivatives may be suitable for further development as therapeutic compounds for 
human ALS.  
However, the mechanism of action for MT2 and Emtin peptides remains to be 
elucidated. MT2 is known to have several neuroprotective functions, with putative 
intracellular roles in ameliorating oxidative stress, correcting metal dyshomeostasis, and 
preventing apoptosis. As an extracellular ligand of the LRP receptors, MT-1/2 induces 
intracellular pathways involved in neurite outgrowth and neuronal survival, such as the 
PI3K/Akt pathway. In comparison, Emtin peptides are also known to induce neuronal 
survival and outgrowth via LRP receptors, but are not metallated. Thus, in principle 
Emtin peptides have less metal-binding capacity than MT-1/2, indicating that the trend 
of Emtins to increase survival time in SOD1 mice is likely more to do with LRP binding 
rather than any antioxidant or metal-homeostatic capacity of Emtin peptides.  
The current lack of biomarkers for ALS in the pre-symptomatic phase means that 
treatments should ideally be effective from after the onset of disease symptoms. Emtin 
peptides, tested in a small cohort of SOD1 mice, showed some improvement in survival 
time when administered after the onset of disease symptoms, and therefore could 
represent a potential therapeutic for human ALS. Future work on the Emtin peptides 
should first employ a large pre-clinical study in SOD1 mice and rats, to ensure that the 
effects seen in this small pilot study can be replicated in a larger cohort, and to establish 
dose-dependent effects on survival. Cell culture work, eliciting the effects and 
mechanisms of action of Emtins on cultured motor neurons, could help to further 
evaluate these peptides as potential therapeutic molecules for human ALS.   
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6.5 The SOD1 model of ALS 
The SOD1 mouse model of ALS is the most commonly-used animal model for human 
ALS. While the SOD1 model has undoubtedly been useful in describing mechanisms of 
motor neuron degeneration, its relevance to human sporadic ALS has been questioned. 
Although human ALS and rodent SOD1-mediated ALS show clinical and pathological 
similarities, SOD1-mutation-mediated ALS accounts for only 2-3% of human ALS 
cases, and the exact mechanisms of neuronal degeneration in SOD1 mice and human 
ALS patients may differ (Martin et al. 2007). It is therefore important to consider 
whether results obtained from pre-clinical trials in the SOD1 mouse can be effectively 
translated to sporadic ALS. Differences between human sporadic ALS and rodent 
SOD1-mediated ALS may account for the robust effects of several ALS therapeutic 
molecules when tested in SOD1 mice, but the failure of these same compounds when 
introduced into clinical trials (Benatar 2007).   
A final common pathway between SOD1-mediated ALS, non-SOD1 FALS, and 
sporadic ALS has not been definitively identified, although as discussed in Chapter 1, 
oxidative stress may form one such convergence point. The more recent discoveries of 
RNA processing, protein degradation dysfunction, and hexanucleotide repeats in 
C9orf72 may provide more mechanistic insight into the disease processes of ALS. In 
particular, elucidating the mechanism of action of TDP43-mediated ALS will prove 
valuable for the future study of sporadic ALS and FTD.  
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6.6 Thesis summary 
Chapter 1 identifies oxidative stress and neuroinflammation as key pathologies in the 
aetiology of ALS, with oxidative stress in particular acting as a convergence point 
between several putative ALS causes either as a primary insult or as a consequence of 
upstream pathology.  
Chapter 2 has identified that the increase in microglial cells in the SOD1 spinal cord 
ventral horn is largely associated with an increase in microglia expressing the M2-type 
marker Arg1, although a smaller concomitant increase in microglia expressing the M1-
type marker, iNOS, was also observed. These changes indicate duelling pro- and anti-
inflammatory processes occurring in the spinal cord of SOD1 mice. An increase in MT-
1/2 levels, thought to be a neuroprotective response to degenerating motor neurons, was 
also observed over time.  
Chapter 3 trialled the antioxidant compound Gemals as a treatment in post-symptomatic 
SOD1 mice, yet found no significant effects on survival time. However, confounding 
factors in this study may limit its interpretation in terms of the effectiveness of Gemals 
treatment.  
Chapter 4 trialled the neuroprotective protein MT2, and treadmill exercise, as pre-
symptomatic treatments in SOD1 mice, with an increase in survival time observed for 
MT2-treated SOD1 mice but not exercise-treated SOD1 mice.  
Chapter 5 explored a pilot study of the MT2 derivatives, Emtin peptides, administered 
after symptom onset in SOD1 mice. Emtin peptides showed a small increase in survival 
time, although this effect was not significant in this small cohort. However, Emtin 
peptides may represent a promising candidate for further development into a therapeutic 
molecule for increasing neuronal survival in ALS.  
Therapeutics targeting multiple aspects of pathology in ALS are required in order to 
maintain surviving motor neurons and limit functional decline in ALS. Similarly, it is 
clear that more research into the basic mechanisms of ALS, and methods for early 
detection of ALS, are required in order to effectively treat this devastating 
neurodegenerative disease. 
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Supplementary Data 
Supplementary Data 1: General notes on model fitting 
Linear mixed models were fitted in SPSS Statistics 20 (IBM), using the following 
conditions for likelihood estimation: 
Maximum iterations = 100 
Maximum step-halvings = 10 
Log-likelihood convergence = Absolute (0) 
Parameter convergence = Absolute (0.000001) 
Hessian convergence = Absolute (0) 
Maximum scoring steps = 1 
Singularity tolerance = 0.000000000001 
Type III sum of squares was used for fixed effects 
Variance/covariance matrix (G) structure = unstructured 
When fitting each model, maximum likelihood (ML) estimation was used to check the 
improved fit of fixed effects, by comparing log likelihoods (as -2LL, in smaller-is-better 
format) with a chi squared test (χ2) with degrees of freedom (df) equal to the number of 
parameters differing between models.  
Restricted maximum likelihood (REML) estimation was used to check the improved fit 
of random effects, by comparing restricted log likelihoods (-2RLL) as above.  
Both ML and REML log likelihoods (-2LL and -2RLL, respectively) are reported for 
the relevant models; however, it should be noted that the model specifications (fixed 
effects and covariance parameter estimates) are reported as obtained from ML 
estimation rather than REML estimation.  
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Supplementary Data 2: Fitting a linear mixed model to SOD1 and WT 
body weight trajectories 
Fixed effects of the final model (Model 6, below) are summarised in Chapter 2, Table 
2.4 and Figure 2.10.  
Factors: Age = Age in days, continuous covariate; Genotype = dummy-coded binary 
variable, where 0 = WT and 1 = SOD1; interaction parameters between eg. 
Genotype*Age are therefore only applicable to SOD1 mice. 
Model 1: Linear trajectory, no random effects 
Body weightij = β0 + β1*Age + εij         (εij = errors for subject i at age j, εij ~ iid N(0,σ
2
)) 
Factors:  Fixed factors: Intercept, Age 
Random factors: (none) 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper Sig (p-value) 
Intercept (β0) 17.964030 17.624058 18.304002 <0.001 
Age (β1) 0.020006 0.017121 0.022890 <0.001 
 
Estimates of covariance parameters: 
Parameter Estimate Std. Error 
Residual 2.944904 0.119976 
Model fit (fixed effects):  -2LL = 4721.134 
 
Model 2: Quadratic trajectory, no random effects 
Body weightij = β0 + β1*Age + β2*Age
2
 + εij 
Factors:  Fixed factors: Intercept, Age, Age
2
 
Random factors: (none) 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper Sig (p-value) 
Intercept (β0) 14.681763 13.720716 15.642811 <0.001 
Age (β1) 0.083179 0.065600 0.100759 <0.001 
Age
2
 (β2) -0.00277 -0.000354 -0.000201 <0.001 
 
Estimates of covariance parameters: 
Parameter Estimate Std. Error 
Residual 2.825273 0.115102 
Model fit (fixed effects):  -2LL = 4671.161 
  Difference from Model 1 = χ2(4721.134 - 4671.161, df=1), p<0.001 
 The quadratic model (Model 2) fits the data significantly better than the linear model 
(Model 1).  
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Model 3: Cubic trajectory, no random effects 
Body weightij = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + εij 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
 
Random factors: (none) 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper Sig (p-value) 
Intercept (β0) 3.759549 1.183858 6.335241 0.004 
Age (β1) 0.413304 0.338744 0.487863 <0.001 
Age
2
 (β2) -0.003348 -0.004028 -0.002669 <0.001 
Age
3
 (β3) 0.000009 0.000007 0.000011 <0.001 
 
Estimates of covariance parameters: 
Parameter Estimate Std. Error 
Residual 2.650180 0.107968 
 
Model fit (fixed effects):  -2LL = 4595.068 
  Difference from Model 2 = χ2(4671.161 – 4595.068, df=1), p<0.001 
  
The cubic model (Model 3) fits the data significantly better than the quadratic model 
(Model 2). 
 
Model fit (random effects):  -2RLL = 4653.988 
 
Model 4: Cubic trajectory, random intercept 
Body weightij = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + εij + ui  
εij = within-subject variance = errors for subject i at age j, εij ~ N(0,σ
2
) 
ui = between-subject variance = variance around intercept for subject i, ui ~ N (0, σ0
2
) 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
 
Random factors: Intercept 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper Sig (p-value) 
Intercept (β0) 6.738034 5.229137 8.246931 <0.001 
Age (β1) 0.337954 0.297155 0.378752 <0.001 
Age
2
 (β2) -0.002716 -0.003089 -0.002343 <0.001 
Age
3
 (β3) 0.000007 0.000006 0.000008 <0.001 
 
Estimates of covariance parameters: 
Parameter Estimate Std. Error 
Residual 0.771785 0.031843 
Intercept (subject=ID) 2.232236 0.582854 
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Model fit (fixed effects):  -2LL (log likelihood) = 3249.436 
Model fit (random effects): -2RLL (log likelihood) = 3309.259 
  Difference from Model 3 = χ2(4653.988 – 3309.259, df=1), p<0.001 
  
Unique starting body weights for each mouse (random intercept, Model 4) account for a 
significant portion of the overall variance in the cubic model, giving a significantly 
better model fit than when no randomeffects are included (Model 3). 
 
Model 5: Cubic trajectory, random intercept and slope 
Body weightij = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + εij + u0i + u1i*Age 
εij = within-subject variance = errors for subject i at age j, εij ~ N(0,σ
2
) 
u0i = between-subject variance = variance around intercept for subject i  
u1i = between-subject variance = variance around slope for subject i  
ui = [
   
   
] ~ N (0, G) G = [
          
       
 
  
]    
n.b. G, a 2x2 matrix for two random effects (intercept and slope), is unstructured 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper Sig (p-value) 
Intercept (β0) 11.010998 9.664808 12.357188 <0.001 
Age (β1) 0.217180 0.184939 0.249421 <0.001 
Age
2
 (β2) -0.001570 -0.001852 -0.001289 <0.001 
Age
3
 (β3) 0.000004 0.000003 0.000004 <0.001 
 
Estimates of covariance parameters: (G) 
Parameter  Estimate Std. Error 
Residual  0.368620 0.015413 
Intercept + Age      
(subject=ID)     
                               
Var.(Intercept); σ2u0 4.385741 1.216009 
Covar.(Intercept, slope); σ u0,u1 -0.039050 0.012020 
Var.(slope); σ2u1 0.000531 0.000143 
Var., variance; Covar., covariance; corresponding to the random effects 
variance/covariance matrix, G. 
 
Model fit (fixed effects):  -2LL (log likelihood) = 2484.105 
Model fit (random effects): -2RLL (log likelihood) = 2541.979 
  Difference from Model 4 = χ2(3309.259 – 2541.979, df=2), p<0.001 
Including both unique starting body weights and unique rates of change over time for 
individual mice (random intercept and slope, Model 5) accounts for a significant 
portion of the overall variance in the cubic model, giving a significantly better model fit 
than when random intercept is included as the only random effect (Model 4). 
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Model 6: Cubic trajectory, random intercept and slope, with genotype  
(final model; a summary of fixed effects parameters is presented in Chapter 2) 
Body weightij = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + β4*Genotype + β5*Genotype*Age 
+ β6*Genotype*Age
2
 + β7*Genotype*Age
3
 + εij + u0i + u1i*Age 
εij = within-subject variance = errors for subject i at age j, εij ~ N(0,σ
2
) 
u0i = between-subject variance = variance around intercept for subject i  
u1i = between-subject variance = variance around slope for subject i  
ui = [
   
   
] ~ N (0, G) G = [
          
       
 
  
]    
n.b. G, a 2x2 matrix for two random effects (intercept and slope), is unstructured 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
, Genotype, Age*Genotype, 
Age
2
*Genotype, Age
3
*Genotype 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper p-value 
Intercept (β0) 14.504774 12.957579 16.051968 <0.001 
Age (β1) 0.128064 0.093210 0.162919 <0.001 
Age
2
 (β2) -0.000853 -0.001157 -0.000549 <0.001 
Age
3
 (β3) 0.000002 0.000001 0.000003 <0.001 
Genotype (β4) 0.182480 -1.973811 2.338771 0.868 
Genotype*Age (β5) -0.066064 -0.117532 -0.014596 0.012 
Genotype*Age
2
 (β6) 0.001096 0.000626 0.001565 <0.001 
Genotype*Age
3
 (β7) -0.000005 -0.000007 -0.000004 <0.001 
 
Estimates of covariance parameters: (G) 
Parameter  Estimate Std. Error 
Residual  0.219971 0.009216 
Intercept + Age      
(subject=ID)            
 
Var.(Intercept); σ2u0 2.771801 0.770205 
Covar.(Intercept, slope); σ u0,u1 -0.011721 0.004209 
Var.(slope); σ2u1 0.000104 0.000031 
Var., variance; Covar., covariance; corresponding to the random effects 
variance/covariance matrix, G. 
 
Model fit: (fixed effects):  -2LL (log likelihood) = 1843.907 
   Difference from model 1 = χ2(2484.105 – 1843.907, df=4), p<0.001 
   Including genotype in the model (Model 6) significantly improved the 
   model fit to the data compared to the cubic model excluding genotype as 
   a factor (Model 5). 
Model fit (random effects): -2RLL (log likelihood) = 1958.998  
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Supplementary Data 3: Fitting a mixed model to body weight 
trajectories of MT2-treated and exercised SOD1 mice 
Fixed effects of the final model (Model 3, below) are summarised in Chapter 4, Table 
4.3 and Figure 4.4. 
Factors:  
Age = Age in days, continuous covariate, censored at 42 days (6 weeks of age, start of 
treatment). 
Exercise = dummy-coded binary variable, where exercised SOD1 mice = 1 and 
sedentary SOD1 mice = 0. 
Drug = dummy-coded binary variable, where MT2-treated SOD1 mice = 1  and 
vehicle-treated SOD1 = 0.   
The process of model fitting was carried out as described in Supplementary Data 2. For 
brevity, a summary of model fit to determine model shape is provided below.  
Summary of model fitting: 
Model 
trajectory 
Random 
effects 
-2LL 
(ML) 
-2RLL 
(REML) 
Fit improvement 
Linear - 6551.276  - 
Quadratic - 6060.683  Fixed effects: p<0.001 vs. linear 
model 
Cubic - 6000.729 6064.434 Fixed effects: p<0.001 vs. quadratic 
model 
Cubic Intercept  3121.209 Random effects: p<0.001 from 
cubic model with no random effects 
Cubic 
(Model 1) 
Intercept, 
slope 
 2818.106 Random effects: p<0.001 from 
model with random intercept alone 
 
 
 
Model 1: Cubic trajectory, random intercept and slope  
Body weight = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + εij + u0i + u1i*Age  
(see Supplementary Data 2 for error term notation) 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper Sig (p-value) 
Intercept (β0) 17.576294 17.262493 17.890096 <0.001 
Age (β1) 0.007678 0.000911 0.014446 0.026 
Age
2
 (β2) 0.000705 0.000592 0.000819 <0.001 
Age
3
 (β3) -0.000006 -0.000007 -0.000006 <0.001 
 
Estimates of covariance parameters: 
Parameter  Estimate Std. Error 
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Residual  0.204463 0.006897 
Intercept + Age      
(subject=ID)            
                                 
Var.(Intercept) 1.273455 0.241583 
Covar.(Intercept, slope) -0.002332 0.001178 
Var.(slope) 0.000048 0.000011 
Var., variance; Covar., covariance; corresponding to the random effects 
variance/covariance matrix. 
Model fit (fixed effects):  -2LL (log likelihood) = 2754.600 
  
Model 2: Cubic trajectory, random intercept and slope, with Exercise parameters 
Body weight = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + β4*Exercise + β5*Exercise*Age  
   + β6*Exercise*Age
2
 + β7*Exercise*Age
3
 + εij + u0i + u1i*Age 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
, Exercise, Exercise*Age, 
Exercise*Age
2
, Exercise*Age
3
 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper p-value 
Intercept (β0) 17.558523 17.122241 17.994804 <0.001 
Age (β1) 0.008845 -0.000642 0.018333 0.068 
Age
2
 (β2) 0.000730 0.000569 0.000890 <0.001 
Age
3
 (β3) -0.000007 -0.000008 -0.000006 <0.001 
Exercise (β4) 0.048568 -0.578484 0.675621 0.878 
Exercise*Age (β5) -0.003474 -0.016889 0.009940 0.612 
Exercise*Age
2
 (β6) -0.000025 -0.000250 0.000199 0.824 
Exercise*Age
3
 (β7) 0.000001 0.000000 0.000002 0.220 
 
Estimates of covariance parameters:  
Parameter  Estimate Std. Error 
Residual  0.200393 0.006760 
Intercept + Age      
(subject=ID)            
                                 
Var.(Intercept) 1.272323 0.241299 
Covar.(Intercept, slope) -0.002310 0.001172 
Var.(slope) 0.000048 0.000011 
Var., variance; Covar., covariance; corresponding to the random effects 
variance/covariance matrix. 
Model fit (fixed effects):  -2LL (log likelihood) = 2718.779 
  Difference from model 1 = χ2(2754.600 – 2718.779, df=4), p<0.001 
Including Exercise as a factor in the body weight model improved the model fit, as 
measured by decreasing -2LL values, yet the parameter estimates for exercised mice 
(β4-β7) were not significantly different from those of sedentary mice. Thus, while 
exercise/sedentary status contributed to explaining some of the variation between 
treatment groups, the body weight trajectories of exercised and sedentary mice did not 
differ significantly.  
______________________________________________________Supplementary Data 
______________________________________________________________________ 
______________________________________________________________________ 
 
235 
 
Model 3: Cubic trajectory, random intercept and slope, with Exercise 
(exercise/sedentary) and Drug (MT2/vehicle) parameters 
Body weight = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + β4*Exercise + β5*Exercise*Age  
   + β6*Exercise*Age
2
 + β7*Exercise*Age
3
 + β8*Drug+ β9*Drug*Age  
   + β10*Drug*Age
2
 + β11*Drug*Age
3
 + εij + u0i + u1i*Age 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
, Exercise, Exercise*Age, 
Exercise*Age
2
, Exercise*Age
3
, Drug, Drug*Age, Drug*Age
2
, 
Drug*Age
3
 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper p-value 
Intercept (β0) 17.363634 16.837901 17.889367 <0.001 
Age (β1) 0.021013 0.009705 0.032322 <0.001 
Age
2
 (β2) 0.000478 0.000285 0.000671 <0.001 
Age
3
 (β3) -0.000006 -0.000007 -0.000005 <0.001 
Exercise (β4) 0.023367 -0.604711 0.651446 0.941 
Exercise*Age (β5) -0.002076 -0.015401 0.011250 0.760 
Exercise*Age
2
 (β6) -0.000049 -0.000273 0.000175 0.669 
Exercise*Age
3
 (β7) 0.000001 0.000000 0.000002 0.151 
Drug (β8) 0.418199 -0.210027 1.046425 0.189 
Drug*Age (β9) -0.025340 -0.038716 -0.011964 <0.001 
Drug*Age
2
 (β10) 0.000510 0.000285 0.000735 <0.001 
Drug*Age
3
 (β11) -0.000003 -0.000004 -0.000001 <0.001 
 
Estimates of covariance parameters:  
Parameter  Estimate Std. Error 
Residual  0.198360 0.006693 
Intercept + Age      
(subject=ID)            
                                 
Var.(Intercept) 1.276821 0.242147 
Covar.(Intercept, slope) -0.002386 0.001147 
Var.(slope) 0.000045 0.000010 
Var., variance; Covar., covariance; corresponding to the random effects 
variance/covariance matrix. 
Model fit (fixed effects):  -2LL (log likelihood) = 2697.062 
  Difference from model 2 = χ2(2718.779 – 2697.062, df=4), p<0.001 
Including Drug as a factor in the body weight model improved the model fit, as 
measured by decreasing -2LL values. The parameter estimates for MT2-treated mice 
differed from those of vehicle-treated mice, indicating that the body weight trajectories 
of MT2-treated mice were significantly different compared to vehicle-treated mice.  
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Model 4: Cubic trajectory, random intercept and slope, with Exercise 
(exercise/sedentary), Drug (MT2/vehicle), and Exercise*Drug parameters 
Body weight = β0 + β1*Age + β2*Age
2
 + β3*Age
3
 + β4*Exercise + β5*Exercise*Age  
   + β6*Exercise*Age
2
 + β7*Exercise*Age
3
 + β8*Drug+ β9*Drug*Age  
   + β10*Drug*Age
2
 + β11*Drug*Age
3
 + β12*Exercise*Drug  
   + β13*Drug*Age + β14*Drug*Age
2
 + β15*Drug*Age
3
 + εij + u0i  
   + u1i*Age 
Factors:  Fixed factors: Intercept, Age, Age
2
, Age
3
, Exercise, Exercise*Age, 
Exercise*Age
2
, Exercise*Age
3
, Drug, Drug*Age, Drug*Age
2
, 
Drug*Age
3
, Exercise*Drug, Exercise*Drug*Age, Exercise*Drug*Age
2
, 
Exercise*Drug*Age
3
 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, 
lower 
95% CI, 
upper 
p-value 
Intercept (β0) 17.311491 16.714817 17.908166 <0.001 
Age (β1) 0.022860 0.009924 0.035796 0.001 
Age
2
 (β2) 0.000470 0.000248 0.000693 <0.001 
Age
3
 (β3) -0.000006 -0.000007 -0.000004 <0.001 
Exercise (β4) 0.135588 -0.737744 1.008921 0.758 
Exercise*Age (β5) -0.006105 -0.024843 0.012633 0.523 
Exercise*Age
2
 (β6) -0.000027 -0.000347 0.000293 0.867 
Exercise*Age
3
 (β7) 0.000001 -0.000001 0.000002 0.316 
Drug (β8) 0.536375 -0.337797 1.410548 0.225 
Drug*Age (β9) -0.029863 -0.048782 -0.010945 0.001 
Drug*Age
2
 (β10) 0.000541 0.000221 0.000861 0.001 
Drug*Age
3
 (β11) -0.000003 -0.000004 -0.000001 0.001 
Exercise*Drug (β12) -0.243375 -1.498343 1.011594 0.700 
Exercise*Drug*Age (β13) 0.009398 -0.017341 0.036136 0.491 
Exercise*Drug*Age
2
 (β14) -0.000068 -0.000518 0.000382 0.767 
Exercise*Drug*Age
3
 (β15) 0.000000 -0.000002 0.000002 0.929 
 
Estimates of covariance parameters:  
Parameter  Estimate Std. Error 
Residual  0.198192 0.006687 
Intercept + Age      
(subject=ID)            
                                 
Var.(Intercept) 1.272228 0.241323 
Covar.(Intercept, slope) -0.002334 0.001139 
Var.(slope) 0.000044 0.000010 
Var., variance; Covar., covariance; corresponding to the random effects variance/covariance matrix. 
Model fit (fixed effects):  -2LL (log likelihood) = 2695.162 
  Difference from model 3 = χ2(2697.062 – 2695.162, df=4), p=0.754 
 The addition of interaction terms between Exercise*Drug did not improve the fit of the 
model to the data, indicating that no synergistic effects were present between exercise 
treatment and MT2 treatment. As a result, the final model presented in Chapter 4 was 
Model 3, above, containing Exercise parameters and Drug parameters, but without 
including an interaction term.  
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Supplementary Data 4: Fitting a mixed model to body weight 
trajectories of Emtin-treated and control SOD1 mice 
Fixed effects of the final model (Model 2, below) are summarised in Chapter 5, Table 
5.4 and Figure 5.3. 
Factors:  
Age = Age in days, continuous covariate 
Treatment = dummy-coded categorical variable; 
‘EmtinAc’ is encoded by EmtinAc-treated SOD1 mice = 1 and control SOD1 mice = 0. 
‘EmtinB’ is encoded by EmtinB-treated SOD1 mice = 1 and control SOD1 mice = 0. 
The process of model fitting was carried out as described in Supplementary Data 2. For 
brevity, a summary of model fit to determine model shape is provided below.  
Summary of model fitting: 
Model 
trajectory 
Random 
effects 
-2LL 
(ML) 
-2RLL 
(REML) 
Fit improvement 
Linear - 1717.129  - 
Quadratic - 1584.622 1615.791 Fixed effects: p<0.001 vs. linear 
model 
Cubic - 1583.377  Fixed effects: p=0.264 vs. quadratic 
model; no improvement in fit 
Quadratic Intercept  826.631 Random effects: p<0.001 vs. 
quadratic model with no random 
effects 
Quadratic 
(Model 1) 
Intercept, 
slope 
722.235 751.726 Random effects: p<0.001 vs. model 
with random intercept alone 
 
 
Model 1: Quadratic trajectory, random intercept and slope 
Body weight = β0 + β1*Age + β2*Age
2
 + εij + u0i + u1i*Age 
(see Supplementary Data 2 for error term notation) 
Factors:  Fixed factors: Intercept, Age, Age
2
 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper Sig (p-value) 
Intercept (β0) 1.520609 -0.189412 3.230630 0.081 
Age (β1) 0.312842 0.289456 0.336228 <0.001 
Age
2
 (β2) -0.001329 -0.001417 -0.001241 <0.001 
 
Estimates of covariance parameters: 
Parameter  Estimate Std. Error 
Residual  0.181894 0.011626 
Intercept + Age      Var.(Intercept) 3.474587 1.237779 
______________________________________________________Supplementary Data 
______________________________________________________________________ 
______________________________________________________________________ 
 
238 
 
(subject=ID)            
                                 
Covar.(Intercept, slope) -0.015722 0.006300 
Var.(slope) 0.000094 0.000037 
Var., variance; Covar., covariance; corresponding to the random effects 
variance/covariance matrix. 
Model fit (fixed effects):  -2LL (log likelihood) = 722.235 
 
Model 2: Quadratic trajectory, random intercept and slope, with Treatment 
(EmtinAc/EmtinB) parameters 
Body weight = β0 + β1*Age + β2*Age
2
 + β3*EmtinAc + β4*EmtinAc*Age  
   + β5*EmtinAc*Age
2
 + β6*EmtinB + β7*EmtinB*Age  
   + β8*EmtinB*Age
2
 + εij + u0i + u1i*Age 
(see Supplementary Data 2 for error term notation) 
Factors:  Fixed factors: Intercept, Age, Age
2
, EmtinAc, EmtinAc*Age, 
EmtinAc*Age
2
, EmtinB, EmtinB*Age, EmtinB*Age
2
 
Random factors: Intercept, slope 
Estimates of fixed effects: 
Parameter Estimate (β) 95% CI, lower 95% CI, upper p-value 
Intercept (β0) -4.449126 -7.501088 -1.397165 0.004 
Age (β1) 0.420456 0.376231 0.464681 <0.001 
Age
2
 (β2) -0.001774 -0.001943 -0.001604 <0.0001 
EmtinAc (β3) 7.543884 3.421179 11.666589 <0.001 
EmtinAc*Age (β4) -0.143378 -0.202179 -0.084577 <0.001 
EmtinAc*Age
2
 (β5) 0.000596 0.000372 0.000821 <0.001 
EmtinB (β6) 8.034302 3.981721 12.086882 <0.001 
EmtinB*Age (β7) -0.140318 -0.197457 -0.083178 <0.001 
EmtinB*Age
2
 (β8) 0.000578 0.000362 0.000794 <0.001 
 
Estimates of covariance parameters: 
Parameter  Estimate Std. Error 
Residual  0.168984 0.010795 
Intercept + Age      
(subject=ID)            
                                 
Var.(Intercept) 2.730534 0.982709 
Covar.(Intercept, slope) -0.012786 0.005322 
Var.(slope) 0.000087 0.000034 
Var., variance; Covar., covariance; corresponding to the random effects 
variance/covariance matrix. 
Model fit (fixed effects):  -2LL (log likelihood) = 684.849 
   Difference from Model 1 = χ2(722.235 – 684.849, df=6), p<0.001 
The addition of Treatment (EmtinAc, EmtinB) parameters to the model explained a 
significant portion of the variation as seen by decreasing -2LL values. The parameter 
estimates for EmtinAc-treated and EmtinB-treated SOD1 mice were significantly 
different from those of control SOD1 mice, indicating that treatment with Emtin 
peptides significantly affected body weight trajectory over time. 
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Appendix 
Behavioural testing procedures for mouse motor phenotype 
This document is not a task risk assessment, nor a standard operating procedure.  
All investigators attempting these procedures must have prior training in animal 
handling. 
 
Stride test 
One mouse at a time was removed from its home cage and placed on a transport cage 
lid, then scruffed with the left (or preferred) hand of the investigator. Scruffing should 
attempt to gather as much skin as possible in order to limit limb movement when 
applying paint to the paws. With the mouse scruffed, paint which had been diluted to a 
thin consistency with water was applied to the paws with a paintbrush – blue for hind 
paws and red for front paws. The mouse was then placed onto the start of the strip 
between the dividers, and walked along the strip of paper between the dividers towards 
the wire basket. Upon entering the wire basket, the mouse was retrieved by its tail, and 
had its paws dipped into the petri dish containing water in order to remove paint, then 
was transferred into a tissue-lined cage to dry the feet. The mouse was then returned to 
its home cage.  
 
 
 
Rotarod 
Coordinated motor performance was assessed using a 5-lane mouse rotarod (TSE 
Systems). Mice were acclimatised to the rotarod from approximately 85-90 days of age, 
with three once-daily sessions. Each acclimatisation session consisted of 5 minutes on 
the rotarod drum at a constant speed of 3rpm – while the mice were learning to stay on 
the rotating drum, they were partly supported to stay on the drum, and prevented from 
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falling off the drum, by the investigator placing their hand below the drum to as a 
platform and safety net. The mice were then trained to stay on the accelerating rotarod, 
with at least two once-daily sessions consisting of a 3rpm-16rpm acceleration over 3 
minutes. In testing sessions, the speed at which mice were unable to stay on the rotating 
drum during an acceleration from 3rpm-16rpm over 3 minutes was recorded. As few 
mice achieved the maximum score of staying on the rotarod up to 16rpm, future studies 
using the rotarod should commence training prior to the onset of disease symptoms.  
 
Grip strength meter 
Grip strength was measured in newtons (N) with a grip strength meter (Columbus 
Instruments) mounted on a stand. Each mouse was scruffed, held over the grip strength 
meter equipped with triangular bar, and moved backwards at a constant speed, gripping 
the bar with its hind paws and generating a maximum force measurement. The 
maximum force recorded from three attempts was used for analysis.  
 
Wire hang duration test 
To perform wire hang duration testing, mice were removed from their home cage, and 
placed on a wire cage lid. The cage lid was then gently inverted and held approximately 
20cm above a large transport cage with foam padding at the bottom (A, below). The 
mouse gripped onto the bars (B, below), while the cage lid was held inverted for a 
maximum of 60 seconds. The latency to fall, from the best of three attempts, was 
recorded as the wire hang duration.  
 
As an interesting aside, it was noted that the first 3-4 weeks of testing were highly 
variable for both genotypes. The home cages for all mice featured a clear plastic lid 
rather than metal bars – the only wire structure in the home cage would be the food 
hopper, so these mice effectively had no prior training in gripping an inverted set of 
wire bars. The first few weeks of testing may have effectively only served as a training 
period, hence the variable measurements obtained. For future use of the wire hang 
duration test, it would be recommended to train mice in the wire hang duration 
procedure for a period of some weeks prior to recording data for analysis.   
 
  
 
